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CD4 T Cells Regulate Adenovirus Vector-Elicited Cellular and Humoral Immune Responses 
 
 
Abstract 
 
The processes that regulate viral vector vaccine-elicited cellular and humoral immune responses 
remain poorly defined. Thus, in this thesis, the role of CD4+ T cells – master regulators of 
adaptive immunity – in modulating adenovirus (Ad) vector-elicited cytotoxic CD8+ T cell 
responses and transgene-specific antibody responses was investigated. CD4+ T cell help is 
critical for the induction of CD8+ T cell and antibody responses, but the mechanisms and timing 
of help to each of these two arms of the immune system are distinct. CD4+ T cell help is required 
immediately and continuously for one week to drive functional CD8+ T cell effector 
differentiation and prevent dysfunction. Elevated signaling via PD-1, decreased IL-2 signaling, 
and increased non-canonical NFAT signaling all appear important for driving this CD8+ T cell 
dysfunction and impairing effector functionality. Absence of CD4+ T cells at the time of Ad 
vector immunization prevents the development of antigen-specific antibody responses. However, 
if the CD4+ T cell population is allowed to recover then fully functional antigen-specific 
antibody responses develop without the re-administration of antigen. Thus, CD4+ T cell help is 
absolutely required for the development of antibody responses following Ad vector 
immunization, but, intriguingly, help can be provided at a time separate from initial antigen 
exposure. Collectively, CD4+ T cell help and the appropriate timing of this help are critical for 
the generation of optimal CD8+ T cell and antibody responses following Ad vector immunization. 
These data advance our understanding of how CD4+ T cells regulate Ad vector-elicited cellular 
and humoral immune responses, and may improve rational vaccine design. 
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Chapter 1: Introduction 
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ADENOVIRAL VACCINE VECTORS 
Adenoviruses 
Adenoviruses are non-enveloped, icosahedral, double-stranded DNA viruses that replicate in the 
nucleus of infected cells and do not integrate their DNA into the chromosomes of the infected 
host cell (1). The adenovirus family consists of multiple distinct genotypes. To date, complete 
genomes for 71 human adenovirus genotypes are recorded in Genbank (genbank.gov; November 
2015), and novel human and non-human primate origin adenoviruses are identified with 
regularity (2-6). Distinct adenovirus genotypes share genomic organization characteristics and, 
viral genes are broadly divided into “early” and “late genes”. The early genes encode proteins 
responsible for initiation of viral transcription, viral replication, and host immune modulation, 
while the late genes consist of the 11 structural proteins required to assemble a viral particle (7). 
The late genes are predominantly controlled by the major late promoter (MLP) and individual 
genes are expressed by differential mRNA splicing (8, 9). While genotypes share genomic 
organization and basic replication characteristics, unique genotypes display differences in 
primary attachment receptor usage, tissue tropism, and intracellular trafficking patterns (10). 
Neutralizing antibodies to a given genotype are usually minimally cross-reactive between 
genotypes, and hence many genotypes are also distinct serotypes (11). The amenability of 
genetic manipulation of DNA viruses, lack of viral DNA integration, shared genomic 
architecture between genotypes, distinct biological properties of virus genotypes, and high 
immunogenicity make adenoviruses ideal platforms for viral vector development. 
 
Development and construction of adenoviral vectors 
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The standard “vectorization” process involves the deletion of the E1 and E3 early gene regions, 
which generates approximately 4 kb of genomic space for the insertion of a foreign transgene of 
interest (12), usually inserted in the location of the deleted E1 region (13-15). Deletion of the E1 
region renders the adenovirus replication-incompetent (16). The E3 region encodes immune 
evasion genes, one of which functions to down-regulate the expression of MHC class I, and this 
region is dispensable for replication in tissue culture (17, 18). Replication-incompetent Ad 
vectors were initially explored as delivery systems for gene therapy (19, 20). As gene therapy 
tools, Ad vectors expressing an exogenous transgene of interest showed promise in vivo in both 
small animal models as well as in non-human primates. However, a major limitation of the 
technology is the rapid immune-mediated clearance of transduced cells, primarily by CD8+ T 
cells (21-23). This ability to elicit robust transgene-specific immunity is the reason why Ad 
vectors are now being extensively pursued as candidate vaccine platforms.  
The first description of a replication-incompetent Ad vector as a vaccine platform was 
against pseudorabies virus (14). This vector construct expressed the transgene product under 
control of the adenovirus MLP with the transgene inserted into the deleted E1 region, but this 
construct was only modestly immunogenic. Replacement of the MLP transgene promoter with 
the cytomegalovirus (CMV) promoter (13), while keeping the transgene placement with the 
genome the same, enhanced transgene expression and substantially improved immunogenicity. 
This vector layout is the standard vector architecture currently in use (5, 6, 24).  
 
Preclinical and clinical evaluation of adenoviral vaccine vectors 
Replication-incompetent recombinant Ad vectors are currently being investigated as candidate 
vaccines for a number of infectious diseases that are of considerable public health concern, 
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including HIV-1 (25, 26), hepatitis C virus (6, 27, 28), tuberculosis (29), malaria (30), and Ebola 
virus (31, 32), amongst others.  
In an early phase human trial of a candidate malaria vaccine using an Ad vector prime 
followed by a poxvirus vector boost, there was a significant delay in parasitaemia when 
volunteers were challenged with a heterologous malaria strain (30). This delay in morbidity was 
strongly correlated with the magnitude of the malaria-specific IFN-γ+ CD8+ T cell response. In a 
non-human primate model, Ad vectors expressing Ebola antigens elicited CD8+ T cell responses 
that were strongly correlated with protection from lethal Ebola virus infection (31), and 
utilization of an Ad-poxvirus prime-boost regimen induced durable CD8+ T cell-mediated 
protection (32). These data demonstrate that Ad vector-elicited T cell responses can be protective 
in multiple diseases, both in pre-clinical and clinical studies. 
Additional human clinical trials have demonstrated that Ad vector-based regimens induce 
robust immune responses against hepatitis C virus (HCV), Mycobacterium tuberculosis (Mtb), 
and respiratory syncytial virus (RSV) antigens. Two phase I human trials of Ad vectors for HCV, 
alone or combined with a poxvirus boost, have demonstrated substantial induction of HCV-
specific CD4+ and CD8+ T cell responses (27, 28), and in non-human primates T cell responses 
are critical for viral control (33, 34). Ad vectors are also being actively investigated in the 
context of Mtb infection as a boosting vector for Bacille Calmette-Guerin (BCG)-primed humans 
(29). Such an approach has displayed protective efficacy against pulmonary tuberculosis in 
multiple animal models (35-37). Moreover, Ad vectors are being developed against RSV, where 
they have demonstrated good safety profiles and induced robust T cell and antibody responses in 
a human phase I clinical trial (38). Further studies are required to determine if these vaccine 
regimens prove efficacious against these diseases, but the immunogenicity data are promising. 
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Adenovirus vectors have been most extensively studied in the development of an HIV 
vaccine. In non-human primate challenge studies, adenovirus serotype 26 (Ad26) vector-elicited 
T cell responses correlated with reduced viral loads and increased survival after infection with a 
heterologous, pathogenic strain of SIV (39, 40). More recently, Ad26 vector-based immunization 
regimens have been shown to elicit antibody responses, which can partially protect non-human 
primates from viral infection upon challenge with a difficult-to-neutralize strain of SIV or SHIV 
(simian/human immunodeficiency virus chimera) (40-42). Vaccine regimens based on these data 
have entered human clinical testing (25, 26). To date, some of the most promising pre-clinical 
HIV vaccine results have involved Ad vector-based vaccine regimens. 
Unfortunately, efficacy trials in humans of a candidate adenovirus serotype 5 (Ad5)-
based HIV-1 vaccine failed to demonstrate vaccine-induced protection (43-45). The first reported 
failures were in the related Merck STEP and Phambili trials (43, 45), and the second was 
HVTN505 (44). Two key factors likely contributed to the failure of these trials: 1) the specific 
vaccine regimen utilized, and 2) the choice of transgene antigens. Both trials utilized an Ad5-
derived vector, and it is now appreciated that a large fraction of the global population has high 
Ad5-specific neutralizing antibody responses (46). In animal models, high titers of vector-
specific antibodies dampen vaccine-elicited immunity (47). This concept is discussed in more 
detail in a following section. Additionally, the specific vaccine regimens likely also contributed. 
The STEP and Phambili trials utilized a homologous Ad5 prime-boost regimen, and we now 
appreciate that homologous prime-boost regimens are less immunogenic, and show reduced 
efficacy in non-human primate models than heterologous prime-boost regimens (39). The 
HVTN505 study utilized a DNA prime-Ad5 vector boost regimen, but in non-human primate 
models this immunization regimen fails to induce immunity that protects animals from viral 
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challenge with a difficult-to-neutralize virus strain, and only partially protects against an easy-to-
neutralize virus strain (48). These data suggest that the immune responses elicited by the 
HVTN505 vaccine protocol may have been of insufficient magnitude and/or functionality to 
protect from infection. Finally, the choice of vector insert(s) is critical to the successful 
development of an HIV vaccine given the huge global genetic diversity of the virus (49), and 
selection of optimal transgene antigens is an ongoing area of research (50-52). Despite these 
discouraging setbacks, revised and improved Ad vector-based vaccine strategies continue to 
show promise as candidate vaccine regimens against HIV as well as an array of other diseases of 
considerable importance to global health. 
 
Adenoviral vectors as tools for studying fundamental immunology 
Replication-incompetent viral vectors are useful tools for investigating immune regulatory 
pathways due to their unique biology. Viral and bacterial infections either induce brief immune 
activation and brief antigen expression (acute infections) or prolonged immune activation and 
prolonged antigen expression (chronic infections) (53, 54). By contrast, replication-incompetent 
Ad vectors induce transient innate immune activation (55), with serum cytokine levels returning 
to baseline by day 3 post-immunization. However, transgene expression can be detected iv vivo 
for many weeks post-immunization (56-58). Both the degree of innate immune activation and the 
duration and amount of antigen have strong influences on the resultant CD8+ T cell responses 
(59, 60). Thus, investigating how T cell responses are regulated following Ad vector 
immunization can provide fundamental insight into how the immune system responds to a 
unique means of activation. 
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ADENOVIRAL VECTOR-INDUCED IMMUNE RESPONSES: T CELLS 
CD4+ T cell responses 
CD4+ T cells recognize peptide antigen presented in the context of MHC class II, and were 
initially described as “T helper” cells due to their ability to provide critical positive signals that 
orchestrate effector functions of other innate and adaptive cell types (61). One of the key 
functions of CD4+ T cells is to provide positive helper signals to CD8+ T cells and B cells. 
Mechanisms of how CD4+ T cells provide help to CD8+ T cells is discussed below, and the 
mechanisms of CD4+ T cell help to B cells is discussed in the section on antibody responses. 
Data presented in this thesis demonstrate that help to CD8+ T cells and B cells by CD4+ T cells is 
critical following Ad vector immunization. The current understanding of Ad vector-elicited 
CD4+ T cell responses is reviewed below, with a specific focus on gaps in knowledge. 
CD4+ T cells are a highly plastic cell population, which is capable of differentiating into 
multiple subsets expressing different transcriptional programs, and producing a diverse array of 
cytokines depending on the stimulating environment (62). Historically, several subsets of T 
helper (TH) cells have been identified, including: TH1 cells that provide antiviral immunity, TH2 
cells that are involved in parasite immunity and allergy, TH17 cells that are involved in 
inflammatory responses and autoimmune diseases, TFH cells that are specialized to provide help 
to B cells, and Tregs that are a suppressor cell population and limit self-reactive immune 
responses (63-67). Additional TH cell subsets with new functions are being identified with some 
regularity (68-71). However, studies have demonstrated that in vivo these differentiation states 
are not terminal, and that CD4+ T cells can interconvert between these states depending on the 
stimulus, or can express characteristics of multiple TH lineages simultaneously (72, 73). CD4+ T 
cells display a complex biology, which can even be highly immunopathogenic (74). Thus, a 
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more complete understanding of their regulation and function can enhance rational vaccine 
design. 
 Despite their critical role in regulating innate and adaptive immune responses, relatively 
little is known about Ad vector-elicited CD4+ T cell responses. It has been demonstrated that 
following intramuscular immunization of mice and rhesus monkeys, Ad vectors induce robust 
poly-functional TH1 type CD4+ T cell responses, as characterized by the production of IFN-γ, 
TNF-α, and IL-2 (39, 47, 75). In a mouse model of Leishmania major infection, the frequency of 
these poly-functional vaccine-elicited CD4+ T cells was inversely correlated with lesion size (75), 
which demonstrates the protective capacity of Ad vector-elicited CD4+ T cells in pertinent 
disease models. Thus, Ad vector vaccination can elicit functional TH1 CD4+ T cell responses. 
Ad vectors can also elicit CD4+ T cell responses that appear to exhibit an immune-
modulatory phenotype. It has been reported that increasing the immunizing dose of an Ad5 
vector from 107 vp to 1010 vp actually decreases the TH1 poly-functionality of the resultant CD4+ 
T cell response, and instead induces a CD4+ T cell population that produces large amounts of the 
immunosuppressive cytokine IL-10 (76). Additionally, the high-dose vaccine was actually less 
effective than the low-dose vaccine at eliciting protection from L. major infection, although this 
effect was not attributable to IL-10 production. Mechanistically, the signals that regulate the 
induction of poly-functional CD4+ T cell responses versus IL-10-producing less-functional CD4+ 
T cell responses following Ad vector immunization remain to be determined. Furthermore, 
whether decreased Ad vector vaccine efficacy with increased vaccine dose is a generalizable 
characteristic of Ad vectors, or a unique trait of Ad5-derived vectors, remains to be determined. 
Substantial additional work is required to more completely understand the induction of TH1-type 
CD4+ T cell responses by Ad vector vaccination. 
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 As discussed previously, Ad vector vaccination can also induce transgene-specific 
antibody responses (38, 41). The induction of antibody responses to the majority of antigens 
requires helper signals from CD4+ TFH cells (77). It has been previously demonstrated that the 
absence of CD4+ T cells impairs the development of Ad vector-specific neutralizing antibodies 
(22, 78). Given the requirement for CD4+ T cells in the induction of antibody responses it is 
logical to conclude that Ad vectors must induce TFH CD4+ T cells. However, to date, no studies 
have directly investigated the induction of TFH CD4+ T cells by Ad vector vaccination. The role 
of CD4+ T cell subsets in the regulation of antibody responses by Ad vector vaccination remains 
to be explored. In chapter 4 of this thesis I will discuss my findings with regards to CD4+ T cells 
and the regulation of Ad vector-induced antibody responses. 
 
CD8+ T cell responses 
Substantial work using prototypic intracellular pathogens has generated a rather complete model 
of how CD8+ T cell responses are primed and maintained following acute infection. However, 
given the unique biology of replication-incompetent Ad vectors, it is important to determine how 
accurately these models describe the processes that regulate Ad vector-elicited CD8+ T cell 
responses. This section will review the current knowledge of the regulation of Ad vector-elicited 
CD8+ T cell responses with a specific emphasis on current gaps in knowledge. Areas where this 
thesis provides novel insights are noted. 
 Following acute infection or immunization, CD8+ T cells undergo extensive proliferation 
and differentiation into several heterogeneous subsets of effector and memory cells (79). 
Complete priming of a CD8+ T cell requires three signals: 1) T cell receptor (TCR) engagement 
with cognate peptide antigen presented in the context of MHC class I, 2) ligation of co-
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stimulatory receptors, and 3) provision of stimulatory cytokines (80). These three signals can 
simultaneously impact proliferation of responding CD8+ T cells, their phenotype, and function 
(81-85). Thus, when investigating the pathways that regulate Ad vector-elicited CD8+ T cell 
responses, the impact of a given pathway on both accumulation of antigen-specific cells and their 
phenotype/function must be considered. 
In mice, effector and memory CD8+ T cells can be differentiated through the expression 
of the cell surface proteins KLRG1 and CD127 (IL-7Rα). KLRG1hiCD127lo expressing cells are 
termed “terminal effector” and exhibit strong cytotoxic potential, but minimal secondary 
proliferative potential. KLRG1loCD127hi expressing cells are “memory precursors” that are 
capable of long-term survival (59, 79, 86-88). Memory precursor cells can be further subdivided 
into CD62L-CCR7- effector memory (TEM) cells, which have the ability to enter non-lymphoid 
tissues but have minimal secondary proliferative capacity, and CD62L+CCR7+ central memory 
(TCM) cells, which localize within lymphoid tissues and have the greatest proliferative capacity 
upon secondary antigen exposure (89). Differentiation into effector or memory precursor cells is 
regulated by the interaction of multiple transcription factors, such as T-box family proteins, Foxo 
family proteins, Batf, and TCF-1, and transcriptional repressors, such as Id family proteins and 
Blimp-1 (90-98). Recent analyses using multi-dimensional cytometry by time-of-flight (CyTOF) 
has demonstrated that subdividing CD8+ T cells into just these few cell states is an over-
simplification, and that in reality a huge number of unique T cell subsets can be identified (99). 
However, the simplified segregation of CD8+ T cells into effector (KLRG1hiCD127lo), effector 
memory (CD127hiCD62L+), and central memory (CD127hiCD62L+) remains experimentally 
useful. 
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In experimental models of acute viral infection, upon antigen exposure the majority of 
CD8+ T cells differentiate into highly cytotoxic effector cells with a KLRG1hiCD127lo phenotype. 
However, upon antigen clearance, KLRG1hi CD8+ T cells die and the CD127hi CD8+ T cells 
preferentially survive (88). Over time these surviving cells upregulate CD62L expression, and 
this coincides with the ability of these cells to produce IL-2 and thereby become fully-functional 
TCM cells (89). However, following Ad vector immunization a substantial portion of Ag-specific 
CD8+ T cells do not upregulate CD127 (100-103), and this defect in CD127 upregulation is 
especially pronounced in Ad5-induced responses compared to other serotype vectors (Ad26, 
Ad28, and Ad35). Regardless of vector serotype used, upregulation of CD62L and capacity to 
produce IL-2 are relatively low compared to what is observed following acute viral infection (57, 
100-103). Given these unusual phenotypic and functional characteristics, Ad vector-elicited 
CD8+ T cell responses represent ideal tools for the identification of novel mechanisms of 
immune regulation. The pathways that regulate differentiation of Ad vector-elicited CD8+ T cells 
into functional effector cells are unknown, and the mechanisms underlying the atypical memory 
differentiation are only beginning to be elucidated (discussed below). The data presented in 
chapters 2 and 3 of this thesis provide compelling evidence that CD4+ T cells are critical 
regulators of CD8+ T cell effector differentiation. 
Data from several studies have begun to unravel the mechanisms underlying the non-
canonical memory characteristics of Ad vector-elicited CD8+ T cell responses. Ad vector 
induced type I interferons are necessary for promoting memory differentiation of CD8+ T cells 
and for the acquisition of increased poly-functional cytokine production capacity (103), and the 
lack of type I interferons induced by Ad5 (55, 103) likely partially explains the severe 
impairment in poly-functional CD8+ T cell responses elicited by this vector. Prolonged transgene 
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expression impairs differentiation of Ad5-induced CD8+ T cell responses towards a 
CD127hiCD62L+ phenotype (57). Additional work is required to more completely identify the 
pathways that regulate the phenotype and function of Ad vector-elicited CD8+ T cell responses. 
 The induction of CD8+ T cell responses requires priming by CD11c+ dendritic cells 
(DCs) (104), and the coordinated action of multiple subsets of these professional antigen 
presenting cells (APCs) is required for optimal priming (105, 106). Consistent with this, 
following Ad vector immunization, CD11c+ DCs present antigen, and only this subset induces 
proliferation of naïve CD8+ T cells in vitro (107). In this study, the CD8+ lymphoid DC subset 
was the most efficient at inducing CD8+ T cell proliferation in vitro. Batf3-/- mice lack the CD8+ 
CD11c+ subset (108), and these mice have severely impaired CD8+ T cell responses following 
Ad vector immunization (109, 110). CD8+ DCs have the greatest ability to present extracellular 
antigens in the context of MHC class I (termed cross-presentation) (108), and the importance of 
this DC subset in priming Ad vector-elicited CD8+ T cell responses suggests that direct 
transduction of dendritic cells in vivo by Ad vectors is not the major mechanism of T cell 
priming. Collectively, these studies suggest that cross-presentation of Ad vector-derived 
transgene products by CD8+ DCs appears to be a critical for priming CD8+ T cell responses. 
Intriguingly, one report has demonstrated that transgene-specific CD8+ T cell responses 
can develop following Ad vector immunization of mice that lack MHC class I expression on 
hematopoietic origin cells (111). In this study, B6 mice were irradiated, reconstituted with Kb-/- 
or Kb-/-Db-/- bone marrow, and immunized with an Ad5 vector expressing SIINFEKL [Kb-
restricted epitope of chicken ovalbumin (OVA)] or GP33 [Db-restricted epitope of lymphocytic 
choriomenengitis virus (LCMV)]. The resultant antigen-specific CD8+ T cell responses exhibited 
delayed expansion and a reduced effector function and phenotype, but CD8+ T cell responses 
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were functional enough to control SIINFEKL-bearing tumors or LCMV infection significantly 
better than unimmunized controls. Using a “tetracycline-OFF” vector, it has also been reported 
that prolonged transgene-expression for between 30 an 60 days is required for the normal 
accumulation and differentiation of Ad vector-induced CD8+ T cell responses (57). Silencing of 
transgene expression prior to day 30 significantly reduced the magnitude of the Ag-specific 
CD8+ T cell response, and the responding cells produced less of the effector cytokine TNF-α and 
expressed a more memory phenotype with elevated expression of CD127 and CD62L. Together, 
these studies suggest a model where CD8+ DCs are the primary cells for priming robust Ad 
vector-elicited CD8+ T cell responses, but that long-term antigen presentation on non-
hematopoietic cells also plays an important role in the maintenance and effector differentiation 
of these responses. 
In addition to TCR engagement CD8+ T cells require supplemental signals through co-
stimulatory receptors (signal 2) (112). These receptors are comprised of immunoglobulin (Ig) 
superfamily proteins, such as CD28, and tumor necrosis factor receptors (TNFR) superfamily 
proteins, such as CD70, OX-40, and 4-1BB. All of these receptors bind to ligands that are 
membrane-bound proteins, and thus direct cell-cell contact is required for signal 2 to be 
transmitted to T cells. The most well-studied co-stimulatory signaling pathway is CD80/CD86 
expressed on APCs interacting with CD28 expressed on T cells (113). CD80 and CD86 double-
knockout mice immunized with Ad vectors have undetectable Ag-specific CD8+ T cells at the 
time of peak-immunogenicity (110). Absence of CD28 also dramatically impairs Ag-specific 
CD8+ T cell responses, but not to the equivalent degree as in the CD80/CD86 deficient mice 
(110). Intriguingly, in CD28 deficient mice, T cell responses of equal magnitude to those 
observed in wild type animals ultimately developed by day 60 post-immunization, but these cells 
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exhibit long-term functional defects in cytokine production, anamnestic potential, and the ability 
to control viral infections. Thus, signals via the CD80/CD86 pathway are critical for the 
accumulation and development of functional Ad vector-elicited CD8+ T cells. 
Signaling via TNFR family proteins is also important for the development of functional 
Ad vector-elicited CD8+ T cell responses, but the data are less conclusive. Blockade of CD70 
(the ligand for CD27) prior to intravenous Ad vector immunization reduces the magnitude of Ag-
specific CD8+ T cell responses by ~50% (114). However, CD8+ T cell responses were only 
assessed at a single time point post-immunization and functional analysis was not performed. 
Furthermore, it remains to be determined if CD8+ T cell responses elicited by intravenous versus 
the standard intramuscular immunization regimen are regulated equivalently. One study found no 
perturbation in the frequency of Ag-specific CD8+ T cells following Ad vector immunization of 
OX-40 KO mice, with no assessment of phenotype or functionality (110). However, an earlier 
study found that specific absence of OX-40 expression on CD8+ T cells results in decreased 
proliferation, cytotoxic capacity, cytokine production, and anamnestic potential (115). The 
reason for these discrepancies remains to be determined. This same study also determined that 
cell-intrinsic signaling via 4-1BB on CD8+ T cells actually restrains responses following Ad 
vector immunization, as deletion of 4-1BB increases the magnitude of the response, cytokine and 
cytotoxic capacity, and increases anamnestic potential (115). Thus, TNF family receptors appear 
to play critical roles in modulating Ad vector-elicited CD8+ T cell responses, but substantial 
further work is required in this area to clarify the role of this family of receptors. 
 The final set of signals required for optimal priming of CD8+ T cells are stimulatory 
cytokines (signal 3). The first described and most extensively studied of these signal 3 cytokines 
are IL-12 and type I interferons (116-118). More recently, IL-21 has also been shown to have 
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“signal 3” properties (119). With regards to Ad vector immunization, type I interferons have an 
anti-proliferative effect on Ad28- and Ad35-induced CD8+ T cell responses when the dose of 
vector is low (5x107 viral particles), but have no impact on CD8+ T cell responses following the 
standard 1x109 viral particle dose (103). Absence of type I interferon signaling has no impact on 
CD8+ T cell responses induced by low or high dose Ad5 immunization. A role for IL-12 in 
modulating Ad vector-elicited responses has not been directly tested, but serological analysis of 
rhesus monkeys immunized with several different serotype Ad vectors observed no IL-12 
induction (55). Although not conclusive, these data suggest that IL-12 does not play a major role 
in regulating CD8+ T cell responses following Ad vector vaccination. IL-21R KO mice exhibit 
modest defects in the frequency of antigen-specific CD8+ T cells following primary 
immunization and these cells exhibit major defects in anamnestic potential, but no perturbation 
in primary phenotype or cytokine producing potential are observed (120). Thus, of the three 
well-characterized signal 3 cytokines, IL-21 appears the most important in the context of Ad 
vector vaccination, but even this cytokine appears to have only a minor role in regulating the 
frequency of Ad vector-elicited CD8+ T cells. Thus, more work is required to understand the 
pathways that regulate the proliferation CD8 T cell responses induced by Ad vector 
immunization. In chapter 2 and 3, I will present data that CD4+ T cells regulate CD8+ T cell 
proliferation, and this help may replace the need for signal 3 cytokines for these responses. 
In experimental systems other than Ad vector immunization, differentiation to cytotoxic 
and cytokine producing effector cells does not occur when signal 3 cytokine signaling is 
inhibited. However, with regards to Ad vector immunization, no studies have comprehensively 
defined the signals that regulate effector function of Ad vector-elicited CD8+ T cell responses. In 
this thesis I will present compelling data that CD4+ T cell-derived signals are critical for CD8+ T 
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cell effector differentiation following Ad vector vaccination, and that CD4+ T cells are key 
regulators of vaccine-induced CD8+ T cell responses. A summary of the literature with regards to 
CD4+ T cell help to CD8+ T cells follows. 
 
CD4+ T cell help to CD8+ T cell responses 
A key regulator of CD8+ T cell responses is CD4+ T cells, as their absences leads to proliferative 
and functional defects (121-130). Interestingly, the importance of CD4+ T cell help and the 
pathways involved varies greatly based on the specific experimental system (131). In several 
well-studied infection models CD8+ T cells display unimpaired expansion in the absence of 
CD4+ T cells (132-134). In contrast, CD4+ T cell help mediated by CD40 signaling is required 
for the development of primary CD8+ T cell responses following exposure to antigens that 
induce weak innate inflammatory responses (122, 135, 136). CD4+ T cells also play a critical 
role in reducing CD8+ T cell exhaustion following chronic infection (137, 138). Thus, while 
CD4+ T cell help is critical in many settings to promote and maintain functional CD8+ T cell 
responses, this help can be highly context dependent. The helper function of CD4+ T cells 
following immunization with viral vector vaccines remains poorly defined. 
 The optimal expansion of an Ad vector-elicited primary CD8+ T cell response requires 
CD4+ T cell help. CD4+ T cell help is required for induction of transgene-specific CD8+ T cell 
responses (139, 140). Viral vector-specific CD8+ T cell responses also develop following 
immunization, and these responses are sufficient to clear transduced cells (141). The clearance of 
transduced cells requires CD4+ T cells (21), and therefore, it appears that vector-specific CD8+ T 
cell responses also require CD4+ T cell help. Given the requirement for CD4+ T cell help for 
primary expansion of CD8+ T cell responses, Ad vectors appear to behave like other “less 
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inflammatory” infection/immunization systems (mentioned above). Consistent with this, 
antagonism of the CD40 signaling pathway (by antibody or gene knockout) impairs the 
development of vector-specific CD8+ T cell responses (136, 142-144). As absence of CD4+ T 
cells and absence of signaling via the CD40 pathway induce the same phenotype, and as ligation 
of CD40 can replace the need for CD4+ T cells in other systems (128-130), it is presumed that 
this also reflects a mechanism of CD4+ T cell help in the context of Ad vector immunization. In 
summary, CD4+ T cell help is required for the robust induction of CD8+ T cell responses by Ad 
vector vaccination. 
 Despite a clear role for CD4+ T cells in regulating Ad vector-elicited CD8+ T cell 
responses, many unknowns remain. In other low-inflammation experimental systems where 
CD4+ T cell help is required for priming of CD8+ T cell responses, CD4+ T cell-derived IL-2 has 
also been implicated as a critical mechanism (122). The role of IL-2 in regulating Ad vector-
elicited CD8+ T cell responses has not been assessed. While CD40L expression and production 
of IL-2 by CD4+ T cells are the two best described mechanisms of CD4+ T cell help, CD4+ T 
cells can produce a large array of cytokines and express several other cell surface ligands that 
can induce DC maturation (145-147). IL-21, a cytokine produced by CD4+ T cells, has been 
shown to be important in maintaining CD8+ T cell frequency and functionality during chronic 
viral infection (148-150), and absence of IL-21 impairs primary frequency and anamnestic 
potential of Ad vector-elicited CD8+ T cell responses (120), as mentioned above. However, the 
impact on the frequency of primary CD8+ T cell responses is modest compared to the major 
defects seen in the absence of CD4+ T cell, and therefore suggests other CD4+ T cell-derived 
signals are also required. If consideration of other CD4+ T cell-derived cytokines is restricted to 
just the canonical TH1 cytokines of IFN-γ, TNF-α, and IL-2, then a paucity of data exists 
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regarding the role of CD4+ T cell-derived IFN-γ and TNF-α in regulating CD8+ T cell responses, 
despite strong data that these two cytokines have important impacts on CD8+ T cell function 
(151, 152). Furthermore, a role for CD4+ T cells in regulating CD8+ T cell effector 
differentiation following priming with a low-inflammation immunization/infection, such as Ad 
vectors, has not been described. Following LCMV infection, CD4+ T cells restrain effector 
differentiation (124), but if such a role exists for CD4+ T cells in the context of Ad vector 
immunization remains unknown. Despite the initial direct in vivo observation that CD4+ T cells 
can regulate CD8+ T cell responses being made over 30 years ago (153), our understanding of 
how CD4+ T cells provide help to CD8+ T cells remains incomplete. The data presented in this 
thesis will substantially enhance our understanding of how CD4+ T cells promote primary Ad 
vector-elicited CD8+ T cell responses, and will for the first time demonstrate a critical role for 
CD4+ T cells in the acquisition of cytotoxic effector function by CD8+ T cells. 
 
ADENOVIRAL VECTOR-INDUCED IMMUNE RESPONSES: ANTIBODIES 
There is growing interest in the use of Ad vectors as vaccine platforms for the induction of 
antibody responses. However, an understanding of the processes that control these responses is 
lacking. This section will review the current knowledge of antibodies elicited by Ad vector 
immunization, and identify areas where the data presented in this thesis provide novel insights. 
 
Fundamentals of Ad vector-elicited antibody responses 
Ad vectors elicit two types of antibody responses: 1) transgene-specific antibodies, and 2) 
vector-specific neutralizing antibodies. In the context of HIV vaccine development it has 
recently been demonstrated that Ad vectors can elicit robust transgene-specific antibody 
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responses (40-42). In these studies, Ad vector prime followed by either heterologous Ad vector 
boost, poxvirus boost, or recombinant protein boost induces antibody responses that were 
capable of partially protecting non-human primates from a heterologous difficult-to-neutralize 
SIV or SHIV (simian/human immunodeficiency virus) viral challenge. Additionally, a recent 
phase I trial of a candidate Ad vector-based respiratory syncytial virus (RSV) vaccine elicited 
robust RSV-specific antibody responses in human volunteers (38). However, data is lacking with 
regards to fundamental knowledge of how Ad vector-elicited transgene-specific antibody 
responses are regulated, and substantial work is required in this area. 
In contrast to the scarce data regarding transgene-specific antibodies, there has been more 
research into understanding vector-specific antibody responses. Vector-specific neutralizing 
antibodies are a major impediment to effective use of Ad vectors as gene therapy or vaccine 
platforms. Pre-existing vector-specific immunity dramatically reduces the efficiency of transgene 
delivery upon vector administration (22), and thereby reduces the potency of vaccine-elicited T 
cell responses (154-156). Vector-specific neutralizing antibodies can be present in an individual 
due to either pre-existing immunity by prior natural exposure to a given serotype adenovirus, or 
by immunization with an Ad vector of a given serotype. As a cogent example, in a phase IIb/III 
clinical trial of a candidate Ad serotype 5 (Ad5) vector-based HIV vaccine, high titer baseline 
Ad5-specific immunity was found to significantly reduce the immunogenicity of the candidate 
vaccine (43). Thus, vector-specific immunity is a major technical hurdle for the utilization of Ad 
vectors as vaccine platforms. 
To circumvent the issue of pre-existing immunity two related strategies have been 
employed: 1) development of novel Ad vectors derived from adenoviruses with low sero-
prevalence, and 2) modification of viral vectors of high sero-prevalence origin to express 
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neutralization determinants of low sero-prevalence virus types. In all three phase IIb/III HIV-I 
clinical trials utilizing Ad vectors, Ad5 vectors were utilized (43-45), and Ad5 vectors have been 
the most extensively studied. However, sero-prevalence analysis from sub-Saharan Africa has 
identified Ad5-specific neutralizing antibody titers of >1000 in between 43% and 50% of 
individuals (5, 15, 24). Thus, alternative serotype Ad vectors, of both human and non-human 
primate origin, have been developed (5, 6, 15, 24). These vectors display virus-specific titers 
>1000 in 35% of individuals for the most sero-prevalent vector, Ad28, down to 0% of 
individuals for multiple of the non-human primate-derived vectors. Most importantly, these 
alternate serotype vectors exhibit no reduction in immunogenicity in animals with high titers of 
Ad5-specific neutralizing antibodies (15, 157). Thus, development of novel, alternate serotype 
Ad vectors represents a promising avenue to circumvent pre-existing immunity. 
An alternate approach is to modify the Ad5-derived vector to circumvent pre-existing 
immunity. The major neutralization determinant of adenovirus vectors is the seven hyper-
variable regions (HVR) (1-7) of the hexon surface protein of the virus capsid (158, 159). A 
chimeric Ad5HVR48(1-7) virus vector, where the Ad5 HVRs are replaced with the HVRs from 
the serologically distinct Ad48 virus, bypasses pre-existing Ad5-specific neutralizing antibodies. 
This chimeric vector can elicit robust immune responses in mice and non-human primates with 
pre-existing Ad5 immunity (159). However, a potential limitation of such an approach is that 
only specific backbone-HVR chimeras result in viable viral vectors (160). Thus, Ad vectors can 
be specifically engineered to reduce issues of pre-existing vector-specific immunity. 
In summary, Ad vector vaccination can elicit both desirable transgene-specific antibody 
responses, the goal of vaccination, and undesirable vector-specific neutralizing antibody 
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responses, which can reduce vaccine immunogenicity and prevent the use of homologous prime-
boost regimens. 
 
Regulation of Ad vector-elicited antibody responses by CD4+ T cells 
Understanding how Ad vector-elicited transgene-specific and vector-specific antibody responses 
may provide novel insights into antibody biology, and thereby improve vaccine design. As 
induction of transgene-specific antibody responses are the goal of vaccination, insights into the 
regulation of these responses is of particular interest. Unfortunately, the regulation of these 
responses remains poorly described, and studies in this area are sorely needed. 
 Thankfully, there are substantial data on how vector-specific antibody responses are 
regulated. One of the key regulators of antibody responses are CD4+ T cells, and absence of 
these cells at the time of antigen-exposure results in tolerance towards the antigen (161-163). 
The development of an antibody response is a complex multi-step process that involves the 
formation of a B cell germinal center, a dynamic physical structure within the secondary 
lymphoid tissue (164). The germinal center is where B cells undergo affinity maturation by AID-
mediated somatic hyper-mutation and class-switch recombination (165, 166). The formation and 
maintenance of germinal centers is absolutely dependent on CD4+ TFH cells (64). Consistent with 
this model, the development of vector-specific neutralizing antibodies is dependent on the 
presence of CD4+ T cells (22, 78). TFH cells provide help to B cells by cell surface bound ligand-
receptor interactions, as well as through soluble cytokines (77). One of the major signaling 
pathways in this process is ligation of CD40 expressed on B cells by CD40L expressed on CD4+ 
T cells (167, 168). The CD40 signaling pathway is required for the development of vector-
specific antibody responses upon Ad vector administration (136, 144, 169, 170). However, as 
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CD4+ T cell regulation of antibody responses requires many more signals than just CD40, 
substantial work remains to generate a complete picture of the pathways involved in the 
induction of vector-specific antibody immunity. 
 Despite growing interest in the use of Ad vectors as priming platforms for the induction 
of vaccine-induced antibody responses, relatively little is known regarding the regulation of 
these responses. With respect to vector-specific neutralizing antibodies, prior studies suggest that 
the same processes described in other experimental systems regulate these responses. However, 
the degree to which this is accurate with regards to specific signaling pathways remains to be 
determined. Furthermore, extensive work is required to understand, even in the broadest terms, 
how transgene-specific antibody responses are regulated. Chapter 4 of this thesis describes the 
role of CD4+ T cells in regulating Ad vector-induced transgene-specific antibody responses, and 
by doing so identifies novel parameters for CD4+ T cell regulation of antibody responses.  
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ABSTRACT 
Despite the widespread use of replication-incompetent recombinant adenovirus (Ad) vectors as 
candidate vaccine platforms, the mechanism by which these vectors elicit CD8+ T cell responses 
remains poorly understood. Our data demonstrate that induction and maintenance of CD8+ T cell 
responses by Ad vector immunization is longitudinally dependent on CD4+ T cell help for a 
prolonged period of time. Depletion of CD4+ T cells in wild type mice within the first eight days 
following Ad immunization resulted in dramatically reduced induction of antigen-specific CD8+ 
T cells, decreased T-bet and Eomesodermin expression, impaired KLRG1+ effector 
differentiation, and atypical expression of the memory markers CD127, CD27, and CD62L. 
Moreover, these CD8+ T cells failed to protect against a lethal recombinant Listeria 
monocytogenes challenge. Depletion of CD4+ T cells between week 1 and week 4 following 
immunization resulted in increased contraction of memory CD8+ T cells. These data demonstrate 
a prolonged temporal requirement for CD4+ T cell help for vaccine-elicited CD8+ T cell 
responses in mice. These findings have important implications in the design of vaccines aimed at 
eliciting CD8+ T cell responses and may provide insight into the impaired immunogenicity of 
vaccines in the context of AIDS and other CD4+ T cell immune deficiencies.
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INTRODUCTION 
Adenovirus vectors have garnered significant attention as candidate vaccine platforms due to 
their large transgene coding capacity and potent immunogenicity. Ad vector-based vaccines are 
being pursued for a number of viral infections, including ebola (1), influenza (2), hepatitis C (3, 
4), rabies (5) and HIV-1 (6). Recently we have evaluated an Ad26 vector-based vaccine for HIV-
1 in clinical trials (7, 8), and preclinical studies with Ad26-based vaccine regimens in non-human 
primates resulted in partial protection against acquisition of infection as well as virologic control 
following SIVmac251 challenges (9-11). Virologic control correlated with vaccine-elicited SIV-
specific CD8+ T cell responses (9-12). However, relatively little is known about the CD4+ T cell 
requirement to generate CD8+ T cell memory responses following vaccination. 
Prior reports have evaluated Ad vectors as candidate vaccine and gene therapy platforms 
and have identified a role for CD8+ T cells in the clearance of transduced cells (13). Several 
follow-up studies have demonstrated prolonged transgene expression in the absence of CD4+ T 
cells at the time of vector administration, thus providing evidence that CD4+ T cells play an 
important role in priming the CD8+ T cell response following Ad vector administration (13-16). 
More recent studies have demonstrated that the frequency of antigen-specific CD8+ T cells was 
impaired in the absence of CD4+ T cells at the time of vector administration (17, 18). Lack of 
CD4+ T cells also resulted in primary CD8+ T cell responses of low magnitude and function in 
several disease and vaccination models (19-22). In contrast, in certain viral and bacterial 
infections, CD8+ T cell responses were induced in the absence of CD4+ T cells, although the 
long-term functional potential and maintenance were still impaired (23-30). CD4+ T cell help has 
also been reported to be required at the time of priming to elicit CD8+ T cell responses with 
normal recall potential upon secondary antigen exposure (31-33). These studies show the 
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requirement of CD4+ T cell help at the time of CD8+ T cell priming, but the temporal 
requirements of CD4+ T cell help for the generation of CD8+ T cell responses have not 
previously been determined. 
In the present study, we sought to determine the temporal requirements of CD4+ T cell 
help for the development, maintenance and functionality of memory CD8+ T cells induced by 
Ad26 (34) and Ad5HVR48 (35) vectors expressing SIV Gag, SIV Env, and LCMV GP antigens. 
We selected Ad26 and Ad5HVR48 vectors for detailed study as they are both currently being 
evaluated in phase I clinical trials as vaccine candidates. We found that CD4+ T cell help was 
required not only at the time of priming but also for eight days post-immunization to drive the 
induction and optimal effector differentiation of the primary CD8+ T cell response. Moreover, 
CD4+ T cell help was required for four weeks post-immunization for controlling the contraction 
of memory CD8+ T cells. 
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MATERIALS AND METHODS 
Mice, immunizations, and challenge. Six- to ten-week-old C57BL/6, B6.SJL-ptprca (CD45.1+), 
B6.129S2-Cd4tm1Mak/J (CD4 KO), B6.129S2-H2dlAb1-Ea/J (MHC II KO), B6.129S2-
Cd40lgtm1Imx/J (CD40L KO), and B6.129P2-Cd40tm1Kik/J (CD40 KO) animals were purchased 
from The Jackson Laboratory (Bar Harbor, ME). Mice were immunized with the previously 
described E1/E3 deleted Ad26, or Ad5HVR48(1-7) vectors expressing SIV Gag or SIV Env 
from the strain SIVmac239, or LCMV GP (11, 34-36). Mice were immunized i.m. in the quadriceps 
with 109 viral particles of each vector in a volume of 100µl divided equally between the two legs. 
For co-administration of SIV Gag and SIV Env expressing vectors the final injection volume of 
100µl was held constant. Mice were challenged with 1.75x105 to 2.5x105 cfu of recombinant 
Listeria monocytogenes expressing the LCMV epitope GP33-41 (Lm-GP33) by i.v. injection (a 
kind gift of Dr. Hao Shen)(37). Precise dose was back calculated following each experiment by 
plating on BHI-Agar plates, as previously described (38). All animal experiments were in 
accordance with Beth Israel Deaconess Medical Center Institutional Animal Care and Use 
Committee guidelines. 
Monoclonal antibody administration. The monoclonal anti-CD4 antibody GK1.5 (BioXcell) 
was administered by two i.p. injections of 500µg in a 500µl volume on sequential days. One day 
after the second injection, blood was collected and CD4+ T cell depletion was confirmed (data 
not shown) by staining with the non-competing anti-CD4 antibody clone RM4-4 (BD 
Biosciences). 
Tissue processing and flow cytometry. Single cell suspensions of tissues were generated as 
previously described, with slight modification (39). Briefly, liver tissue was not treated with 
EDTA or collagenase. Peripheral blood mononuclear cells (PBMC) were isolated from whole 
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blood by Ficoll-Hypaque density centrifugation at 1900 rpm for 20 min. MHC class I tetramer 
staining was performed using an H-2Db tetramer loaded with the immunodominant AL11 peptide 
(AAVKNWMTQTL) or GP33-41 peptide (KAVYNFATM) as previously described (40). 
Biotinylated class I monomers were kindly provided by the NIH Tetramer Core Facility (Emory 
University, GA). Background staining of cells from naïve animals was ≤0.1%. Surface staining 
was performed with anti-CD8α (53-6.7), -CD4 (RM4-5), -CD44 (IM7), -CD127 (A7R34), -
CD62L (MEL-14), -KLRG1 (2F1), -CD122 (TM-β1), and -CD27 (LG.3A10). Transcription 
factor staining was performed by first permeabilizing the cells with the FoxP3 
Fixation/Permeabilization kit (eBioscience) and subsequently staining with anti-T-bet (4B10). 
Annexin V staining was performed using an Annexin V staining kit (BioLegend). All antibodies 
were purchased from BD Biosciences, eBioscience, or BioLegend. Vital exclusion dye was 
purchased from Invitrogen. After fixation, samples were acquired on an LSR II flow cytometer 
(BD Biosciences) and data was analyzed using FlowJo v9.3.3 (Treestar). 
Intracellular cytokine staining. Intracellular cytokine staining was performed as previously 
described with slight modification (41). Briefly, 2x106 splenocytes were re-stimulated for 1.5hrs 
at 37°C with 2µg/ml of AL11 peptide or 1µg/ml of an overlapping SIVmac239 Gag or SIVmac239 
Env peptide pool. At this time anti-CD28 (37.51), and -CD49d (R1-2) antibodies were added. 
After this incubation, Brefeldin A (BD Biosciences) was added and samples incubated for an 
additional 4.5hrs at 37°C. Cells were subsequently washed, stained with surface antibodies, 
permeabilized with Cytofix/Cytoperm (BD Biosciences) and stained with an anti-IFN-γ 
(XMG1.2) antibody. 
CFSE labeling and adoptive cell transfer. Splenocytes were processed as described above. 
CD8+ T cells were enriched by negative selection using the CD8a+ enrichment kit II following 
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the manufacturers instructions (>90% purity) (Miltenyi). CFSE labeling was performed as 
previously described (42). After labeling, 1.5x104 Db/AL11+ CD8+ T cells were transferred by i.v. 
injection into congenic marker differentiated naïve animals. For Figure 8, CFSE labeling was not 
performed and 5x104 Db/AL11+ CD8+ T cells were transferred; all other preparation steps were 
identical. 
RNA extraction, cDNA synthesis, and qPCR. Splenocytes were processed as described above. 
CD8+ T cells were enriched by negative selection using the CD8a+ enrichment kit II following 
the manufacturers instructions (>90% purity) (Miltenyi). Db/AL11+ CD8+ T cells were 
subsequently sorted to >95% purity on a FACS Aria (BD Biosciences). Cells were centrifuged at 
10,000rpm for 5 minutes and pellets were resuspended in 1ml of TRIzol (Invitrogen) and stored 
at -80°C for further processing. RNA extraction and cDNA synthesis were performed as 
previously described (43, 44). Briefly, RNA extraction was performed using the RNAdvance 
Tissue Isolation kit (Agencourt). cDNA synthesis was performed using the Ovation Pico WTA 
v2 kit (NuGEN) per the manufacturers instructions. Quantitative PCR was performed using the 
SYBR Green quantification system (QIAGEN). The following primers were used: Gapdh 
forward 5'- AGGTCGGTGTGAACGGATTTG -3' and reverse 5'- 
TGTAGACCATGTAGTTGAGGTCA -3' (45); Prdm1 forward 5’-
CACACAGGAGAGAAGCCACA-3’ and reverse 5'-TTGATTCGGGTCAGATCCTC-3' (46); 
Bcl6 forward 5’-CGCAACTCTGAAGAGCCACCTGCG-3’ and reverse 5’-
TTTGTGACGGAAATGCAGGTTA-3’ (47); Tbx21 forward 5'-
AGCAAGGACGGCGAATGTT-3’ and reverse 5'-GGGTGGACATATAAGCGGTTC-3' (48); 
Eomes forward 5'-TGAATGAACCTTCCAAGACTCAGA-3' and reverse 5'-
GGCTTGAGGCAAAGTGTTGACA-3' (49); Id2 forward 5’-
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ACCAGAGACCTGGACAGAAC-3’ and reverse 5’-AAGCTCAGAAGGGAATTCAG-3’ and 
Id3 forward 5’-GACTCTGGGACCCTCTCTC-3’ and reverse 5’-
ACCCAAGTTCAGTCCTTCTC-3’ (50); and Tcf7 forward 5’-
AGCTTTCTCCACTCTACGAACA-3’ and reverse 5’-AATCCAGAGAGATCGGGGGTC-3’ 
(51). Data were acquired on a StepOnePlus Real-Time PCR System (Applied Biosystems). Cycle 
conditions were: 95°C for 10min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. 
Gene expression was normalized across samples by Gapdh expression levels. 
Statistical analysis. Statistical analysis was performed using a two-tailed non-parametric Mann-
Whitney U test or Mantel-Cox test using Prism v6.0c (GraphPad Software Inc). In all cases the 
CD4+ T cell deficient animals or CD40/L knockout animals were compared to the wild 
type/untreated controls. 
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RESULTS 
CD4+ T cell help is required for the induction of CD8+ T cell responses following Ad vector 
immunization 
We initially assessed the requirement for CD4+ T cell help for the induction of primary CD8+ T 
cell responses following Ad26 vector immunization (34). C57BL/6, CD4 KO, or MHC class II 
KO mice were immunized intramuscularly with 109 vp of Ad26 expressing SIV Gag (Ad26-Gag). 
Following immunization, robust Gag-specific CD8+ T cell responses were detected in wild type 
animals by CD8+ T cells binding to the immunodominant Db-restricted AL11 peptide (Db/AL11) 
tetramer (40) (Fig. 2.1A and B). This response peaked at day 14 post-immunization and 
subsequently contracted, consistent with prior observations (34, 40). In contrast, in CD4+ T cell 
deficient animals (CD4 KO or MHC class II KO), the AL11 epitope-specific CD8+ T cell 
responses were largely abrogated (p<0.01; Fig. 2.1A and B). 
 To confirm that these observations were generalizable to multiple epitopes, C57BL/6, 
CD4 KO, and MHC class II KO animals were immunized with 109 vp each of Ad26 vectors 
expressing SIV Gag and SIV Env. Twenty-eight days post-immunization, splenocytes were 
harvested and IFN-γ production by CD8+ T cells was assessed by ex vivo re-stimulation with 
overlapping SIV Gag and SIV Env peptide pools. Gag- and Env-specific responses were detected 
in wild type animals by percentage of SIV-specific IFN-γ+ CD8+ T cells (Fig. 2.1C and D). The 
frequency of Gag- and Env-specific IFN-γ+ CD8+ T cells was significantly impaired in CD4 KO 
and MHC class II KO mice as compared to wild type animals (p<0.01; Fig. 2.1C and D). These 
data confirm that the defect seen in CD8+ T cell responses in the absence of CD4+ T cells by 
Db/AL11 tetramer binding was generalizable to multiple antigens.  
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 To confirm that our observations with Ad26-based vectors were generalizable to other Ad 
vector serotypes, C57BL/6, CD4 KO, and MHC class II KO animals were immunized with 109 
vp each of Ad5HVR48-Gag and Ad5HVR48-Env (11, 35). Concordant with the data generated 
following Ad26 immunization, the Gag- and Env-specific CD8+ IFN-γ+ T cell responses 
following Ad5HVR48 immunization were significantly impaired on day 28 post-immunization 
in CD4 KO and MHC II KO animals as compared to wild type animals (p<0.01; Fig. 2.1E). 
Collectively, these data demonstrate that the induction of primary CD8+ T cell responses 
following Ad vector immunization critically requires CD4+ T cell help at the time of priming. 
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Figure 2.1. CD4+ T cell help is required for the development of CD8+ T cell responses 
following intramuscular Ad vaccination. (A and B) C57BL/6, CD4 KO, or MHC class II KO 
mice were immunized i.m. with 109 vp of Ad26-Gag or were unimmunized (naïve C57BL/6). 
Animals were bled longitudinally and SIV Gag-specific CD8+ T cells were quantified by 
tetramer staining. Representative plots (A) and group averages (B) for Db/AL11+ cells as a 
percent of CD8+ T cells are shown. Data are from n=8/group (pooled from two independent 
experiments). (C and D) C57BL/6, CD4 KO, or MHC class II KO mice were co-immunized 
intramuscularly with 109 vp each of Ad26-Gag and Ad26-Env. Splenocytes were harvested on 
day 28 post-immunization and stimulated with the indicated peptide pool. Representative plots of 
IFN-γ+ CD8+ T cells (C) and group averages (D) are shown. Data are from n=8/group (pooled 
from two independent experiments). (E) C57BL/6, CD4 KO, or MHC class II KO mice were co-
immunized intramuscularly with 109 vp each of Ad5HVR48-Gag and Ad5HVR48-Env. 
Splenocytes were harvested on day 28 post-immunization and stimulated with the indicated 
peptide pool. Percent of IFN-γ+ cells as a fraction of CD8+ T cells are shown. Data are from 
n=8/group (pooled from two independent experiments). Mean ± SEM are shown; *, P<0.01. 
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Longitudinal interruption of CD4+ T cell help impairs the expansion and increases 
contraction of CD8+ T cell responses 
We next sought to determine for how long CD4+ T cell help was required post-immunization for 
the induction of CD8+ T cell responses. To accomplish this, CD4+ T cells were depleted by 
administration of the monoclonal anti-CD4 antibody GK1.5 on two consecutive days starting at 
various time points following immunization (52). Depletion of CD4+ T cells was begun prior to 
immunization (day -1) or on day 1 through 13 post-immunization (Fig. 2.2A). All mice were 
immunized intramuscularly with 109 vp of Ad26-Gag on day 0, and PBMC were evaluated 
longitudinally to assess Db/AL11+ CD8+ T cell responses. 
Db/AL11+ CD8+ T cell responses in the untreated group were detected on day 7 (data not 
shown), peaked on day 14, and contracted by day 28 (Fig. 2.2B, black bar). Depletion of CD4+ T 
cells prior to immunization completely ablated the Db/AL11+ CD8+ T cell response (Fig. 2.2B-D), 
consistent with the data from CD4 KO and MHC II KO animals in the previous experiment (Fig. 
2.1A). Administration of an isotype control antibody had no impact on CD4+ T cell frequency or 
the Db/AL11-specific CD8+ T cell response (data not shown). Depletion of CD4+ T cells starting 
on day 1 to day 8 post-immunization resulted in dramatically lower Db/AL11+ CD8+ T cell 
responses from day 14 onwards (P<0.05; Fig. 2.2B and C). Earlier depletion of CD4+ T cells led 
to more pronounced impairment of Db/AL11+ CD8+ T cell responses. Mice that were depleted of 
CD4+ T cells on or after day 9 exhibited initial CD8+ T cell response magnitudes that were 
comparable to untreated animals (Fig. 2.2B and C). These data suggest a critical requirement for 
CD4+ T cell help for the induction of CD8+ T cell responses for eight days following 
immunization. 
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We next examined Db/AL11+ CD8+ T cell responses in various tissues. Consistent with 
the data from peripheral blood, Db/AL11+ CD8+ T cell responses in both spleen and liver on day 
28 were also reduced in animals depleted of CD4+ T cells with similar kinetics (Fig. 2.2D). 
Moreover, the absolute number of functional AL11-specific IFN-γ+ CD8+ splenocytes on day 28 
by ICS assays was also reduced in animals depleted of CD4+ T cells as compared with untreated 
controls (Fig. 2.2E). 
We next asked whether CD4+ T cells were also important during the contraction phase of 
the CD8+ T cell responses. Animals depleted of CD4+ T cells beginning on day 9 to day 13 
exhibited equivalent initial Db/AL11+ CD8+ T cell magnitudes as compared to untreated controls 
(day 14). However, we observed greater contraction of the Gag-specific CD8+ T cell responses 
(p<0.001; Fig. 2.2B inset) in the mice depleted of CD4+ T cells on day 9-13 as compared to 
untreated controls, suggesting a requirement for longitudinal CD4+ T cell help for controlling the 
contraction of CD8+ T cell responses. 
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Figure 2.2. Temporal requirement for CD4+ T cell help for the induction and expansion of 
CD8+ T cell responses following Ad vaccination. (A) C57BL/6 mice were depleted of CD4+ T 
cells by i.p. administration of mAb GK1.5 (anti-CD4) beginning on day -1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, or 13 and immunized i.m. with 109 vp of Ad26-Gag on day 0. Untreated controls are 
designated by !. (B) Mice from each treatment group were bled at the indicated time points and 
AL11-specific CD8+ T cells were assessed by Db/AL11 staining. Inset, the fold-decrease in the 
number of AL11-specific CD8+ T cells in blood from day 14 to day 28 post-immunization is 
shown. Groups of mice administered with anti-CD4 beginning on day 9 to day 13 were pooled 
for analysis. (C and D) On day 28 post-immunization the total number of AL11 peptide-specific 
CD8+ T cells per 106 PBMC (C) or per tissue (D) were quantified by Db/AL11 staining. (E) On 
day 28 post-immunization the total number of AL11 peptide-specific CD8+ T cells was assessed 
by ex vivo re-stimulation with AL11 peptide followed by intracellular cytokine staining for IFN-
γ. Data are from n=7-22/group (pooled from two to six independent experiments). Mean ± SEM 
are shown; *, P<0.001. 
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Longitudinal interruption of CD4+ T cell help alters effector differentiation and survival of 
CD8+ T cells 
We next examined the phenotype of Db/AL11+ CD8+ T cells from mice that were depleted of 
CD4+ T cells on day 4 to day 13 post-immunization. Of note, depletion prior to day 4 resulted in 
insufficient antigen-specific CD8+ T cells for analysis. Terminal effector and memory precursor 
cells were differentiated by surface marker expression of KLRG1+ and CD127+, respectively, as 
previously reported (53-55). On day 28 post-immunization, the frequency of Db/AL11+ CD8+ T 
cells that were KLRG1+CD127- terminal effector cells was reduced in mice depleted of CD4+ T 
cells, with a corresponding increase in the frequency that were KLRG1-CD127+ memory 
precursor cells (p<0.05; Fig. 2.3A and B). The earlier CD4+ T cells were depleted, the lower the 
frequency of terminal effector cells and the greater the frequency of potential memory precursor 
cells. This trend was also observed in Db/AL11+ CD8+ T cells from the blood and liver (Fig. 
2.3C and D). No differences in the proportion of Db/AL11+ CD8+ T cells that were 
KLRG1+CD127+ or KLRG1-CD127- was observed between the groups (Fig. 2.3A). Depletion of 
CD4+ T cells after day 8 did not appear to impact these phenotypic markers. Overall, there was a 
decrease in the absolute number of both the KLRG1+CD127- and KLRG1-CD127+ populations 
of Db/AL11+ CD8+ T cells in the spleens of mice depleted of CD4+ T cells prior to day 8 (Fig. 
2.3E). Thus, the altered frequency of KLRG1+CD127- and KLRG1-CD127+ cells is not due to a 
specific survival defect of one subset, but instead may reflect altered differentiation of CD8+ T 
cells in mice depleted of CD4+ T cells post-immunization. 
Given the increase in the percentage of Db/AL11+ CD8+ T cells that were KLRG1-
CD127+ following CD4+ T cell depletion from day 4-7 post-immunization, we sought to  
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Figure 2.3. Effector differentiation of CD8+ T cells is dependent on CD4+ T cell help 
following Ad vaccination. C57BL/6 mice were depleted of CD4+ T cells by i.p. administration 
of mAb GK1.5 (anti-CD4) beginning on day 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or were left untreated 
(!), and were immunized i.m. with 109 vp of Ad26-Gag on day 0. On day 28 post-immunization, 
animals were sacrificed and tissues were harvested. KLRG1 and CD127 expression on Db/AL11+ 
CD8+ T cells was assessed. (A and B) Representative flow plots (A) and group averages (B) of 
KLRG1 and CD127 expression on Db/AL11+ CD8+ T cells in the spleen. (C and D) Group 
summary of KLRG1 and CD127 expression of Db/AL11+ CD8+ T cells in blood (C) and liver (D). 
(E) Absolute number of KLRG1+CD127- or KLRG1-CD127+ Db/AL11+ CD8+ T cells in the 
spleen. Anti-CD4 treatment on day -1, 1, 2, and 3 post-immunization had insufficient numbers of 
Db/AL11+ cells for analysis. Data are from n=8-16/group (pooled from two to four independent 
experiments), except for PBMC anti-CD4 day 9, 10, and 12 groups which are n=3-4/group (one 
experiment). Mean ± SEM are shown; *, P<0.05. 
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determine whether CD4+ T cell depletion also altered the expression of other memory-associated 
surface markers. Expression of CD62L and CD27 has been correlated with a long-term memory 
phenotype (39, 56). We examined the expression of these markers on Db/AL11+ CD8+ T cells 
from the spleen at day 28 post-immunization of untreated controls or animals that were depleted 
of CD4+ T cells on day 5 (reduced peak CD8+ T cell response and reduced terminal effector 
phenotype), day 8 (reduced peak CD8+ T cell response but normal terminal effector phenotype), 
or day 11 (normal peak CD8+ T cell response and normal terminal effector phenotype) post-
immunization. Depletion of CD4+ T cells on day 8 or 11 post-immunization progressively led to 
a significant reduction in CD27 expression on Db/AL11-specific CD8+ T cells (p<0.05; Fig. 
2.4A). Conversely, depletion of CD4+ T cells resulted in an increase in the fraction of Db/AL11+ 
CD8+ T cells that were CD62L+ as compared to the untreated controls (p<0.03; Fig. 2.4A), and 
earlier CD4+ T cell depletion resulted in higher CD62L expression. These data suggest that 
absence of CD4+ T cell help led to dysfunctional expression of memory-associated markers and 
not in fact accelerated conversion to memory precursor cells. 
To characterize further the impact of CD4+ T cell depletion on effector phenotypes, we 
investigated the expression of transcriptional regulators that drive CD8+ T cell effector 
differentiation. The transcription factors T-bet, Eomesodermin (Eomes), and T cell factor 1, as 
well as the transcriptional regulators Blimp-1, Bcl-6, Id2, and Id3 have reported roles in dictating 
effector versus memory differentiation of CD8+ T cells (49, 50, 57-63). On day 28 post-
immunization, we assessed the expression of these transcriptional regulators in sorted Db/AL11+ 
CD8+ T cells from the spleen of untreated controls, or in mice depleted of CD4+ T cells on day 5 
or day 8 post-immunization. We observed by qRT-PCR that Tbx21 (encodes T-bet) expression 
by Db/AL11+ CD8+ T cells from mice depleted of CD4+ T cells on day 5 was 4-fold down-
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regulated relative to the untreated controls (p=0.067; Fig. 2.4C). This group also exhibited a 10-
fold down-regulation of Eomes and Bcl6 as compared to untreated controls (p<0.04; Fig. 2.4C). 
We observed only modest differences in the expression of Prdm1 (encodes Blimp-1), Id2, Id3, 
and Tcf7 (encodes T cell factor 1) (Fig. 2.4C). No significant differences were observed in mice 
depleted of CD4+ T cells on day 8 post-immunization. We confirmed the reduced expression of 
T-bet on Db/AL11+ CD8+ T cells by flow cytometry from animals depleted of CD4+ T cells as 
compared to untreated controls (p<0.001; Fig. 2.4B). Eomes and T-bet have been demonstrated 
to act in concert to promote effector differentiation and expression of CD122 (49). Consistent 
with this, in animals depleted of CD4+ T cells on day 5 post-immunization there was decreased 
expression of CD122 as compared to untreated controls (p=0.038; Fig. 2.4A). These data suggest 
that the defect in effector phenotype seen following depletion of CD4+ T cells is consistent with 
aberrant expression of transcriptional regulators involved in effector CD8+ T cell differentiation. 
 Our earlier findings identified that the contraction of Db/AL11+ CD8+ T cell responses 
were increased following CD4+ T cell depletion post-immunization (Fig. 2.2B). To investigate 
the mechanism of this increased contraction, we evaluated expression of the apoptotic marker 
Annexin V on CD8+ T cells on day 28 post-immunization from mice depleted of CD4+ T cells on 
day 5, 8, or 11 post-immunization. We observed that the antigen-specific CD8+ T cells from 
these mice depleted of CD4+ T cells exhibited increased Annexin V expression (54%, 41%, and 
21%, respectively), as compared to 15% of Db/AL11+ CD8+ T cells from the untreated control 
animals (p<0.04; Fig. 2.4D). These data suggest that CD4+ T cells play a key role in not only the 
induction but also the survival of antigen-specific CD8+ T cell responses (27). 
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Figure 2.4. CD8+ T cells in mice depleted of CD4+ T cells exhibit an abnormal phenotype 
following intramuscular Ad vaccination. C57BL/6 mice were depleted of CD4+ T cells by i.p. 
administration of mAb GK1.5 (anti-CD4) on day 5, 8, or 11, or left untreated (!), and 
immunized i.m. with 109 vp of Ad26-Gag. On day 28 post-immunization, animals were 
sacrificed and splenocytes were isolated. (A and B) Expression level of the indicated protein as 
percentage (A) or MFI (B) on gated Db/AL11+ cells. Dashed lines indicate CD44lo CD8+ (naïve) 
T cells and solid shaded histograms indicate Db/AL11+ CD8+ T cells. Data are from n=8-
16/group (pooled from two to four independent experiments). (C) Gene expression of sorted 
Db/AL11+ CD8+ T cells from untreated animals or animals treated with GK1.5 (anti-CD4) on day 
5 or day 8 post-immunization was determined by quantitative real-time PCR. Gene expression 
was normalized to Gapdh. Data are from n=4-6/group (pooled from two independent 
experiments). (D) Annexin V expression and uptake of vital dye by Db/AL11+ cells was assessed. 
Data are from n=8/group (pooled from two independent experiments). Mean ± SEM are shown; 
#, P=0.067; *, P<0.05. 
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CD8+ T cells primed with reduced CD4+ T cell help fail to protect against lethal 
recombinant Listeria monocytogenes challenge 
We next sought to determine the impact of longitudinal depletion of CD4+ T cells on the ability 
of vaccine-elicited CD8+ T cells to protect against a lethal recombinant Listeria monocytogenes 
challenge. To accomplish this we utilized Ad26-GP followed by challenge on day 30 following 
immunization with Lm-GP33 (Fig. 2.5A). Longitudinal depletion of CD4+ T cells following 
immunization with 109 vp of Ad26-GP resulted in a reduced frequency of Db/GP33+ CD8+ T 
cells (Fig. 2.5B), consistent with our previous findings (Fig. 2.2). No Db/GP33+ CD8+ T cells 
were detected when depletion of CD4+ T cells was performed on day -1 or 5, with progressively 
less impairment following depletion of CD4+ T cells on day 8 or 11. Depletion of CD4+ T cells 
on day 8 post-immunization resulted in altered expression on KLRG1 and CD127 on Db/GP33+ 
CD8+ T cells, and to a lesser degree when depletion of CD4+ T cells was performed on day 11 
post-immunization (Fig. 2.5C). 
Challenge of unvaccinated mice with Lm-GP33 resulted in 100% mortality by day 4 
post-immunization (Fig. 2.5D). In contrast, mice immunized 30 days prior with Ad26-GP 
exhibited a significant delay and reduction in mortality compared to unvaccinated controls 
(p<0.0001; Fig. 2.5D). Mice immunized with Ad26-GP and depleted of CD4+ T cells on day 8 
(impaired frequency and altered phenotype) exhibited comparable mortality to unvaccinated 
control animals (p=0.13) and significantly impaired protective efficacy compared to vaccinated 
untreated mice (p=0.02; Fig. 2.5D). These data demonstrate that depletion of CD4+ T cells 8 
days post-immunization resulted in CD8+ T cells that failed to protect against a lethal 
recombinant Listeria challenge. 
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Figure 2.5. CD8+ T cells primed with reduced CD4+ T cell help fail to protect against lethal 
recombinant Listeria monocytogenes challenge. (A) C57BL/6 mice were depleted of CD4+ T 
cells by i.p. administration of mAb GK1.5 (anti-CD4) on day 8 or left untreated  (!), and 
immunized with 109 vp of Ad26-GP. On day 30 post-immunization mice were challenged with 
1.75x105-2.5x105 cfu of Lm-GP33. (B) Frequency of Db/GP33+ CD8+ T cells in the blood on day 
30 post-immunization. (C) KLRG1 and CD127 expression on Db/GP33+ CD8+ T cells in the 
blood on day 30 post-immunization. (D) Survival of mice following Lm-GP33 challenge. Data 
are from n=16-32/group (A-C) or n=7-19/group (D) pooled from 2-4 independent experiments. 
Mean ± SEM are shown; #, P=0.08; *, P<0.05. 
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Prolonged requirement for CD4+ T cell help for controlling the contraction of CD8+ T cell 
responses 
Since depletion of CD4+ T cells on day 9-13 during the expansion phase of the immune response 
led to an increased contraction of antigen-specific CD8+ T cells (Fig. 2.2B) and increased 
apoptosis (Fig. 2.4D), we sought to determine how long CD4+ T cell help was required following 
immunization to regulate the contraction of antigen-specific CD8+ T cells. Mice were depleted of 
CD4+ T cells on day -1, 7, 14, 21, or 28 relative to immunization with 109 vp of Ad26-Gag on 
day 0 (Fig. 2.6A). Consistent with previous experiments, depletion of CD4+ T cells on day -1 
resulted in complete abrogation of Db/AL11+ CD8+ T cell responses, and depletion on day 7 
resulted in markedly lower Db/AL11+ CD8+ T cell responses relative to untreated controls (Fig. 
2.6B). Depletion of CD4+ T cells on days 14, 21, or 28 resulted in more rapid decay of the 
Db/AL11+ CD8+ T cell response as compared with untreated mice as a function of the day of 
depletion (Fig. 2.6B). On day 90, the frequency of Db/AL11+ CD8+ T cells in untreated control 
animals was 3.74% of CD8+ T cells while the frequency of Db/AL11+ CD8+ T cells was 
significantly lower in animals depleted of CD4+ T cells on day -1 (0.04%, below the limit of 
detection; p=0.002), day 7 (1.97%; p=0.005), day 14 (2.0%; p=0.016), or day 21 (1.84%; 
p=0.0007), and a trend was observed in animals depleted of CD4+ T cells on day 28 (2.79%; 
p=0.11; Fig. 2.6B). When the magnitude of the response on day 90 was normalized to the peak 
of the response on day 14, the degree of contraction of the Db/AL11+ CD8+ T cell responses was 
significantly greater in mice depleted of CD4+ T cells on day 14 or 21 post-immunization 
(p<0.05), and a trend was observed in mice depleted of CD4+ T cells on day 28 post-
immunization (p=0.08; data not shown). Thus, depletion of CD4+ T cells on day 7, 14, or 21 led 
to an ~2-fold reduction in frequency of Db/AL11+ CD8+ T cells on day 90 as compared to 
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untreated controls. However, the impact of increased contraction of vaccine-elicited CD8+ T 
cells on protective efficacy remains to be determined. 
 Given our previous observations of abnormal phenotypes of Db/AL11+ CD8+ T cells 
following early interruption of CD4+ T cell help (Fig. 2.3 and 2.4), we assessed the long-term 
expression of KLRG1 and CD127 in animals depleted of CD4+ T cells on days -1, 7, 14, 21, or 
28. Depletion of CD4+ T cells on day 7 resulted in CD8+ T cells that did not undergo the normal 
phenotypic evolution observed in the untreated controls. The frequency of Db/AL11+ CD8+ T 
cells that expressed KLRG1 and CD127 failed to increase over time in the mice depleted of 
CD4+ T cells on day 7 and was significantly lower at day 50 and 90 post-immunization as 
compared to the untreated controls (P<0.05; Fig. 2.6C). Animals depleted of CD4+ T cells on day 
14, 21, or 28 post-immunization exhibited a less abnormal phenotypic evolution (Fig. 2.6C), 
consistent with the early need for CD4+ T cell help to program this process. These data 
demonstrate a prolonged role for CD4+ T cells in controlling the contraction of antigen-specific 
CD8+ T cell responses.  
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Figure 2.6. Normal contraction of the CD8+ T cell response requires prolonged CD4+ T cell 
help. (A) C57BL/6 mice were depleted of CD4+ T cells by i.p. administration of mAb GK1.5 
(anti-CD4) on day -1, 7, 14, 21, or 28, or left untreated (!), and immunized i.m. with 109 vp of 
Ad26-Gag. (B) Animals were bled longitudinally and Gag-specific CD8+ T cells were quantified 
by Db/AL11 tetramer staining. (C) Frequency of KLRG1 and CD127 expression on Db/AL11+ 
CD8+ T cells in blood. Data are from n=8-12/group (pooled from two to three independent 
experiments). Mean ± SEM are shown; *, P<0.05. 
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CD8+ T cells that receive at least eight days of CD4+ T cell help exhibit normal anamnestic 
potential 
Given that the provision of CD4+ T cell help for at least eight days post-immunization resulted in 
CD8+ T cells that exhibited a largely normal phenotype, we sought to determine if these cells 
also had acquired the normal memory characteristic of anamnestic expansion upon antigen re-
exposure. Therefore, we performed adoptive transfer experiments of AL11-specific CD8+ T cells 
from mice depleted of CD4+ T cells into naive animals followed by secondary antigen exposure. 
As outlined in Figure 2.7A, CD45.1+ congenic mice immunized with 109 vp of Ad26-Gag were 
either untreated or depleted of CD4+ T cells on day 8, 11, or 14. On day 28 post-immunization, 
splenic CD8+ T cells were purified and equal numbers of CFSE-labeled Db/AL11+ CD8+ T cells 
were transferred into CD45.2+ congenic mice. One day after cell transfer, recipient animals were 
immunized with 109 vp of Ad5HVR48-Gag and the expansion of Db/AL11+ CD45.1+ CD8+ T 
cells was evaluated. Eight days following immunization, the Db/AL11+ CD8+ CD45.1+ donor T 
cells from untreated controls and the donor cells from mice depleted of CD4+ T cells expanded to 
nearly equivalent levels (Fig. 2.7B and D). All of the Db/AL11+ CD8+ CD45.1+ donor T cells had 
also completely diluted CFSE by day 8 post-boost (Fig. 2.7C), which is consistent with the 
robust expansion of the population. These data suggest two possible options: either CD4+ T cells 
are not required to program anamnestic responses in the Ad system (17) or this CD4+ T cell 
mediated anamnestic programming occurs within eight days of immunization (27, 64, 65). 
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Figure 2.7. CD8+ T cells primed with at least eight days of CD4+ T cell help proliferate 
upon secondary antigen exposure. (A) CD45.1+ mice were depleted of CD4+ T cells by i.p. 
administration of mAb GK1.5 (anti-CD4) on day 8, 11, or 14, or left untreated, and immunized 
i.m. with 109 vp of Ad26-Gag (day 0). On day 28 post-immunization, CD8+ T splenocytes were 
pooled, enriched by negative selection, and labeled with CFSE. 1.5x104 Db/AL11+ CD8+ T cells 
were transferred by tail vein injection into naïve CD45.2+ recipients. One day following transfer, 
animals were immunized i.m. with 109 vp of Ad5HVR48-Gag. (B) Representative plots of 
Db/AL11+ CD45.1+ donor cells as a fraction of CD8+ T cells in the spleen on day 8 or 14. (C) 
Representative histograms of CFSE dilution in the donor Db/AL11+ CD45.1+ CD8+ T cell 
population on day 8 post-boost (open histogram) or the donor CD45.1+ CD8+ T cell population 
with no boosting immunization (solid histogram). (D) Absolute number of Db/AL11+ CD45.1+ 
CD8+ T cells in the spleen on day 8 or 14 post-immunization. Frequency of donor Db/AL11+ 
CD45.1+ CD8+ T cells at the time of immunization (day 0) is based on 10% engraftment. Data 
are from n=6-13 recipient mice/group on day 8 (pooled from three independent experiments) and 
n=5 recipient mice/group on day 14 (from one experiment). Mean ± SEM are shown. 
! 66!
The CD40 signaling pathway is not critical for initial CD8+ T cell priming but is required 
for anamnestic CD8+ T cell expansion 
Several reports have identified the CD40 signaling pathway as a major mechanism for the 
provision of CD4+ T cell help, both for the generation of primary CD8+ T cell responses and for 
the programming of anamnestic responses (21, 31-33, 66, 67). Therefore, we evaluated the 
importance of this signaling pathway for the generation of Ad vector-elicited CD8+ T cell 
responses. C57BL/6, CD40L KO, and CD40 KO mice were immunized intramuscularly with 109 
vp of Ad26-Gag. On day 28 post-immunization, no significant differences in the number of 
Db/AL11+ CD8+ T cells between wild type and CD40 pathway deficient (CD40L KO or CD40 
KO) animals were observed (Fig. 2.8A). Consistent with this, the absolute number of Gag-
specific CD8+ T cells that secreted IFN-γ was comparable between the wild type and CD40L KO 
and CD40 KO animals (Fig. 2.8B). Moreover, splenic Db/AL11+ CD8+ T cells from wild type, 
CD40L KO, and CD40 KO animals expressed equivalent levels of KLRG1 and CD127 (Fig. 
2.8C). Collectively, these data suggest that signaling via CD40 is not critical for the initial 
generation of Ad vector-elicited primary CD8+ T cell responses. 
 To determine the role of CD40 signaling in the generation of anamnestic CD8+ T cell 
responses, Ad26-Gag primed C57BL/6, CD40L KO, and CD40 KO animals were boosted with 
109 vp of Ad5VHR48-Gag on day 56. The frequency of Db/AL11+ CD8+ T cells in the blood 
prior to priming was equivalent between groups (Fig. 2.8D). Upon boosting, the Db/AL11+ CD8+ 
T cell population in wild type animals expanded 15-fold by day 7 post-boost and had begun to 
contract by day 14 (Fig. 2.8D and E). However, in CD40L KO and CD40 KO animals, the 
Db/AL11+ CD8+ T cell population expanded significantly less by day 7 post-boost than in wild 
type animals (P<0.03; Fig. 2.8D and E). 
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Finally, to determine if signaling via CD40 was required at the time of priming or 
boosting, on day 50 equal numbers of Db/AL11+ CD8+ T cells from wild type or CD40L KO 
Ad26-Gag-immunized animals were transferred into congenic (CD45.1+) naïve hosts (Fig. 2.8F).  
Following an Ad5HVR48-Gag immunization, the recall potential of donor Db/AL11+ CD8+ T 
cells was assessed. The number of donor Db/AL11+ CD8+ T cells from CD40L KO animals was 
significantly reduced following Ad5HVR48-Gag immunization in peripheral blood, spleen, and 
liver compared to donor Db/AL11+ CD8+ T cells from wild type animals (P<0.05; Fig. 2.8F). 
These data suggest that while CD40-derived signals are not required for the generation of a 
primary CD8+ T cell response, CD40 is critical for programming anamnestic potential upon 
secondary antigen challenge. Collectively these experiments demonstrate a prolonged and 
multifaceted role for CD4+ T cell help to generate optimal Ad vector-induced CD8+ T cell 
responses (Fig. 2.9). 
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Figure 2.8. CD40 signaling is required for programming CD8+ T cells with anamnestic 
potential. (A-C) C57BL/6, CD40L KO, and CD40 KO animals were immunized i.m. with 109 
vp of Ad26-Gag (n=8/group pooled from two independent experiments). (A) The number of 
Db/AL11+ CD8+ T cells in the spleen of immunized animals on day 28 post-immunization. (B) 
Splenocytes were harvested on day 28 post-immunization and the number of IFN-γ+ CD8+ T 
cells was quantified following stimulation with an overlapping SIV Gag peptide pool. (C) 
KLRG1 and CD127 expression were assessed on splenic Db/AL11+ CD8+ T cells on day 28 post-
immunization. (D and E) C57BL/6, CD40L KO, and CD40 KO animals were immunized i.m. 
with 109 vp of Ad26-Gag and on day 56 post-prime were boosted with 109 vp of Ad5HVR48-
Gag (n=4/group from one experiment). (D) The frequency of Db/AL11+ CD8+ T cells per 106 
PBMC following the boost was assessed. (E) The fold-change in frequency of Db/AL11+ CD8+ T 
cells per 106 PBMC from one day pre-boost to day 7 post-boost was assessed. (F) C57BL/6 or 
CD40L KO animals were immunized intramuscularly with 109 vp of Ad26-Gag. On day 50 post-
immunization, 5x104 Db/AL11+ CD8+ T cells were enriched by negative selection and transferred 
intravenously to congenically marked (CD45.1+) naïve recipients (n=8-9/group from two 
independent experiments). One day post-transfer, recipient mice were immunized i.m. with 109 
vp of Ad5HVR48-Gag. On day 12 post-secondary immunization, the number of donor Db/AL11+ 
CD45.2+ CD8+ T cells in PBMC, spleen, and liver was assessed. Mean ± SEM are shown; #, 
P=0.06; *, P<0.05. 
! 69!
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. Schematic representation of longitudinal requirement for CD4+ T cell help. 
Summary of longitudinal requirement for CD4+ T cell help for the induction of CD8+ T cell 
responses, effector differentiation, and normal contraction following Ad vector vaccination. The 
requirement for CD4+ T cell help was prolonged but waned over time. 
! 70!
DISCUSSION 
In this study we demonstrate that immunization with Ad vectors requires CD4+ T cell help for 
the induction and optimal sustainment of CD8+ T cell responses not only at the time of priming 
but also for a prolonged period of time following immunization. We observed that CD4+ T cell 
help was required for eight days post-immunization for primary induction of CD8+ T cell 
responses and normal effector differentiation. Moreover, CD4+ T cells were critical for four 
weeks post-immunization for controlling the contraction of CD8+ T cell responses. CD40 
signaling was required to program CD8+ T cells with anamnestic potential but did not appear 
critical for initial CD8+ T cell priming. Taken together, these data demonstrate that the need for 
CD4+ T cell help to generate Ad vector-induced CD8+ T cell responses is multi-faceted and 
prolonged over time (Fig. 2.9). 
Our data suggest that Ad vector-based vaccines and potentially also other vaccines may 
exhibit reduced cellular immunogenicity in patients with reduced CD4+ T cell function, such as 
in patients with advanced AIDS or following hematopoietic stem cell transplantation (HSCT) as 
a result of insufficient CD4+ T cell help. Consistent with this hypothesis, HIV-1-infected patients 
and HSCT patients have been reported to develop impaired antibody responses following 
vaccination against influenza virus, hepatitis B virus, Haemophilus influenza type B, tetanus-
reduced diphtheria-reduced pertussis (Tdap), and yellow fever virus (68-72). Most previous 
studies have focused on vaccine-elicited antibody responses, and the requirement for CD4+ T cell 
help to generate CD8+ T cell responses by vaccination has remained poorly understood. Our data 
suggest that prolonged CD4+ T cell help is required for the induction and sustainment of optimal 
vaccine-elicited cellular immune responses. 
! 71!
Prior studies have reported that CD4+ T cell help is required at the time of priming to 
generate robust Ad vector-elicited CD8+ T cell responses (17, 18). However, the timing of CD4+ 
T cell help for the development of primary CD8+ T cell responses has not been previously 
reported to the best of our knowledge. Our data confirm and extend the observation of a 
requirement for CD4+ T cell help at the time of vaccine priming with multiple serotypes of Ad 
vectors. Longitudinal depletion of CD4+ T cells identified a prolonged role for CD4+ T cell help 
in the expansion and contraction of CD8+ T cell responses. In contrast, Yang and colleagues (17) 
did not detect any differences in CD127, CD62L, and CD122 between Ad5-elicited antigen-
specific CD8+ T cells that did or did not receive CD4+ T cell help. This difference may reflect the 
inherent difference between the ability of Ad5- and Ad26-induced CD8+ T cells to express 
memory markers, as has been recently reported (36, 73). Furthermore, the largest differences in 
phenotype observed in the current study related to KLRG1 expression, which was not assessed in 
this prior study (17). 
A number of reports have identified that pathogens/vaccines can be broadly divided into 
two categories based on whether CD4+ T cell help is required for induction of primary CD8+ T 
cell responses [reviewed in (30)]. Most candidate vaccine platforms (including adenovirus 
vectors) fall into the category of requiring CD4+ T cell help for the induction of primary CD8+ T 
cell responses. In contrast, the widely used viral infection model LCMV generates a primary 
CD8+ T cell response in the absence of CD4+ T cell help (23). Following LCMV infection of 
CD4 KO animals, the CD8+ T cell response is initially of normal magnitude but has impaired 
memory potential characterized by T-bet-mediated suppression of CD127, CD27, and CD62L 
expression (74). In contrast, we identified that following Ad vector immunization, the absence of 
CD4+ T cells resulted in impaired effector differentiation (KLRG1 and CD122) and atypical 
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memory marker expression (CD127, CD27, and CD62L), and this corresponded to a decrease in 
T-bet and Eomes expression. These data suggest that in the absence of CD4+ T cell help 
adenovirus vector-induced CD8+ T cell responses fail to receive the necessary signals to up-
regulate T-bet and Eomes and hence do not properly initiate the program of effector 
differentiation. Thus it appears that in addition to their ability to drive CD4+ T cell-independent 
expansion, a fundamental difference between these two classes of antigenic stimuli is their 
intrinsic ability to induce effector T cell differentiation. 
 Impaired maintenance of the CD8+ T cell population in the absence of CD4+ T cells has 
been reported in other systems (27, 29, 65). In these prior studies, CD4+ T cells were removed at 
only a single time post-infection and thus the temporal requirements for CD4+ T cell help could 
not be assessed. Consistent with these reports, we observed accelerated contraction of CD8+ T 
cells following longitudinal depletion of CD4+ T cells. We extended these observations by 
demonstrating a prolonged requirement for CD4+ T cell help that lasted at least four weeks and 
declined over time. Future studies will be required to determine how this accelerated contraction 
alters protective efficacy of these vaccine elicited CD8+ T cells. 
CD4+ T cells have a well-established role in programming memory CD8+ T cells to be 
capable of expansion upon secondary antigen exposure, and CD40-derived signals are a major 
mechanism of this process (20, 27, 31-33, 64). However, a previous report has demonstrated in 
the Ad system that CD8+ T cells have unimpaired anamnestic potential when primed in the 
absence of CD4+ T cells (17). Given no detectable AL11-specific CD8+ T cell responses in our 
system when CD4+ T cells were depleted prior to priming it was not possible to directly 
investigate a role for CD4+ T cell programming of anamnestic potential at priming, but we 
observed no defect in anamnestic expansion when CD4+ T cells were depleted after priming. 
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However, we observed impaired recall responses in CD8+ T cells from mice that lacked the 
CD40 signaling pathway. There are two possible conclusions from these data. First, anamnestic 
programming occurs rapidly following priming (27, 64, 65). Alternatively, anamnestic 
programming in the Ad system occurs independent of CD4+ T cell help (17), but still requires 
CD4 T cell-independent CD40 signaling, which has been reported following influenza infection 
(75). Future experiments will be required to fully elucidate the relationship between CD4+ T cell 
help, CD40 signaling, and the programming of anamnestic potential following Ad vector 
immunization. 
This study illustrates the multi-faced role of CD4+ T cells in the development and 
maintenance of Ad vector-induced CD8+ T cell responses. CD4+ T cell help at different points in 
time was required for CD8+ T cell priming, effector differentiation, and regulating contraction 
(Fig. 2.9). The relative importance of CD4+ T cell help gradually waned over time following 
immunization, but was required for eight days for CD8+ T cell priming and 28 days for 
regulating contraction. Thus it appears that CD4+ T cells do not simply program functional CD8+ 
T cells through a single or transient signaling event, but instead modulate CD8+ T cell frequency 
and functionality via an active process over a prolonged period of time. Future efforts to 
optimize CD4+ T cell responses, especially in situations of impaired CD4+ T cell frequency such 
as HIV infection, may lead to increased immunogenicity and durability of CD8+ T cell responses 
elicited by Ad vector-based vaccines and possibly other vaccine platforms as well. 
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ABSTRACT 
CD4+ T cell help is critical for optimal CD8+ T cell expansion after priming. However, a role for 
CD4+ T cells in regulating the initial steps of CD8+ T cell effector differentiation is not well 
established. Here we demonstrate that absence of CD4+ T cells at the time of adenovirus vector 
immunization leads to immediate CD8+ T cell dysfunction. Unhelped CD8+ T cells exhibit 
reduced ex vivo cytotoxicity and decreased capacity to produce cytokines. These cells express 
elevated levels of inhibitory receptors and exhibit transcriptomic exhaustion and anergy profiles 
by gene set enrichment analysis. AP-1-independent NFAT signaling appears to be important in 
driving this dysfunction. This state is imprinted within 3 days of immunization. Impaired 
expansion and effector differentiation of unhelped CD8+ T cell is caused by reduced IL-2 and 
elevated PD-1 signaling. This study identifies a novel, previously undescribed role of CD4+ T 
cells to prevent immediate dysfunction and features of exhaustion in CD8+ T cells following 
antigen priming.  
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INTRODUCTION 
CD4+ T cells are key regulators of CD8+ T cell function, as the absence of CD4+ T cell help at 
priming leads to impaired responses, including reduced expansion (1-3), hyper-effector 
differentiation (4, 5), and reduced anamnestic potential (6-8). Induction of primary CD8+ T cells 
by several non-inflammatory antigens requires CD4+ T cell help, which is mediated by CD40 
signaling (2, 9, 10). Replication-incompetent Adenovirus (Ad) vector vaccines are important 
clinically relevant tools for probing immune regulatory pathways, and require CD4+ T cell help 
for the induction of robust primary CD8+ T cell responses (11-14). However, this help is 
provided through a CD40-independent mechanism (11). Thus, further work is required to 
identify the mechanism of CD4+ T cell help following immunization with viral vector vaccines. 
Following vaccination or infection that is acutely controlled, CD8+ T cells typically 
differentiate into two distinct highly functional effector and memory populations (15). A role for 
CD4+ T cells in regulating CD8+ T cell differentiation is not well defined. In the lymphocytic 
choriomeningitis model unhelped CD8 + T cells differentiate into a hyper-effector state due to 
excessive T-bet expression (4), and in the vaccinia virus model conflicting reports identify no 
role for CD4+ T cells in regulating effector CD8+ T cell differentiation (16) or hyper-effector 
differentiation of unhelped CD8+ T cells (5). In contrast, following Ad vector immunization, 
unhelped CD8+ T cells fail to express effector phenotype markers (11). Whether these 
phenotypic defects reflect altered functionality remains to be addressed. Thus, further work is 
required to fully understand what role CD4+ T cells have in regulating CD8+ T cell effector 
function upon viral vector immunization, and how CD4+ T cells regulate this process. 
In this study we sought to clearly define the role of CD4+ T cells in regulating CD8+ T 
cell effector differentiation, and how this is accomplished. We demonstrate that in the absence of 
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CD4+ T cell help CD8+ T cells induced by vaccination with a replication-incompetent viral 
vector differentiate to a dysfunctional state, which has many of the phenotypic and functional 
characteristics of CD8+ T cell exhaustion. However, in contrast to the progressive process of 
chronic infection-induced exhaustion, this dysfunction is programmed at priming and defects in 
differentiation are observed within days of immunization. CD8+ T cells express both exhaustion 
and anergy transcriptional signatures, and this includes exhaustion and anergy signatures for AP-
1-independent NFAT target genes. These data are consistent with a model in which excessive 
AP-1-independent NFAT signaling is critical for driving dysfunctional differentiation. 
Functionally, experimental modulation of either PD-1 or IL-2 signaling during priming partially 
prevents dysfunctional differentiation and rescues effector functionality. In sum, we identify a 
novel immediate role for CD4+ T cells in programming effector differentiation and preventing 
immediate exhaustion-like dysfunction of CD8+ T cells following viral vector immunization.  
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MATERIALS AND METHODS 
Mice and vectors. Six- to ten-week-old C57BL/6, B6.SJL-ptprca (CD45.1+), B6.129S2-
Cd4tm1Mak/J (CD4 KO), B6.129S2-H2dlAb1-Ea/J (MHC II KO), C57BL/6-Tg(TcraTcrb)1100Mjb/J 
(OT-I), and B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II) mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Thymectomized animals underwent adult thymectomy at the 
Jackson Laboratory (Bar Harbor, ME). CD45.1/2+ OT-I TCR-Tg and B6.129S4-Il2ratm1Dw/J 
(CD25 KO) OT-I mice were bred in house. E1/E3 deleted Ad5-SIINFEKL-Luc, Ad5-tTA-
SIINFEKL-Luc, Ad5-OVA, and Ad5HVR48(1-7)-Gag have been previously described (34, 58-
60). Mice were immunized intramuscularly with 109 viral particles of the indicated vector in the 
quadriceps using 100 µl divided equally between the two legs. Ad5-tTA-SIINFEKL-Luc was 
used at 1010 viral particles per mouse. NYVAC-Env has been previously described (61) and was 
used at 106 pfu per mouse. All animal experiments were performed in accordance with the 
Institutional Animal Care and Use Committee guidelines of Beth Israel Deaconess Medical 
Center. 
Monoclonal antibody administration. The monoclonal αCD4 antibody (GK1.5; BioXcell) was 
administered by two IP injections of 500 µg one day prior to immunization and on the day of 
immunization. To maintain CD4 T cell depletion, this injection regimen was repeated every 21 
days following immunization. αPD-L1 (10F.9G2; BioXCell), αPD-1 (29F.1A12; BioLegend), or 
isotype IgG2b (clone LTF-2; BioXCell) were administered by 200 µg IP injections every third 
day, as previously described (35).  
Recombinant IL-2 administration. Mouse recombinant IL-2 (R&D Systems) resuspended in 
0.1% normal mouse serum was given 1 µg IP twice daily from day 3 to 12, per published dosing 
protocols (41, 62). 
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Doxycycline administration. 500 µg of doxycycline (MP Biomedicals) was injected IP on day 
14 as previously described (34). Mice were subsequently given food containing 625 mg/kg 
doxycycline (Harlan Teklad) to maintain doxycycline levels long-term. 
Tissue processing. Single cell suspensions of splenocytes and lymph nodes were generated by 
grinding the tissue through a 70 µm filter (Fisher Scientific). Tissue red blood cells were lysed 
by Ammonium-Chloride-Potassium (ACK) treatment for three minutes. Cellular debris was 
further clarified by passage through a 30 µm filter (Miltenyi Biotec). For purification of 
peripheral blood mononuclear cells (PBMC) Ficoll-Histopaque density centrifugation was 
performed at 1900 rpm for 20 min. 
Flow cytometery. Identification of antigen-specific cells by MHC class I tetramer staining was 
performed using either H-2Db tetramer loaded with the immunodominant AL11 peptide 
(AAVKNWMTQTL) of SIVmac239 Gag (63) or H-2Kb tetramer loaded with the immunodominant 
OVA257-264 (SIINFEKL) epitope from chicken ovalbumin (64). Biotinylated class I monomers 
were kindly provided by the NIH Tetramer Core Facility (Emory University, Atlanta, GA). 
Background staining of cells from naïve animals was ≤0.1%. Surface staining was performed for 
30 minutes at 4 °C. The following antibodies were used for staining: αCD8α (53-6.7), -CD4 
(RM4-5), -CD44 (IM7), -CD45.2 (104), -CD45.1 (A20), -TCRα V2 (B20.1), -CD127 (A7R34), -
KLRG1 (2F1), -CD27 (LG.3A10), -CD43 (1B11), -PD-1 (RMP1-30), -Tim-3 (RMT3-23), -
LAG-3 (C9B7W), -2B4 (eBio244F4), -CD25 (PC61), -CD28 (37.51), -OX-40 (OX-86), -4-1BB 
(17B5), -CD71 (RI7217), -CD98 (RL388), -CD11a (2D7), and -CD69 (H1.2F3). For detection of 
Granzyme B, cells were surface stained and then permeabilized for 15 min at room temperature 
with Cytofix/Cytoperm (BD Biosciences). Permeabilized cells were subsequently stained with 
αGranzyme B (GB11). Ki-67 detection was performed using BD Perm Buffer 2 (BD 
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Biosciences) for 15 min at room temperature followe by αKi-67 (B56) staining. For intracellular 
cytokine staining, cells were incubated for 5 hrs at 37 °C with 2 µg/ml of OVA257-264 peptide 
(AnaSpec) or 1 µg/ml of overlapping SIVmac239 Env peptide pool (NIH AIDS Reagent Program). 
At the time of peptide incubation, Brefeldin A and Monensin (BD Biosciences) and αCD107a 
(ID4B) were added. After peptide incubation cells were surface stained, washed, permeabilized 
with Cytofix/Cytoperm (BD Biosciences) for 20 min at 4 °C, and subsequently stained with 
αIFN-γ (XMG1.2) and -TNF-α (MP6-XT22). All antibodies were purchased from BD 
Biosciences, eBioscience, BioLegend, or Life Technologies. Dead cells were excluded by use of 
vital exclusion dye (Life Technologies). Annexin V staining was performed using an Annexin V 
staining kit (BioLegend). Samples were acquired on an LSR II flow cytometer (BD Biosciences) 
and analyzed using FlowJo v9.7.2 (Treestar). 
ex vivo killing assay. ex vivo cytotoxic potential of CD8+ T cells was measured as previously 
described (65). Briefly, EL-4 cells (ATCC) were pulsed with 2 µM OVA257-264 peptide 
(AnaSpec) or no peptide for 1hr at 37°C. Peptide pulsed cells were stained with CFSE (Life 
Technologies) and unpulsed cells were stained with CellTrace Violet (Life Technologies) per 
manufacturers instructions. CD8+ T cells were enriched by negative selection using the EasySep 
Mouse CD8+ T cell enrichment kit (StemCell Technologies). The number of effector cells were 
determined by quantification of Kb/OVA+ CD8+ T cells and the appropriate numbers were added 
and the mixtures were incubated for 5 hrs at 37 °C. Following incubation, cells were stained with 
a vital exclusion dye (Life Technologies) to exclude dead cells. Fixed cells were acquired on an 
LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo v9.7.2 (Treestar). Specific 
lysis was calculated as 100 – [100 x ( % survival / average % survival in absence of effector 
cells)]. 
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in vivo luciferase imaging. Quantification of luciferase transgene expression was performed as 
previously described (60, 66). Briefly, hair was removed from the hind legs and ventral posterior 
area of the mouse. Mice were injected IP with 150 µl of 30 mg/ml Luciferin (Caliper Life 
Sciences) per manufacturers instructions. Mice were anesthetized by 4% isofluorane inhalation 
and maintained under anesthesia by nose cone and 1.5% isofluorane. Luminescence was 
quantitated using an IVIS Lumina II charge-coupled device imaging system and Living Image 
software (Caliper Life Sciences). Image integration time was 240 sec, f/stop was 1.2 and binning 
was “large”. 
Microarray. Gene expression profiling was performed as previously described (67, 68). Briefly, 
CD8+ T cells were enriched by negative selection using the CD8+ T cell isolation kit II (Miltenyi 
Biotec). Db/AL11+ CD44+ CD8+ T cells were subsequently sorted to >95% purity on a FACS 
Aria (BD Biosciences). Sorted cells were stored at -80 °C in 1ml of TRIzol (Life Sciences). 
RNA extraction was performed using the RNAdvance Tissue Isolation kit (Agencourt) per 
manufacturers instructions. The cDNA synthesis was performed using the Ovation Pico WTA v2 
kit (NuGEN) following manufacturers instructions. Proper amplification of cDNA was 
confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies) and performed by the 
Harvard Biopolymers Facility. To confirm optimal amplification of mRNA and absence of 
contaminating gDNA (data not shown), qRT-PCR for Rn18s (RefSeq: NR_003278.2) and mouse 
RT2 qPCR primer control (QIAGEN) was performed using the SYBR Green Quantification 
System (QIAGEN). Data were acquired on a StepOnePlus Real-Time PCR System (Applied 
Biosystems). Cycle conditions were: 95 °C for 10 min followed by 40 cycles of 95 °C for 15 sec 
and 60 °C for 1 min. cDNA was subsequently fragmented and biotinylated using an Encore 
Biotin Module 4200 (NuGEN). cDNA was hybridized to Mouse Genome 430 v2.0 chip 
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(Affymetrix) at the Microarray Core of Dana Farber Cancer Institute. RMA method was used to 
process data image files using GenePattern (Broad Institute). 
Functional enrichment and network analysis. Differential gene expression was determined 
using GENE-E v3.0.163 (Broad Institute). Functional enrichment, pathway, and network 
analyses were performed using genes ranked by adjusted P values, fold change, and modified t-
statistics from limma analysis (69). Gene set enrichment analysis (GSEA) was performed using 
GSEA software (http://www.broadinstitute.org/gsea). All 45,282 probes, ranked by limma-
derived modified t-statistics, were imported into the GSEA software. We tested for the 
enrichment of C2 and C7 and C3.tft Molecular Signatures Database. GSEA was run according to 
default parameters: probes for the same gene were collapsed into a single gene symbol 
(identified by its HUGO gene symbol), permutation number = 1000, and permutation type = 
“gene sets.” By convention, a nominal p-value of  <0.05 was used as the cutoff value for 
significance.  Enriched gene sets were grouped into modules according to shared leading edge 
genes using the cytoscape plugin EnrichmentMap (http://www.cytoscape.org/) by calculating the 
Jaccard index between pathways using a threshold of 0.50. The Jaccard index characterizes the 
overlap between two gene sets, relative to the size of their union and stratifies gene sets that 
correspond to similar biological processes. 
Statistical analysis. Statistical analysis was performed using a two-tailed non-parametric Mann-
Whitney U test in Prism v6.0f (GraphPad Software Inc.). 
Accession Numbers. Microarray data is accession number GEO: GSE73001 in the NCBI GEO 
database.
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RESULTS 
Depletion of CD4+ T cells at the time of immunization results in aberrant CD8+ T cell 
differentiation with decreased effector function. 
We utilized an Ad5-based immunization regimen to investigate the impact of CD4+ T cell help 
on CD8+ T cell responses, because this vaccination regimen generates small, but measurable, 
CD8+ T cell responses in the absence of CD4+ T cell help (11-13). Mice were depleted of CD4+ 
T cells by two sequential doses of the αCD4 antibody (clone GK1.5) beginning on the day prior 
to immunization and CD4+ T cell depletion was maintained by re-administration of the antibody 
every 21 days. This regimen led to complete and sustained depletion of CD4+ T cells (Fig. 3.S1A 
– see Appendix for Supplemental Figures). Following intramuscular immunization with Ad5-
SIINFEKL-Luc, there was a 10-fold reduction in the frequency of Kb/OVA+ CD8+ T cells in the 
blood of αCD4 treated mice at the peak of the response compared to untreated control animals 
(Fig. 3.1A). A delay in peak expansion of the antigen-specific CD8+ T cell responses from day 
10 to day 14, and an increased contraction of the responses in the absence of CD4+ T cells was 
also observed. A similar reduction in the frequency of Kb/OVA+ CD8+ T cells was observed in 
the spleen of αCD4 treated mice compared to untreated controls (Fig. 3.S1B). 
We first sought to determine if the absence of CD4+ T cell help at the time of priming 
altered the effector CD8+ T cell differentiation. Differentiation into memory precursor or 
terminal effector cells was determined by the expression of CD127 and KLRG1, respectively 
(17-19). On day 14 post-immunization, Kb/OVA+ CD8+ T cells from αCD4 treated mice 
exhibited a significant impairment in KLRG1 upregulation, and approximately 50% of OVA257-
264-specific CD8+ T cells were undifferentiated KLRG1loCD127lo cells (Fig. 3.1B), and this 
impaired differentiation was maintained long-term (p<0.05; Fig. 3.S1C). A recent report has 
! 93!
identified an alternative scheme for identifying effector phenotype cells as CD43loCD27lo (20). 
This CD43loCD27lo subset was also significantly reduced in αCD4 treated mice compared to 
controls (P<0.01; Fig. 3.S1D). Consistent with these phenotypic data, we observed decreased 
expression of Granzyme B (P<0.01; Fig. 3.1C) and decreased CD107a expression (upon cognate 
peptide restimulation; P<0.01; Fig. 3.1D) on Kb/OVA+ CD8+ T cells from αCD4 treated mice. 
Furthermore, in a 5 hr ex vivo cytotoxicity assay, Kb/OVA+ CD8+ T cells from αCD4 treated 
mice displayed a major defect in cytotoxicity (Fig. 3.1E). These cytotoxic defects resulted in a 
failure to clear transgene expressing cells in αCD4 treated mice (P<0.01; Fig. 3.S1E), consistent 
with a previous report (12). Collectively, these data demonstrate a major defect in CD8+ T cell 
differentiation in the absence CD4+ T cell help. 
Given the impaired effector phenotype and cytotoxicity of CD8+ T cells primed without 
CD4+ T cell help, we sought to determine if these cells displayed alterations in their ability to 
secrete cytokines. There was a significant reduction in the frequency and absolute number of 
CD8+ T cells that produced IFN-γ upon ex vivo restimulation in mice treated with αCD4 
antibody compared to untreated control mice on day 14 (12-fold reduction), day 45 (15-fold 
reduction), and day 80 (15.5-fold reduction) post-immunization (P<0.001; Fig. 3.1F and G). The 
frequency of antigen-specific CD8+ T cells that express IFN-γ was substantially reduced in 
αCD4 treated mice (P<0.001; Fig. 3.1H), and these cells produced less per-cell IFN-γ than did 
cells form untreated control animals (P<0.05; Fig. 3.1I). Finally, the fraction of IFN-γ+ CD8+ T 
cells from αCD4 treated mice that were capable of co-producing TNF-α was significantly 
reduced compared to IFN-γ+ CD8+ T cells from untreated control animals (P<0.001; Fig. 3.1J). 
These results were confirmed using CD4 knockout (KO) and MHC class II KO mice, which 
displayed similar defects in accumulation of Kb/OVA-specific CD8+ T cells, and decreased IFN-
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γ and TNF-α production (Fig. 3.S1F-3.S1H). These data show that, without CD4+ T cell help at 
priming, Ad vector-elicited CD8+ T cells undergo aberrant differentiation consisting of impaired 
effector phenotype, decreased cytotoxicity, and abnormal expression of key transcription factors. 
 
  
! 95!
 
Figure 3.1. Impaired cytotoxicity and cytokine production by CD8+ T cells primed in the 
absence of CD4+ T cells. (A-J) C57BL/6 mice were treated with αCD4 antibody or left 
untreated and immunized intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. (A) Frequency of 
Kb/OVA+ CD8+ T cells in blood. (B) KLRG1 and CD127 expression on Kb/OVA+ CD8+ T cells 
in the spleen on day 14 post-immunization. (C) Expression of Granzyme B on Kb/OVA+ CD8+ T 
cells in the spleen on day 14 post-immunization. (D) Expression of CD107a on IFN-γ+ CD8+ T 
cells following OVA257-264 peptide stimulation of splenocytes from day 14 post-immunization. 
(E) 5 hr killing assay of OVA257-264 peptide pulsed EL-4 cells by pooled splenic CD8+ T cells at 
day 14 post-immunization. Each E:T ratio was performed in duplicate. Continued ! 
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Figure 3.1 (Continued) 
(F) Representative plots of IFN-γ+ CD8+ T cells from the spleen. (G) Absolute frequency of 
IFN-γ+ CD8+ T cells. (H) The fraction of OVA257-264-specific CD8+ T cells that produce IFN-γ. 
(I) Mean fluorescence intensity (MFI) of IFN-γ+ CD8+ T cells. (J) Representative plots of TNF-α 
production by IFN-γ+ CD8+ T cells and group averages. Data are representative (A-E, I) of three 
experiments or pooled (F-H, J) from three experiments. N=5-6/group per experiment. Mean ± 
SEM are shown. ***, P<0.001; **, P<0.01; *, P<0.05; Mann-Whitney U test. 
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CD8+ T cells primed without CD4+ T cell help express multiple inhibitory receptors. 
To better understand how unhelped CD8+ T cells differentiated we also examined the expression 
of inhibitory receptors on antigen-specific CD8+ T cells following immunization of αCD4 treated 
mice. There was a substantial increase in the expression of PD-1 on Kb/OVA+ CD8+ T cells from 
αCD4 treated mice compared to untreated controls (P<0.01; Fig. 3.2A). Increased expression of 
Tim-3, LAG-3, and 2B4 was also observed in αCD4 treated mice (Fig. 3.2A). In both untreated 
controls and αCD4 treated mice, PD-1 expression on Kb/OVA+ CD8+ T cells in the blood 
declined from day 7 to day 14 and then remained steady through day 80, and at all times PD-1 
expression was significantly higher in αCD4 treated mice (P<0.05; Fig. 3.2B). Long-term 
elevated PD-1 expression was also observed on Kb/OVA+ CD8+ T cells from CD4 KO and MHC 
class II KO mice (Fig. 3.S2A). Increased co-expression of multiple inhibitory receptors has been 
shown to correlate with reduced functionality of CD8+ T cells in the context of chronic viral 
infection (21). Kb/OVA+ CD8+ T cells from αCD4 treated mice exhibited significant increases 
(P<0.01) in the fraction of cells that co-expressed 2, 3, or all 4 of the inhibitory receptors PD-1, 
Tim-3, LAG-3 and 2B4 compared to untreated controls (Fig. 3.2C). Thus, CD8+ T cells primed 
in the absence of CD4+ T cell help exhibit increased and prolonged expression of inhibitory 
receptors. 
Increased expression of inhibitory receptors in the absence of CD4+ T cells is 
generalizable to multiple immunization regimens. Following Ad5HVR48-Gag vector 
immunization, unhelped CD8+ T cells specific for the immunodominant Db/AL11 epitope 
recapitulated the dysfunction observed following Ad5-SIINFEKL-Luc immunization (Fig. 
3.S2B-3.S2C and data not shown). Following immunization with a replication-incompetent 
recombinant poxvirus vector (NYVAC-Env), Env-specific responses from αCD4 treated mice 
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were of reduced magnitude, had a less cytotoxic phenotype, and elevated PD-1 expression (Fig. 
3.S2D-3.S2G). These data show that CD8+ T cell dysfunction following viral vector 
immunization in the absence of CD4+ T cells is generalizable to CD8+ T cells of multiple 
specificities, and to multiple replication-incompetent viral vector platforms. 
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Figure 3.2. Elevated expression of inhibitory receptors on CD8+ T cells primed in the 
absence of CD4+ T cells.  (A-D) C57BL/6 mice were treated with αCD4 antibody or left 
untreated and immunized intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. (A) Expression of 
inhibitory receptors PD-1, Tim-3, LAG-3, and 2B4 on Kb/OVA+ CD8+ T cells in the spleen on 
day 14 post-immunization. (B) Longitudinal expression of PD-1 on Kb/OVA+ CD8+ T cells in 
the blood. (C) Co-expression of inhibitory receptors PD-1, Tim-3, LAG-3, and 2B4 on Kb/OVA+ 
CD8+ T cells in the spleen on day 14 post-immunization, either as number of inhibitory receptors 
expressed (top) or specific combinations (bottom). Data are representative of three experiments 
(n=5-6/group per experiment). Mean ± SEM are shown. **, P<0.01; *, P<0.05; Mann-Whitney 
U test. 
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Absence of CD4+ T cells induces early transcriptional signatures of T cell exhaustion and 
anergy in CD8+ T cells. 
Given the multifaceted abnormalities in CD8+ T cells primed without CD4+ T cell help, we 
evaluated the transcriptional profile of these cells. On day 14 post-immunization with 
Ad5HVR48-Gag, Db/AL11+ CD8+ T cells from the spleen of untreated control or αCD4 treated 
mice were sorted and gene expression profiling was performed. Highly upregulated genes in 
Db/AL11+ CD8+ T cells from αCD4 treated mice compared to untreated controls were Havcr2 
(encodes Tim-3), Pdcd1 (encodes PD-1), Cd244 (encodes 2B4), Lag3 (encodes LAG-3), and 
Ctla4 (encodes CTLA4) (Fig. 3.3A). In contrast, highly upregulated genes in Db/AL11+ CD8+ T 
cells from untreated control mice compared to αCD4 treated were Klrg1 (encodes KLRG1), 
Gzmm (encodes Granzyme M), and Gzma (encodes Granzyme A) (Fig. 3.3A). These results 
highlight the over-expression of inhibitory markers by CD8+ T cells as a key difference in the 
absence of CD4+ T cell help. 
To further probe the concerted transcriptional differences between CD8+ T cells primed 
with and without CD4+ T cell help we utilized gene set enrichment analysis (GSEA) (22). GSEA 
analysis identified multiple cell cycle pathways that were down-regulated in Db/AL11+ CD8+ T 
cells from αCD4 treated mice (Fig. 3.3B). Consistent with this, reduced proliferation of 
Db/AL11+ CD8+ T cells from αCD4 treated mice was confirmed experimentally (Fig. 3.S3A). 
Conversely, multiple T cell receptor (TCR) signaling, cytokine signaling (notably STAT5), and 
cell death pathways were enriched in Db/AL11+ CD8+ T cells from αCD4 treated mice (Fig. 
3.3B). Increased apoptosis of Db/AL11+ CD8+ T cells from αCD4 treated mice was also 
confirmed experimentally (Fig. 3.S3B). Together the decreased proliferation and increased 
apoptosis of unhelped Db/AL11+ CD8+ T cells explains their reduced frequencies. 
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 The molecular signatures of CD8+ T cell exhaustion from two previous studies (23, 24) 
were significantly enriched in Db/AL11+ CD8+ T cells from αCD4 treated mice (Fig. 3.3C). The 
converse effector gene signature from each study was significantly enriched in Db/AL11+ CD8+ 
T cells from untreated control animals (Fig. 3.S3C). A molecular signature of T cell anergy was 
also significantly enriched in Db/AL11+ CD8+ T cells from αCD4 treated mice (Fig. 3.3C). 
Leading edge analysis of enriched genes from the exhaustion and anergy signatures identified 
that these two signatures were largely non-overlapping, which suggests the simultaneous 
expression of two distinct transcriptional programs in these cells (Fig. 3.3D and Fig. 3.S3D). 
Expression of a T cell anergy signature was not simply due to absence of signaling via CD28, as 
an antigen-specific CD8+ T cell response was completely absent in CD80/CD86 double KO mice, 
and thus did not recapitulate the absence of CD4+ T cells (Fig. 3.S3E).  The transcriptional 
signature of exhaustion in CD8+ T cells primed without CD4+ T cell help is consistent with the 
elevated expression of inhibitory receptors and hypofunctionality, and the transcriptional 
signature of anergy is consistent with the apparent rapidity of this dysfunction. 
 A recent report has demonstrated that the transcription factor NFAT when acting 
independently of AP-1 can induce expression of exhaustion- and anergy-associated genes (25). 
NFATc1 was substantially over-expressed in Db/AL11+ CD8+ T cells from αCD4 treated mice 
(Fig. 3.3A), and these cells were enriched for signatures of NFAT signaling (Fig. 3.3B). We thus 
hypothesized that AP-1-indendent NFAT signaling (here termed NFATΔAP-1) was driving the 
dual expression of exhaustion and anergy transcriptional signatures. Consistent with this 
hypothesis, the NFATΔAP-1 gene signature was enriched in cells from αCD4 treated mice, as 
were the specific subsets of genes previously shown to be regulated by NFATΔAP-1 and 
involved in anergy or exhaustion (Fig. 3.3E-3.3F). An additional signature for non-canonical 
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NFAT signaling was also significantly enriched (Fig. 3.3E-3.3F). Of note, no AP-1 target 
pathways were enriched in cells from αCD4 treated mice (data not shown). These data are 
consistent with a model where atypical NFAT signaling in antigen-specific CD8+ T cells from 
αCD4 treated mice appears to drive, in part, the simultaneous expression of exhaustion and 
anergy gene signatures in these cells.  
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Figure 3.3. Transcriptional signatures of exhaustion and anergy in CD8+ T cells primed in 
the absence of CD4+ T cells. (A-H) C57BL/6 mice (n=4/group) were treated with αCD4 
antibody or left untreated and immunized intramuscularly with 109 vp of Ad5HVR48-Gag. Gene 
expression profiling of cDNA from sorted Db/AL11+ CD8+ T cells from day 14 post-
immunization was performed. (A) Volcano plot of differentially expressed genes between 
Db/AL11+ CD8+ T cells from untreated or αCD4 antibody treated animals. Select genes are 
highlighted. (B) Gene set enrichment analysis was performed on the C2 dataset from the 
MSigDB (Broad Institute) and select gene signatures of interest with a FDR<0.05 are shown). 
(C) Gene set enrichment analysis was performed of two different molecular signatures of 
exhaustion [GSE9650 (24), GSE30962 (23)] and one signature of anergy [GSE2323 (70)]. 
FDR<0.05 for all gene signatures. (D) Genes within the leading edge of the gene signatures from 
(C). (E-F) Gene set enrichment analysis using gene sets comprised of NFAT target genes, and 
overlap and shared enriched genes in gene signatures. NFATΔAP-1 denotes AP-1-independent 
NFAT target genes as described in (25). 
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Provision of CD4+ T cell help after immunization fails to rescue the dysfunctional 
phenotype of CD8+ T cells primed in the absence of CD4+ T cells. 
Chronic viral infection induces classical CD8+ T cell exhaustion that becomes progressively 
more profound over time (26-28). In contrast, anergic T cells rapidly display functional defects 
(29). Thus, we sought to determine if the defects of CD8+ T cells primed without CD4+ T cell 
help were irreversibly imprinted at priming, or if the differentiation was a progressive process. 
We experimentally reconstituted CD4+ T cell help after immunization to explore whether this 
could rescue the dysfunctional state of CD8+ T cells primed in the absence of CD4 T cells.  A 
recently described experimental system was utilized to generate mice permanently lacking 
endogenous CD4+ T cells (9, 30). CD45.1+ congenic mice underwent adult thymectomy and 
were treated with αCD4 Ab or left untreated as a control (Fig. 3.4A). One month post-αCD4 Ab 
treatment, all αCD4 Ab had been cleared from the serum (data not shown). To correct for the 
lack thymic output, 5x102 naïve OT-I CD8+ T cells (specific for the Kb/OVA257-264 epitope) were 
adoptively transferred into all animals. Finally, mice either received no adoptively transferred 
CD4+ T cells or 5x104 naïve OT-II CD4+ T cells (specific for the I-Ab/OVA323-339 epitope) on 
day -1, 3, 7, or 10 post-immunization (Fig. 3.4A). 
 Mice that received αCD4 antibody and did not receive adoptive transfer of CD4+ T cells 
had OT-I CD8+ T cell responses of a reduced magnitude, and the responding cells expressed less 
KLRG1 and more PD-1 than OT-I cells from control mice that did not receive αCD4 antibody 
(Fig. 3.4B-4D, red lines). These responses recapitulated those seen when endogenous Kb/OVA-
specific CD8+ T cells are measured, which validates the use of the CD8+ T cell adoptive transfer 
system. Adoptive transfer of naïve OT-II CD4+ T cells prior to immunization resulted in 
expansion and differentiation of OT-I CD8+ T cells that was largely equivalent to the responses 
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seen in mice that had not been treated with αCD4 antibody (black versus blue lines; Fig. 3.4B-
3.4D). Thus, adoptive transfer of naïve OT-II CD4+ T cells recapitulates the CD4+ T cell help 
provided by endogenous CD4+ T cells. 
 When naïve OT-II CD4+ T cells were transferred into mice on day 3 post-immunization, 
the expansion of the OT-I CD8+ T cell responses was partially rescued so that at day 14 post-
immunization the responses were equivalent to the control group (purple line; Fig. 3.4B), but the 
peak of the response was delayed and of substantially reduced magnitude compared to the 
control groups. Adoptive transfer of naïve OT-II CD4+ T cells on day 7 or 10 post-immunization 
had no detectable impact on the magnitude of the OT-I CD8+ T cell responses (Fig. 3.4B). 
Despite the modest effect on the magnitude of the CD8+ T cell response, adoptive transfer of 
naïve OT-II CD4+ T cells on day 3 post-immunization did not rescue the expression of KLRG1 
or decrease the expression of PD-1 relative to mice that did not receive adoptive transfer of CD4+ 
T cells (purple versus red lines; Fig. 3.4C and 3.4D). Concordant with these data, adoptive 
transfer of naïve OT-II CD4+ T cells on day 7 or 10 post-immunization also had no impact on the 
phenotype of the CD8+ T cells (green and grey lines; Fig. 3.4C and 3.4D). These data suggest 
that CD4+ T cells are essential during priming to provide help to responding CD8+ T cells, and 
the absence of help during this period results in irreversible dysfunction. 
 Persistent antigen is a critical driving factor in chronic infection-induced exhaustion (31-
33). However, given the immediate irreversible nature of the dysfunction we observed in CD8+ T 
cells primed without CD4+ T cell help, we hypothesized that persistent antigen would not be a 
major causative factor in our system. To test this, we utilized a previously described Ad vector in 
which the transgene is under the control of a tetracycline repressive element (Ad5-tTA-
SIINFEKL-Luc) (34). Despite robust transgene silencing, no alteration in the frequency, 
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phenotype or functionality of antigen-specific CD8+ T cells primed without CD4+ T cells was 
observed (Fig. 3.S4). Together these data suggest that while immediate CD8+ T cell dysfunction 
shares functional, transcriptional, and phenotypic characteristics with chronic infection-induced 
exhaustion, one of the major causative pathways does not appear to be shared. 
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Figure 3.4. Provision of CD4+ T cell help after immunization does not rescue the 
dysfunctional phenotype of CD8+ T cells primed without CD4+ T cell help. (A-D) 
Experimental schematic. CD45.1+ B6 mice underwent adult thymectomy and were treated with 
αCD4 antibody or left untreated 30 days prior to immunization. 5x102 naïve CD45.2+ OT-I CD8+ 
T cells were adoptively transferred one day prior to immunization. Mice were immunized 
intramuscularly with 109 vp of Ad5-OVA. 5x104 naïve CD45.2+ OT-II CD4+ T cells were 
adoptively transferred on day -1, 3, 7, or 10 post-immunization. For one control group no OT-II 
CD4+ T cells were transferred. (B) Frequency of OT-I CD8+ T cells in the blood. (C) Fraction of 
blood OT-I CD8+ T cells expressing KLRG1. (D) PD-1 expression on blood OT-I CD8+ T cells. 
Data are pooled from two experiments (B, C) or representative of two experiments (D). N=4-
5/group per experiment. Mean + SEM are shown. 
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Blockade of PD-1 signaling during priming partially rescues the CD8+ T cell response 
generated without CD4+ T cell help. 
Given the elevated expression of PD-1 on CD8+ T cells primed without CD4+ T cell help, we 
hypothesized that blockade of PD-1 might rescue the differentiation of these cells, as has been 
reported for chronic infections or cancer (35-39). To test this hypothesis, mice were depleted of 
CD4+ T cells or left untreated, immunized with Ad5-SIINFEKL-Luc, and treated with αPD-L1 
antibody or an isotype control on day -1, 2, 5, and 8 post-immunization (Fig. 3.5). Blockade of 
PD-1 signaling (via αPD-L1 antibody) led to a partial rescue (6-fold; P<0.01) in the 
accumulation of Kb/OVA+ CD8+ T cells primed in the absence of CD4+ T cell help (Fig. 3.5A). 
Administration of αPD-L1 antibody significantly increased the fraction of Kb/OVA+ CD8+ T 
cells that expressed KLRG1 and significantly decreased the fraction of cells that were in an 
undifferentiated KLRG1loCD127lo state (P<0.05; Fig. 3.5B). Administration of αPD-L1 antibody 
following Ad5-HVR48-Gag immunization of αCD4 treated mice also partially rescued the 
frequency and KLRG1 expression of Db/AL11+ CD8+ T cells (data not shown). αPD-L1 antibody 
treatment rescued the defect in Granzyme B expression observed in Kb/OVA+ CD8+ T cells 
primed in the absence of CD4+ T cells (P<0.01; Fig. 3.5C). Phenotypic rescue of Kb/OVA+ CD8+ 
T cells by αPD-L1 antibody treatment also corresponded to a substantial increase in cytotoxicity 
as measured using an ex vivo killing assay (Fig. 3.5D). The fraction and number of IFN-γ+ CD8+ 
T cells was significantly increased in αPD-L1 antibody treated mice compared to isotype 
controls (P<0.01; Fig. 3.5E and 3.5F). Finally, αPD-L1 treatment lead to a partial rescue in the 
ability of IFN-γ+ CD8+ T cells to co-produce TNF-α compared to mice that received an isotype 
control antibody (P<0.01; Fig. 3.5E and 3.5F). To confirm these findings we also utilized an 
αPD-1 antibody to block receptor ligation. Treatment with an αPD-1 antibody recapitulated the 
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effect of treatment with an αPD-L1 antibody for all parameters analyzed (Fig. 3.S5). Collectively, 
these data demonstrate signaling via PD-1 early post-immunization plays a critical role in 
modulating the dysfunction observed in CD8+ T cells primed without CD4+ T cell help. 
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Figure 3.5.  αPD-L1 antibody treatment partially rescues differentiation of CD8+ T cells 
primed in the absence of CD4+ T cells. (A-G) C57BL/6 mice were treated with αCD4 antibody 
or left untreated and immunized intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. Mice were 
administered αPD-L1 or isotype control antibody every 3 days beginning one day prior to 
immunization. (A) Representative plots and absolute number of Kb/OVA+ CD8+ T cells in the 
blood on day 10 post-immunization. (B) KLRG1 and CD127 expression on Kb/OVA+ CD8+ T 
cells in the blood on day 10 post-immunization. (C) Expression of Granzyme B on Kb/OVA+ 
CD8+ T cells in the blood on day 10 post-immunization. (D) 5 hour killing assay of OVA257-264 
peptide pulsed EL-4 cells by pooled CD8+ T cells from day 10 post-immunization. E:T ratio was 
performed in duplicate for untreated and αCD4+αPD-L1 and singlet for αCD4+isotype. (E) 
Representative plots of IFN-γ and TNF-α by CD8+ T cells from the spleen upon ex vivo 
stimulation with OVA257-264 peptide. (F) Absolute number of OVA257-264-specific CD8+ T cells 
that produce IFN-γ. (G) Absolute number of OVA257-264-specific CD8+ T cells that co-produce 
IFN-γ and TNF-α. Data are representative of two to four experiments per group (n=5-8/group per 
experiment). Mean ± SEM are shown. **, P<0.01; *, P<0.05; Mann-Whitney U test.  
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Perturbed IL-2 signaling in the absence of CD4+ T cells is involved in CD8+ T cell 
dysfunction. 
We sought to determine if IL-2 signaling was perturbed in CD8+ T cells primed without CD4+ T 
cell help, as IL-2 signaling has a well established role in T cell anergy (40), and a more recently 
described role in CD8+ T cell exhaustion (41). Ova-specific CD8+ T cells were first detectable in 
the draining LNs on day 4 post-immunization (Fig. 3.S6A-3.S6C), consistent with a previous 
report (42). Strikingly, Kb/OVA+ CD8+ T cells from αCD4 treated mice already had a significant 
reduction in expression of CD25 (high affinity IL2Rα receptor) compared to untreated controls 
on day 4 (P<0.01; Fig. 3.6A). Intriguingly, several other genes that are known to be regulated by 
IL-2 signaling, including up-regulation of CD71, CD98, and Granzyme B, as well as increased 
cell size and granularity during proliferation (43-45), were all perturbed in the absence of CD4+ 
T cells (Fig. 3.1 and Fig. 3.S6D-3.S6E). No difference in expression of co-stimulatory receptors 
was observed (Fig. 3.S6D-3.S6E). These data suggest that in the absence of CD4+ T cell help 
there are alterations in IL-2 signaling to CD8+ T cells. 
We thus hypothesized that administration of rIL-2 might correct the dysfunctional 
differentiation of CD8+ T cells in the absence of CD4+ T cell help. Administration of rIL-2 to 
αCD4 antibody treated mice, but not untreated controls, increased the frequency of Kb/OVA+ 
CD8+ T cells by 8.6-fold and the number by 7-fold on day 10 post-immunization (P<0.01; Fig. 
3.6B). Administration of rIL-2 significantly increased Granzyme B expression (P<0.01; Fig. 
3.6C) and also corrected the defect in differentiation to a KLRG1hiCD127lo effector phenotype 
(Fig. 3.6D). Administration of rIL-2 decreased PD-1 expression on Kb/OVA+ CD8+ T cells from 
αCD4 treated mice to levels seen on Kb/OVA+ CD8+ T cells from untreated control animals 
(P<0.01; Fig. 3.6E). However, co-administration of rIL-2 and αPD-L1 antibody did not 
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significantly increase the frequency of Kb/OVA+ CD8+ T cells in the blood compared to either 
treatment alone (Fig. 3.6E). Co-administration of rIL-2 and αPD-L1 antibody also did not impact 
on PD-1, KLRG1, or Granzyme B expression any more than one treatment alone (data not 
shown). Taken together, repeated administration of low dose rIL-2 can partially rescue the 
impaired accumulation and effector differentiation of Kb/OVA+ CD8+ T cells in αCD4 treated 
mice but appears to do so in a redundant manner to blockade of PD-1 signaling. These data 
suggest that administration of rIL-2 is sufficient to properly differentiate unhelped CD8+ T cells 
to a state where they are no longer responsive to blockade of PD-1 signaling. 
  Given these findings, we sought to determine if absence of IL-2 signaling on CD8+ T 
cells was sufficient to recapitulate the absence of CD4+ T cell help. Naïve wild type and CD25 
KO OT-I CD8+ T cells were transferred at a 1:1 ratio into the same recipient (Fig. 3.6G). On day 
10 post-immunization, CD25 KO OT-I CD8+ T cells displayed a massive defect in frequency 
compared to their wild type counterparts (P<0.01; Fig. 3.6H), and these responding cells have 
reduced expression of Granzyme B (P<0.01; Fig. 3.6I). However, CD25 KO OT-I CD8+ T cells 
had unimpaired upregulation of KLRG1 (Fig. 3.6J) and did not over-express PD-1 relative to 
wild type OT-I CD8+ T cells (Fig. 3.6K). Thus, absence of cell-intrinsic high-affinity IL-2 
signaling by CD8+ T cells is sufficient to recapitulate the reduced frequency and reduced effector 
functionality of CD8+ T cells when CD4+ T cells are absent. However, the absence of high-
affinity IL-2 signaling is insufficient to fully recapitulate the dysfunction observed in the absence 
of CD4+ T cells, and suggests that CD4+ T cells provide help by multiple mechanisms. The 
observation that rIL-2 is sufficient to suppress PD-1 expression (Fig. 3.6E), but absence of IL-2 
signaling is not sufficient to induce PD-1 over-expression (Fig. 3.6K) supports the conclusion 
that CD4+ T cell help involves multiple mechanisms. 
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Figure 3.6. Early IL-2 treatment rescues proliferation and effector differentiation of CD8+ 
T cells primed in the absence of CD4+ T cells. (A) Expression of CD25 on Kb/OVA+ CD8+ T 
cells in the iliac LNs. (B-E) C57BL/6 mice were treated with αCD4 antibody or left untreated 
and immunized intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. Mice were administered 
with recombinant mouse IL-2 (rIL-2) or PBS control twice daily from day 3 to 10 post-
immunization. (C) Frequency of Kb/OVA+ CD8+ T cells in blood on day 10 post-immunization. 
(D) Expression of PD-1 on Kb/OVA+ CD8+ T cells in the blood. (C) KLRG1 and CD127 
expression on Kb/OVA+ CD8+ T cells in the blood. (E) Expression of Granzyme B on Kb/OVA+ 
CD8+ T cells in the blood. (F) Mice were administered with recombinant mouse IL-2 (rIL-2) or 
PBS control twice daily from day 3 to 10 post-immunization and αPD-L1 antibody or isotype 
control once every three days beginning on day 0. Frequency of Kb/OVA+ CD8+ T cells in blood 
on day 10 post-immunization. (G-K) WT and CD25 KO OT-I CD8+ T cells were mixed at a 1:1 
ratio and adoptively transferred into congenically marked mice one day prior to immunization. 
Mice were immunized intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. Responses were 
assessed on day 10 for frequency of OT-I cells in the blood (H), Granzyme B expression (I), 
KLRG1 expression (J), and PD-1 expression (J) on OT-I CD8+ T cells. Data are representative 
of two experiments (n=4-5/group per experiment). Mean ± SEM are shown. **, P<0.01; *, 
P<0.05; Mann-Whitney U test. Figure on next page ! 
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Figure 3.6 (Continued)  
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DISCUSSION 
CD4+ T cell help has been shown to be critical in many settings for the optimal expansion of 
CD8+ T cell responses (46). However, the role of CD4+ T cells in the immediate phenotypic 
imprinting of CD8+ T cells remains poorly understood. Our data demonstrate a novel means by 
which CD4+ T cells provide help following Ad vector immunization to prevent early exhaustion-
like dysfunction of vaccine-elicited CD8 T cells. Following Ad vector immunization of CD4+ T 
cell deficient mice, the CD8+ T cell responses are of reduced frequency, have reduced 
cytotoxicity and cytokine production, and exhibit an aberrant phenotype characterized by 
elevated expression of multiple inhibitory receptors. CD8+ T cells elicited without CD4+ T cell 
help expressed transcriptional signatures of CD8+ T cell exhaustion and T cell anergy, which 
appears to be driven, in part, by excessive AP-1-independent NFAT signaling when CD4+ T cells 
were absent. Anergy and exhaustion are largely distinct differentiation states (47), and thus the 
underlying dysfunction of these CD8+ T cells appears to be caused by simultaneous expression 
of multiple inhibitory transcriptional programs. Irreversible abnormalities in CD8+ T cell 
differentiation occurred within days of immunization when CD4+ T cells were absent. This 
dysfunctional differentiation is a multi-faceted process, but we have identified key roles for 
elevated PD-1 and reduced IL-2 signaling. Collectively, this study identifies a previously 
unappreciated role of CD4+ T cells in immediate programming of CD8+ T cell effector 
phenotype, by modulating coordinated activation of key T cell-specific transcription factors, 
including AP-1. 
Previous studies have shown that CD4+ T cells are critical for driving optimal primary 
CD8+ T cell expansion in several experimental systems (2, 3, 5, 9, 16, 48). In this study, we 
demonstrate that CD4+ T cells are required at priming for optimal induction of CD8+ T cells by 
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Ad vector immunization, consistent with previous reports (11-14). In addition to modulating 
CD8+ T cell expansion, we identify a critical role for CD4+ T cells in driving acquisition of CD8+ 
T cell effector functions, which is in contrast to previous reports that, depending on the 
experimental setup, determined CD4+ T cells either had no role in acquisition of effector 
phenotype (16) or restrained effector differentiation (4, 5). We have thus identified CD4+ T cell-
derived signals can be crucial for the acquisition of effector function and phenotype by CD8+ T 
cells. 
Our data show that CD4+ T cell help is required at priming to ensure proper effector 
CD8+ T cell differentiation in this system. Provision of CD4+ T cell help on day 3 after 
vaccination can partially rescue the accumulation of antigen-specific CD8+ T cells, but it does 
not correct the phenotypic dysfunction of CD8+ T cells (Fig. 3.4). We have recently 
demonstrated that the presence of CD4+ T cells is required for several days post-immunization 
for proper expansion and effector differentiation of CD8+ T cells following Ad vector 
immunization (11). In that work, the earlier depletion of CD4+ T cells occurred the more 
profoundly impaired the CD8+ T cell responses were. Synthesizing these studies demonstrates 
that CD4+ T cells provide indispensible signals during priming and then continue to provide 
signals for a week post-immunization to maintain CD8+ T cell proliferation and reinforce the 
established effector differentiation pathway. 
CD8+ T cells primed without CD4+ T cell help display an altered phenotype with elevated 
expression of inhibitory receptors, decreased ex vivo cytotoxicity, decreased ability to produce 
cytokines, and a transcriptional signature of exhaustion (Fig. 3.1-3.3), which are all 
characteristics indicative of exhausted CD8+ T cells (21, 23, 24, 26, 35, 49-51). Blockade of PD-
1 signaling partially rescued responses in our system (Fig. 3.5), as did administration of rIL-2 
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(Fig. 3.6), and both of these treatments rescue exhausted CD8+ T cells (35, 41). However, CD8+ 
T cell exhaustion involves a strong temporal component where CD8+ T cells become 
progressively more impaired the longer the cells remain in an environment of persistent viremia 
(26-28, 52, 53). By contrast, in our model, CD8+ T cell dysfunction occurs within days of 
immunization (Fig. 3.4). Consistent with this, experimental removal of persistent expression of 
antigen in mice depleted of CD4+ T cells did not alter the functionality or phenotype of these 
dysfunctional CD8+ T cells (Fig. 3.S4). In these studies, we describe a novel aberrant CD8+ T 
cell differentiation state that is phenotypically and functionally akin to exhaustion, but occurs 
immediately upon priming. 
When CD8+ T cells fail to receive the complete array of priming signals they 
immediately enter a dysfunctional state termed “split-anergy” (54). This split-anergy is 
characterized by reduced proliferative capacity, but no defects in IFN-γ production or cytotoxic 
function are observed (55). While the CD8+ T cell dysfunction observed in our study occurs 
immediately upon priming and these cells express a transcriptional program of anergy, the 
induced cells have dramatic impairments in IFN-γ production and cytotoxic function, and thus 
are not functionally similar to cells in a state of split-anergy. However, the dysfunctional CD8+ T 
cells we describe and split-anergy CD8+ T cells are responsive to reinvigoration by rIL-2 
administration (Fig. 3.6 and (40), respectively). However, following Ad vector immunization, 
IL-2 was required to endow CD8+ T cell responses with proliferative capacity and effector 
functionality (Fig. 3.6). By contrast, IL-2 signaling to CD8+ T cells in a state of split-anergy 
serves primarily to drive proliferation (40) as these cells maintain robust effector functionality 
(55, 56). Thus, while these unhelped CD8+ T cells have characteristics of anergy, the 
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functionality of these cells is distinct from the previously characterized state of CD8+ T cell 
anergy. 
It has recently been demonstrated that expression of an engineered NFAT that is 
incapable of interacting with AP-1 is sufficient to drive expression of anergy and exhaustion-
related genes (25). Elevated NFAT, but not AP-1 family proteins, were enriched in CD8+ T cells 
from CD4+ T cell deficient mice, and gene signatures of NFAT signaling were significantly 
enriched (Fig. 3.3). Specifically, the gene signature of AP-1-independent NFAT signaling was 
enriched as were the subset of NFAT-regulated genes associated with anergy and exhaustion. 
Thus, we propose a model whereby a major driving factor of the observed CD8+ T cell 
dysfunction is due to elevated non-canonical NFAT signaling. The partial prevention of this 
phenotype by rIL-2 administration suggests that, in the context of Ad vector immunization, 
CD4+ T cell-derived IL-2 is responsible for inducing AP-1 signaling on CD8+ T cells, as has 
been reported in an in vitro model of CD4+ T cell anergy (57). Future experiments will be 
required to test this hypothesis. Additionally, given the clear data that manipulation of IL-2 
signaling can only partially rescue or induce CD8+ T cell dysfunction, additional mechanisms of 
CD4+ T cell help remain to be identified. 
In conclusion, we demonstrate that CD4+ T cells are required immediately upon antigen 
priming for the optimal expansion and effector differentiation of viral vector vaccine induced 
CD8+ T cells. The absence of CD4+ T cell help results in a multi-faceted and immediate 
dysfunction of responding CD8+ T cells that functionally mirrors many of the characteristics of T 
cell exhaustion. These dysfunctional cells express both exhaustion and anergy gene signatures, 
which appears to be due to increased AP-1-independent NFAT signaling. This dysfunction is 
imprinted, in part, by elevated PD-1 signaling and reduced IL-2 signaling. These data suggest a 
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novel mechanism of immediate CD4+ T cell help to prime effector CD8+ T cell function. 
Furthermore, these findings suggest a potential means of improving the immunogenicity of viral 
vector immunization in the context of reduced CD4+ T cell functionality by manipulation of 
these pathways.  
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ABSTRACT 
Replication-incompetent adenovirus (Ad) vectors are used in prime-boost immunization 
regimens to induce robust antigen-specific antibody responses against their expressed transgene 
antigens, but how Ad vector-elicited antibody responses are regulated remains unknown. Here 
we demonstrate that induction of antibody responses can occur at a time displaced from the time 
of Ad vector immunization by depletion of CD4+ T cells. Transient depletion of CD4+ T cells at 
the time of immunization delayed the development of antigen-specific antibody responses but 
did not permanently impair their development or induce tolerance against the encoded transgene. 
Upon CD4+ T cell recovery, transgene-specific serum IgG antibody titers developed and reached 
a concentration equivalent to undepleted control animals. These delayed antibody responses 
exhibited no functional defects with regards to isotype, functional avidity, expansion after 
boosting immunization, or their capacity to neutralize an SIV Env-expressing pseudovirus. The 
development of these delayed transgene-specific antibody responses requires thymus-mediated 
reconstitution of the CD4+ T cell population, and involves the de novo generation of germinal 
center responses. These data demonstrate the ability to modulate the timing of vaccine-elicited 
antibody responses by manipulation of CD4+ T cells and may have important implications for the 
development of vaccines designed to elicit antibody responses. 
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INTRODUCTION 
Replication-incompetent recombinant adenovirus (Ad) vectors are a promising class of candidate 
vaccines for several diseases of major public health importance including human 
immunodeficiency virus-1 (HIV-1) (1, 2) , hepatitis C (1-4), ebola (5, 6), tuberculosis (7), and 
malaria (8). Ad vectors have primarily been pursued as vaccine platforms due to their ability to 
induce strong CD8+ T cell responses (3, 5, 7, 9), but they can also induce robust transgene 
antigen-specific antibody responses (10-12). In a preclinical trial of Ad vector-based HIV-1 
vaccines, Ad vector expressing SIV Env prime followed by a soluble SIV Env protein boost 
resulted in protection of 50% of rhesus monkeys challenged with a difficult-to-neutralize virus, 
and this protection was associated with SIV Env-specific antibody responses (12). The regulation 
of Ad vector-elicited antibody responses, however, remains poorly understood. 
 The induction of antibody responses is typically dependent on CD4+ T cell help (13). In 
the context of antibody induction, CD4+ T cells primary function to promote and maintain B cell 
germinal center responses. A critical mediator of CD4+ T cell help to B cells is via the 
engagement of the CD40 signaling pathway (14). Studies using model antigens have 
demonstrated that the proper development of germinal center responses is a dynamic process 
where CD4+ T cell help, via CD40, is provided for several days (15, 16). We have recently 
described that following Ad vector immunization, CD4+ T cell help is required for a month post-
immunization to properly induce CD8+ T cell responses (17). Thus, we sought to determine 
whether prolonged CD4+ T cell help is also required following Ad vector immunization for the 
induction of transgene-specific antibody responses. 
 In this study, we identified that following Ad vector immunization, CD4+ T cell help is 
required for ten days post-immunization to induce optimal antigen-specific antibody titers. 
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Unexpectedly, we also observed that CD4+ T cell depletion prior to immunization did not result 
in a permanent ablation of antigen-specific antibody responses. Instead, the induction of antibody 
responses was simply delayed until the time at which the CD4+ T cells began to recover. These 
delayed antibody responses exhibited no apparent functional defects. Delayed antigen-specific 
antibody responses were also observed using a protein immunogen formulated in an alum-based 
adjuvant. Thus, in contrast to the current model that the depletion of CD4+ T cells at the time of 
antigen exposure results in tolerance (18-22), we demonstrate that functional antibody responses 
can be induced at a time separate from immunization with Ad vector or protein-based vaccines in 
the context of transient CD4+ T cell depletion.   
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MATERIALS AND METHODS 
Mice, vectors, proteins, and viruses. Six- to ten-week-old C57BL/6, B6.129S2-H2dlAb1-Ea/J 
(MHC II KO), B6.129S2-Cd40lgtm1Imx/J (CD40L KO), and B6.129P2-Cd40tm1Kik/J (CD40 KO) 
mice were purchased from (Jackson Laboratory, Bar Harbor, ME). Thymectomized C57BL/6 
underwent adult thymectomy at the Jackson Laboratory (Bar Harbor, ME). Mice were 
immunized intramuscularly (i.m.) in a volume of 100 µl divided between the two quadriceps. 
The previously described E1/E3 deleted Ad26-SIVmac239 Env or Ad5-SIVmac239 Env were used at 
a dose of 109 or 1010 vp (23). SIV Env 32H gp140 was used at 50 µg + 100 µg Adju-Phos 
(Brenntag) (24). All animal experiments were performed in accordance with the Institutional 
Animal Care and Use Committee guidelines of Beth Israel Deaconess Medical Center. 
Monoclonal antibodies. The monoclonal αCD4 antibody (GK1.5; BioXcell) was administered 
by two intraperitoneal injections of 500 µg on consecutive days. To maintain depletion of CD4+ 
T cells, where applicable, GK1.5 was readministered in two 500 µg doses every 14 to 21 days. 
Serum collection and tissue processing. Blood was collected and serum was clarified by 
collection of the supernatant following centrifugation at 10000 rpm for 5 minutes. Two 
centrifugation steps were performed and following clarification serum was stored at -20 °C for 
further analysis. Splenic and iliac lymph node mononuclear cells were harvested as previously 
described (25). Tissues were ground through a 70 µm strainer (Fisher Scientific), red blood cells 
were lysed by Ammonium-Chloride-Potassium (ACK) treatment for three minutes, and debris 
was removed by subsequent filtering through a 30 µm filter (Miltenyi Biotec). 
Endpoint ELISA. Endpoint enzyme-link immunosorbent assays (ELISAs) were performed as 
previously described (26). Briefly, ELISA plates were coated overnight with 1µg/ml of SIVmac239 
gp140 Env. Plates were blocked for 4 hrs with PBS + 2% BSA + 0.05% Tween 20. Mouse sera 
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was serially diluted, added to the ELISA plate, and incubated for 1 hr. Bound sera was detected 
by 1 hr incubation with peroxidase-conjugated, affinity-purified rabbit anti-mouse secondary 
antibody diluted 1:2000  (Jackson ImmunoResearch Laboratories). Plates were developed and 
read on a Spectramax Plus ELISA plate reader using Softmax Pro 4.7.1 software (Molecular 
Devices). Positive titers were defined as the greatest serum dilution with OD >2-fold above naïve 
negative control serum OD. 
Isotype and urea disruption ELISAs. Isotype and urea disruption ELISAs were performed as 
previously described (27, 28). A semi-quantitative immunoglobulin ELISA protocol described 
previously was followed. Briefly, 0.5 µg/mL SIVmac239 gp140 Env coated ELISA plates were 
blocked with 1% Bovine Serum Albumin (BSA)/0.05% Tween in PBS (PBS-T). After washing, 
diluted samples were added to the plates for 1 hr before washing and the addition of a 1:4000 
dilution of either anti-mouse IgG conjugated to Horseradish peroxidase (HRP), IgG1-HRP, or 
IgG2a-HRP (Southern Biotech). Standards consisted of coating ELISA plate wells with anti-
mouse Kappa (1:3200) and Lambda (1:3200) light chain (Serotec, UK), blocking, washing, and 
then adding a standard five-fold dilution series of purified IgG or IgA (Southern Biotech, UK) 
starting at 1000 ng/mL. Samples and standards were developed using 3,3',5,5'-
Tetramethylbenzidine (TMB) and the reaction was stopped after 5 min with Stop solution 
(Insight Biotechnologies, UK). Absorbance was read on a Spectramax Plus ELISA plate reader 
(Molecular Devices) with SoftMax Pro 4.7.1 software. 
The avidity indices of serum samples were determined by their antibody-antigen binding 
resistance to 8 M urea. Serum samples were pre-diluted to give an OD450 nm readout between 1.0 
and 1.5 in an ELISA and were added to SIVmac239 gp140 Env coated plates. Plates were then 
washed three times with either PBS-T or 8 M urea in PBS-T, before incubating with anti-mouse 
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IgG-HRP. Samples were developed with TMB as described above. The avidity index was 
calculated as the percentage of urea treated OD450 nm/ PBS-T OD450 nm.  
SIV Neutralization assay. SIV-specific neutralization assays were performed as previously 
described using the TZM.bl neutralization assay (29). Briefly, mouse sera was serially diluted 
and incubated for one hour with the Tier 1A neutralization sensitive pseudotype virus 
SIVmac251.TCLA.15 and was subsequently added to TZM.bl cells. A pseudotyped virus 
expressing the envelope gene of murine leukemia virus (MuLV) was used as a negative control. 
After 48 hrs cells were lysed and relative luminescence units were quantified. ID50 was 
calculated as the serum concentration that reduced relative luminescence units by 50% relative to 
a no sera control well. Pseudotyped viruses were prepared as previously described (30). 
Germinal Center B cells. Single cell suspensions of iliac LN mononuclear cells were blocked 
with TruStain fcX (anti-mouse CD16/CD32) antibodies (Biolegend) for 10 min at 4 °C. Cells 
were washed and stained for 30 min at 4 °C with αCD3ε (145-2C11), αCD19 (6D5), αFas 
(15A7), peanut agglutinin (PNA; Vector Labs), αIgM (RMM-1), and αIgD (11-26c.2a). Dead 
cells were excluded by the use of a vital exclusion dye (Life Technologies). All antibodies were 
purchased from BD Biosciences, Affymetrix, or BioLegend, unless noted otherwise. Germinal 
center B cells were identified by flow cytometry as Fas+ PNA+ CD19+, as previously described 
(31). Samples were acquired on an LSR II flow cytometer (BD Biosciences) and analyzed using 
FlowJo v9.8.3 (Treestar). 
Statistics. Mann-Whitney U tests were performed with a significance cutoff of P<0.05.  
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RESULTS 
Ad vector-elicited antibody responses are delayed following the depletion of CD4+ T cells at 
immunization. 
We first sought to determine when CD4+ T cell help is required for the induction of transgene 
antigen-specific antibody responses by Ad vector vaccination. To accomplish this, C57BL/6 
mice were immunized i.m. with 1010 vp of Ad26-SIV Env and depleted of CD4+ T cells by the 
administration of the αCD4 antibody GK1.5 on days -1, 3, 7, 10, 14, 21, or 28 post-immunization 
or left untreated, as a control (Fig. 4.1A). In untreated control mice, robust SIV Env-specific 
serum antibody titers were detected on day 14 post-immunization and were maintained for at 
least 90 days (Fig. 4.1B). Depletion of CD4+ T cells prior to immunization resulted in nearly 
undetectable Env-specific antibody responses at day 14 and 30 post-immunization (Fig. 4.1B). 
Depletion of CD4+ T cells between day 3 and 10 post-immunization had progressively less of an 
impact on Env-specific antibody titers as measured on day 30, and depletion of CD4+ T cells on 
or after day 14 post-immunization had no impact on antibody titers as measured on day 30 (Fig. 
4.1B). As expected, the decrease in antibody titers observed following depletion of CD4+ T cells 
was associated with reductions in the frequency of germinal center B cells in the iliac (draining) 
lymph nodes (LNs) on day 14 post-immunization (Fig. 4.1C and 4.1D). Signaling by CD4+ T 
cells through CD40 is a well-described mechanism by which CD4+ T cells promote antibody 
responses (16). We confirmed that CD40 was an important signaling pathway for antigen-
specific antibody responses following Ad vector immunization, as absence of CD40L or CD40 
resulted in a complete abolishment of Env-specific antibody responses on day 30 post-
immunization (Fig. 4.1E). Thus, following Ad vector immunization, induction of antigen-
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specific antibody responses requires CD4+ T cell help to promote germinal center responses via 
CD40-derived signals, consistent with other experimental systems (32). 
 We next sought to determine whether CD4+ T cells regulated the maintenance of Ad 
vector-induced antibody responses. Unexpectedly, when Env-specific antibody responses were 
measured on day 60 and 90 post-immunization, we observed no significant difference in 
antibody titers between mice that had been previously depleted of CD4+ T cells and the untreated 
control animals (Fig. 4.1B, bottom panels). Despite the lack of detectable serum antibody 
responses on day 30 post-immunization in mice depleted of CD4+ T cells prior to immunization, 
these same animals developed Env-specific antibody titers of equivalent magnitude to untreated 
control mice by day 60 post-immunization. We define the antibody responses that develop on 
day 60 post-immunization after depletion of CD4+ T cells as “delayed antibody responses”. 
Similar delayed Env-specific antibody responses were also observed in mice depleted of CD4+ T 
cells between day 3 and 10 post-immunization. Thus, depletion of CD4+ T cells immediately 
prior to, or after, immunization resulted in a delay but did not prevent the induction of Env-
specific antibody responses.  
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Figure 4.1. Delayed development of antibody responses following depletion of CD4+ T cells. 
(A) C57BL/6 mice were depleted of CD4+ T cells at the indicated day or left untreated and 
immunized intramuscularly with 1010 vp of Ad26-SIV Env. (B) SIV Env-specific serum binding 
antibody titers at the indicated day post-immunization. Grey, no αCD4 treatment; Red, αCD4 
given on the indicated day; white, naive animals. (C and D) Representative flow cytometry plots 
(C) and absolute number (D) of germinal center B cell responses in the iliac LN on day 14 post-
immunization. Gated on CD3ε-CD19+ cells. (E) SIV Env-specific serum binding antibody titers 
in WT, CD40L KO, or CD40 KO mice immunized with 109 vp of Ad26-SIV Env. Each dot 
represents an individual mouse and the line is median (B and E) or mean±SEM (D). 
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Delayed antibody responses following CD4+ T cell depletion are functional. 
We sought to determine whether the delayed antibody responses observed after day 60 in mice 
depleted of CD4+ T cells prior to immunization are functionally normal. We first assessed if the 
delayed antibody responses exhibited alterations in their isotype proportion. The concentration of 
IgG2a isotype Env-specific antibodies increased from day 30 to 90 post-immunization in αCD4 
treated mice, and by day 90 only a statistical trend for differences in antibody concentration in 
αCD4 treated versus untreated mice were observed (p=0.06; Fig. 4.2A). Similarly, IgG1 isotype 
Env-specific antibody concentration increased in αCD4 treated mice between day 30 and 90, and 
reached equivalent antibody concentrations as in untreated control mice by day 90 (untreated 
median = 1409 ng/ml and αCD4 median = 975.5 ng/ml; p=0.6; Fig. 4.2B). On both day 60 and 
90 post-immunization, the ratio of IgG2a to IgG1 isotype antibodies was equivalent between 
αCD4 treated and untreated groups (p=0.3; Fig. 4.2C). Finally, we sought to determine if the 
delayed antibody response that developed following depletion of CD4+ T cells would have 
reduced antigen-binding avidity as measured using a urea disruption assay (27). Env-specific 
antibodies from day 60 or 90 post-immunization of αCD4 treated and untreated mice displayed 
no significant differences in Env-binding avidity by urea disruption ELISA (Fig. 4.2D). Thus, 
the delayed antibody responses exhibited no significant abnormalities in their isotype or binding 
avidity. 
 To further investigate the functionality of these delayed antibody responses we assessed 
whether these responses could expand after a boosting immunization. C57BL/6 mice were 
immunized i.m. with 1010 vp of Ad26-SIV Env and depleted of CD4+ T cells on day -1 or left 
untreated as a control (Fig. 4.3A). Four months after the primary immunization, mice were 
boosted i.m. with 1010 vp of Ad5-SIV Env (Fig. 4.3A). One month after the boosting 
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immunization the αCD4 antibody treated and untreated mice had equivalent median SIV Env-
specific endpoint titers (Fig. 4.3B), which reflected equivalent mean fold-expansion of 54-fold 
and 43-fold, respectively (p=0.8; Fig. 4.3C). As a final measure of functional capacity, we 
assessed the ability of these delayed antibodies to neutralize an SIV Env-expressing pseudovirus. 
No SIV-specific neutralizing antibodies in αCD4 treated mice were detected at one month post-
immunization (Fig. 4.3D), which is consistent with the lack of Env-specific binding antibodies at 
this time point (Fig. 4.1B). However, by four months post-immunization, αCD4 treated mice had 
median neutralizing antibody titers that were not significantly different from those in undepleted 
vaccinated mice (p=0.9; Fig. 4.3D). In both groups, neutralizing antibody titers increased 
following the boosting immunization, and again no differences between the two groups were 
observed (Fig. 4.3D). Collectively, these data demonstrate that the delayed antibody responses 
that developed following depletion of CD4+ T cells at the time of primary Ad vector 
immunization have no detectable defects in boosting capacity, ability to acquire functional 
neutralization capacity, isotype proportion, or antigen-binding avidity. 
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Figure 4.2. Transient depletion of CD4+ T cells at priming does not alter the isotype 
distribution or the antigen-binding avidity of the delayed antibody responses. C57BL/6 
mice were depleted of CD4+ T cells or left untreated and immunized intramuscularly with 1010 
vp of Ad26-SIV Env. Concentration of serum SIV Env-specific IgG2a (A) or IgG1 (B). (C) 
Ratio of SIV Env-specific IgG2a to IgG1 serum antibody titers. (D) Avidity of SIV Env-specific 
serum antibodies as determined by urea disruption assay. Each dot represents an individual 
mouse and for (A-C) median or (D) mean ±SEM is indicated by the line. 
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Figure 4.3. Boosting capacity and functional neutralization capacity of the delayed 
antibody responses that develop following transient CD4+ T cell depletion. (A) C57BL/6 
mice were depleted of CD4+ T cells or left untreated and immunized intramuscularly with 1010 
vp of Ad26-SIV Env and boosted four months post-prime with 1010 vp of Ad5-SIV Env. (B) SIV 
Env-specific antibody titers prior to and following boosting immunization. (C) Fold change in 
SIV Env-specific antibody responses pre- to post-boost. (D) Serum neutralization capacity of 
Tier 1A SIVmac251.TCLA.15 Env-expressing pseudoviruses or a MuLV negative control 
pseudovirus. Each dot represents an individual mouse and for (C) mean ±SEM or (D) median is 
indicated by a line. 
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Continuous absence of CD4+ T cells prevents the development of antibody responses. 
We hypothesized that the development of delayed antibody responses following CD4+ T cell 
depletion reflected the transient nature of CD4+ T cell depletion following a single regimen of 
αCD4 antibody treatment. To test this, C57BL/6 mice were immunized i.m. with 1010 vp of 
Ad26-SIV Env and divided into three experimental groups: 1) treated with αCD4 antibody on 
day -1 (αCD4 at prime); 2) treated with αCD4 antibody on day -1 and again every 14 to 21 days 
(αCD4 repeated); 3) untreated controls (Fig. 4.4A). Administration of αCD4 antibody at prime 
resulted in complete depletion of CD4+ T cells for at least 30 days, but the CD4+ T cell 
population had largely recovered by day 60 (Fig. 4.4B). In contrast, repeated administration of 
αCD4 antibody maintained depletion of CD4+ T cells for at least 60 days (Fig. 4.4B). Repeated 
administration of αCD4 antibody prevented the development of SIV Env-specific antibody 
responses in 18 of 20 mice by day 60 post-immunization (p<0.001; Fig. 4.4C). Consistent with 
the observation that repeated administration of αCD4 antibody prevented the development of a 
delayed antibody response, MHC II KO mice, which permanently lack CD4+ T cells, had no SIV 
Env-specific antibody responses on day 60 post-immunization (Fig. 4.4D). Thus, the recovery of 
CD4+ T cells following αCD4 antibody treatment is necessary for the development of these 
delayed antibody responses. 
We next tested the possibility that the development of delayed antibody responses is due 
to incomplete depletion of CD4+ T cells following treatment, thus resulting in signals from 
residual primed antigen-specific CD4+ T cells. To test this, adult C57BL/6 mice were 
thymectomized and depleted of CD4+ T cells prior to immunization with Ad26-SIV Env. A 
single administration of the αCD4 antibody to thymectomized mice results in a permanent 
depletion of CD4+ T cells, due to an inability to generate new CD4+ T cells (data not shown). On 
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day 60 post-immunization, no SIV Env-specific antibodies were detected in thymectomized mice 
treated at priming with αCD4 antibody (Fig. 4.4E). Thus, our data show that any residual CD4+ 
T cells are insufficient for the generation of a delayed antibody response. Moreover, our data 
further highlight that de novo generation of CD4+ T cells by the thymus is required for the 
delayed antibody response to develop. Collectively, these data demonstrate that the delayed 
antibody response that develops following αCD4 antibody treatment requires thymus-driven 
reconstitution of the CD4+ T cell compartment.  
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Figure 4.4. Repeated depletion of CD4+ T cells prevents the development of the delayed 
antibody response. (A) C57BL/6 mice were depleted of CD4+ T cells a single time (αCD4 at 
prime, red circles), depleted of CD4+ T cells repeatedly (αCD4 repeated, blue circles) or left 
untreated (grey circles) and immunized intramuscularly with 1010 vp of Ad26-SIV Env. (B) 
Frequency of CD4 T cells in the iliac (draining) LNs. (C) SIV Env-specific serum binding 
antibody titers. (D) Serum SIV Env-specific antibody titers on day 60 post-immunization from 
WT or MHC II KO mice immunized with 1010 vp of Ad26-SIV Env. (E) Serum SIV Env-
specific antibody titers on day 60 post-immunization from mice having undergone adult 
thymectomy, or not, and treated with αCD4 antibody, or not, as indicated. Each dot represents an 
individual mouse and for (B) mean ±SEM or (C-E) median is indicated by a line. 
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CD4+ T cell rebound following transient depletion induces normal germinal center 
responses. 
As CD4+ T cells were critical for promoting the formation of germinal center responses 
following Ad vector immunization (Fig. 4.1), we hypothesized that when CD4+ T cells recovered 
following transient depletion, de novo germinal center responses would be induced. On day 30 
post-immunization no germinal center B cells were detected in the iliac lymph nodes of Ad26-
SIV Env immunized mice treated with αCD4 antibody at priming (Fig. 4.5A). However, by day 
60 post-immunization, when the frequency of CD4+ T cells had returned to near basal levels in 
these animals, robust germinal center responses were observed. These responses were equivalent 
in frequency and absolute number of cells to the germinal center responses measured in untreated 
control mice (Fig. 4.5A-C). These germinal center B cells also displayed the normal down-
regulation of IgM and IgD (Fig. 4.5D).  Recovery of CD4+ T cells was required for the induction 
of these delayed germinal center responses as sustained depletion of CD4+ T cells prevented 
germinal centers from developing (Fig. 4.5A-C). Thus, recovery of CD4+ T cells results in the 
generation and expansion of germinal centers, and the development of the delayed antibody 
response. 
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Figure 4.5. Germinal center B cell responses develop following transient depletion of CD4+ 
T cells. C57BL/6 mice were depleted of CD4 T cells a single time (αCD4 at prime, red circles), 
depleted of CD4 T cells repeatedly (αCD4 repeated, blue circles) or left untreated (grey circles) 
and immunized intramuscularly with 1010 vp of Ad26-SIV Env. (A-C) Representative flow 
cytometry plots (A), group average percent (B) or absolute number (C) of germinal center B 
cells in the iliac (draining) LNs on day 60 post-immunization. (D) Expression of IgM and IgD on 
germinal center B cells on day 60-post-immunization. Each dot represents an individual mouse 
and mean ±SEM is indicated by a line. 
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Development of delayed antibody responses occurs following soluble protein immunization. 
We sought to identify other immunization regimens where delayed antibody responses may 
occur following transient depletion of CD4+ T cells. Therefore, we tested adjuvanted soluble 
protein immunogens as an alternate vaccine platform. C57BL/6 mice were immunized i.m. with 
50 µg of trimeric SIV Env gp140 protein formulated in 100 µg of Adju-Phos adjuvant and mice 
were either left untreated, depleted of CD4+ T cells at priming, or repeatedly depleted of CD4+ T 
cells (Fig. 4.6). This immunization regimen induced robust Env-specific titers at day 30 post-
immunization in untreated control mice (Fig. 4.6), and titers were maintained to day 60. In mice 
transiently depleted of CD4+ T cells, no Env-specific antibody responses were detected on day 
30 post-immunization, but by 60 post-immunization these animals had equivalent titers to the 
untreated control animals (Fig. 4.6). Continuous depletion of CD4+ T cells by repeated 
administration of αCD4 antibody prevented the development of Env-specific antibodies on day 
60 (Fig. 4.6). These data demonstrate that a delayed antibody response can occur in the context 
of multiple immunization regimens and is not a unique characteristic of immunization with 
replication-incompetent Ad vectors. 
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Figure 4.6. Delayed antibody responses develop following immunization with an 
adjuvanted soluble protein formulated in Adju-Phos but not following immunization with a 
replication-incompetent poxvirus vector. SIV Env-specific serum antibody titers from 
C57BL/6 mice immunized intramuscularly with 50 µg of SIV Env gp140 + Adju-Phos and 
depleted of CD4+ T cells at the time of immunization (αCD4 at prime), or continuously depleted 
of CD4+ T cells (αCD4 repeated), or left untreated. Each dot represents an individual mouse and 
the line is median. 
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DISCUSSION 
In this study we demonstrate that the induction of transgene antigen-specific antibody responses 
by vaccination can be temporally separated from the time of immunization by the transient 
depletion of CD4+ T cells. CD4+ T cell help was required for the induction of antibody responses. 
However, the transient absence of CD4+ T cells at the time of Ad vector immunization only 
delayed the development of an antibody response until the time at which the CD4+ T cell 
population returned, and we identified no functional defects in these delayed antibody responses 
once they had developed. This is unexpected because previous studies have suggested that 
absence of CD4+ T cells at the time of antigen exposure would induce tolerance (18-22). These 
findings have implications for understating the biology of Ad vector vaccines. 
 CD4+ T cells have many well-established roles in regulating antibody responses against 
an array of antigens (13). One key aspect of this process is sustained provision of positive signals 
to responding B cells by CD4+ T cells (16). Consistent with these findings in other systems, the 
induction of robust antibody responses by Ad vector immunization requires sustained CD4+ T 
cell help for ten days following immunization (Fig. 4.1). Depletion of CD4+ T cells at the time of 
antigen administration was initially suggested as a means to induce B cell tolerance, since 
antigen-specific antibody responses did not develop even after the CD4+ T cell population 
recovered (18-22), and continues to be investigated for this purpose (33). In contrast to these 
reports, we demonstrate that transient CD4+ T cell depletion at the time of immunization with an 
Ad vector or a protein formulated with alum did not induce tolerance to the vaccine antigen. 
Instead, once the CD4+ T cell compartment is reconstituted, robust antigen-specific antibody 
responses develop without the need to experimentally re-administer antigen, and these responses 
appear functionally indistinguishable by our measures from the response induced if CD4+ T cells 
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are present at the time of immunization. Thus, while CD4+ T cell help is required for the 
induction of antigen-specific antibody responses elicited by Ad vectors and soluble proteins 
formulated in an alum-based adjuvant, this help need not be provided at the time of 
immunization. 
We hypothesize that tolerance does not occur following transient CD4+ T cell depletion 
in the context of Ad vector immunization because antigen-specific CD4+ T cell responses may 
develop when the CD4+ T cell population recovers. Transient depletion of CD4+ T cells at the 
time of infection with LCMV Cl-13, a life-long chronic viral infection (34), has also been shown 
to result in a permanent absence of LCMV-specific antibody responses (22) and (data not shown). 
In the context of LCMV Cl-13 infection, when CD4+ T cells are transiently depleted, the 
recovering population is not LCMV-specific (34, 35), possibly due to the presence of viral 
antigen in the thymus, which may result in induction of central tolerance (36). However, 
adoptive transfer of naive LCMV-specific, but not OVA-specific, CD4+ T cells into LCMV Cl-
13-infected mice results in the generation of the LCMV-specific antibody responses (22). In the 
context of chronic LCMV infection, the absence of a delayed antibody response appears to be 
due to a lack of antigen-specific CD4+ T cells upon recovery of CD4+ T cell population. These 
data suggest that generation of antigen-specific CD4+ T cells is necessary for the development of 
a delayed antibody response, and thereby prevent tolerance. Future studies will interrogate this 
proposed model in the context of Ad vector immunization. 
How B cell priming occurs with regards to a delayed antibody response remains unclear. 
Even in response to T cell-dependent antigens, the initial activation of naive B cells by cognate 
binding of antigen to the B cell receptor (BCR) occurs prior to interaction with T cells (37-39). 
Thus, it is possible that the delayed antibody response that occurs following transient depletion 
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of CD4+ T cells is the result of these antigen-experienced B cells receiving the necessary 
activation signals following reconstitution of the CD4+ T cell compartment. Alternatively, the 
delayed antibody response may instead involve B cells that recognize antigen and become 
activated at a time more contemporaneous with the recovery of CD4+ T cells. Future experiments 
will be required to distinguish between these two possibilities and will enhance our 
understanding of this phenomenon. 
The strong dependence of robust antibody responses on CD4+ T cell help has important 
clinical implications. Vaccination in the setting of reduced CD4+ T cell levels, such as in AIDS 
patients or following hematopoietic stem cell transplantation, is challenging as many licensed 
vaccines show a decreased ability to induce antibody responses in these populations (40-44). In 
this study, we demonstrate that following immunization with specific candidate vaccine 
platforms, it is possible to develop high titer, functional antibody responses even when CD4+ T 
cells are absent at the time of immunization. Thus, Ad vectors may be particularly appealing 
vaccine platforms to give in the setting of low CD4+ T cell counts where highly active anti-
retroviral therapy or immune reconstitution can be utilized to reconstitute CD4+ T cell levels 
post-vaccination, as vector-elicited antibody responses can be rescued at least one month post-
vaccination. 
In conclusion, we have shown the role of CD4+ T cell responses in helping to elicit serum 
antigen-specific antibody responses following immunization with non-replicating Ad vectors and 
adjuvanted soluble protein immunogens. Our data demonstrate that antibody responses can be 
induced at a time separated from immunization by manipulation of CD4+ T cells. These findings 
demonstrate that provision of critical CD4+ T cell-derived help signals to B cells can occur 
substantially after the time of initial antigen exposure. Future studies will have to determine if 
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manipulation of this process may be a way to regulate the exact timing of antibody induction 
following vaccination.  
  
! 152!
REFERENCES 
1. Barouch, D. H., J. Liu, L. Peter, P. Abbink, M. J. Iampietro, A. Cheung, G. Alter, A. Chung, 
A.-S. Dugast, N. Frahm, M. J. McElrath, H. Wenschuh, U. Reimer, M. S. Seaman, M. G. Pau, M. 
Weijtens, J. Goudsmit, S. R. Walsh, R. Dolin, and L. R. Baden. 2013. Characterization of 
Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 
HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). J Infect Dis 207: 248–256. 
2. Baden, L. R., S. R. Walsh, M. S. Seaman, R. P. Tucker, K. H. Krause, A. Patel, J. A. Johnson, 
J. Kleinjan, K. E. Yanosick, J. Perry, E. Zablowsky, P. Abbink, L. Peter, M. J. Iampietro, A. 
Cheung, M. G. Pau, M. Weijtens, J. Goudsmit, E. Swann, M. Wolff, H. Loblein, R. Dolin, and D. 
H. Barouch. 2013. First-in-Human Evaluation of the Safety and Immunogenicity of a 
Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). J Infect Dis 207: 
240–247. 
3. Barnes, E., A. Folgori, S. Capone, L. Swadling, S. Aston, A. Kurioka, J. Meyer, R. Huddart, K. 
Smith, R. Townsend, A. Brown, R. Antrobus, V. Ammendola, M. Naddeo, G. O'Hara, C. 
Willberg, A. Harrison, F. Grazioli, M. L. Esposito, L. Siani, C. Traboni, Y. Oo, D. Adams, A. 
Hill, S. Colloca, A. Nicosia, R. Cortese, and P. Klenerman. 2012. Novel adenovirus-based 
vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4: 115ra1. 
4. Colloca, S., E. Barnes, A. Folgori, V. Ammendola, S. Capone, A. Cirillo, L. Siani, M. Naddeo, 
F. Grazioli, M. L. Esposito, M. Ambrosio, A. Sparacino, M. Bartiromo, A. Meola, K. Smith, A. 
Kurioka, G. A. O'Hara, K. J. Ewer, N. Anagnostou, C. Bliss, A. V. S. Hill, C. Traboni, P. 
Klenerman, R. Cortese, and A. Nicosia. 2012. Vaccine vectors derived from a large collection of 
simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4: 
115ra2. 
5. Sullivan, N. J., L. Hensley, C. Asiedu, T. W. Geisbert, D. Stanley, J. Johnson, A. Honko, G. 
Olinger, M. Bailey, J. B. Geisbert, K. A. Reimann, S. Bao, S. Rao, M. Roederer, P. B. Jahrling, 
R. A. Koup, and G. J. Nabel. 2011. CD8(+) cellular immunity mediates rAd5 vaccine protection 
against Ebola virus infection of nonhuman primates. Nat Med 17: 1128–1131. 
6. Stanley, D. A., A. N. Honko, C. Asiedu, J. C. Trefry, A. W. Lau-Kilby, J. C. Johnson, L. 
Hensley, V. Ammendola, A. Abbate, F. Grazioli, K. E. Foulds, C. Cheng, L. Wang, M. M. 
Donaldson, S. Colloca, A. Folgori, M. Roederer, G. J. Nabel, J. Mascola, A. Nicosia, R. Cortese, 
R. A. Koup, and N. J. Sullivan. 2014. Chimpanzee adenovirus vaccine generates acute and 
durable protective immunity against ebolavirus challenge. Nat Med 20: 1126–1129. 
7. Smaill, F., M. Jeyanathan, M. Smieja, M. F. Medina, N. Thanthrige-Don, A. Zganiacz, C. Yin, 
A. Heriazon, D. Damjanovic, L. Puri, J. Hamid, F. Xie, R. Foley, J. Bramson, J. Gauldie, and Z. 
Xing. 2013. A Human Type 5 Adenovirus-Based Tuberculosis Vaccine Induces Robust T Cell 
Responses in Humans Despite Preexisting Anti-Adenovirus Immunity. Sci Transl Med 5: 
205ra134–205ra134. 
8. Ewer, K. J., G. A. O'Hara, C. J. A. Duncan, K. A. Collins, S. H. Sheehy, A. Reyes-Sandoval, 
A. L. Goodman, N. J. Edwards, S. C. Elias, F. D. Halstead, R. J. Longley, R. Rowland, I. D. 
Poulton, S. J. Draper, A. M. Blagborough, E. Berrie, S. Moyle, N. Williams, L. Siani, A. Folgori, 
! 153!
S. Colloca, R. E. Sinden, A. M. Lawrie, R. Cortese, S. C. Gilbert, A. Nicosia, and A. V. S. Hill. 
2013. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-
MVA immunisation. Nature Communications 4: 2836. 
9. Liu, J., K. L. O'Brien, D. M. Lynch, N. L. Simmons, A. La Porte, A. M. Riggs, P. Abbink, R. 
T. Coffey, L. E. Grandpre, M. S. Seaman, G. Landucci, D. N. Forthal, D. C. Montefiori, A. 
Carville, K. G. Mansfield, M. J. Havenga, M. G. Pau, J. Goudsmit, and D. H. Barouch. 2009. 
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 
87–91. 
10. Barouch, D. H., J. Liu, H. Li, L. F. Maxfield, P. Abbink, D. M. Lynch, M. J. Iampietro, A. 
SanMiguel, M. S. Seaman, G. Ferrari, D. N. Forthal, I. Ourmanov, V. M. Hirsch, A. Carville, K. 
G. Mansfield, D. Stablein, M. G. Pau, H. Schuitemaker, J. C. Sadoff, E. A. Billings, M. Rao, M. 
L. Robb, J. H. Kim, M. A. Marovich, J. Goudsmit, and N. L. Michael. 2012. Vaccine protection 
against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 
89–93. 
11. Barouch, D. H., K. E. Stephenson, E. N. Borducchi, K. Smith, K. Stanley, A. G. McNally, J. 
Liu, P. Abbink, L. F. Maxfield, M. S. Seaman, A.-S. Dugast, G. Alter, M. Ferguson, W. Li, P. L. 
Earl, B. Moss, E. E. Giorgi, J. J. Szinger, L. A. Eller, E. A. Billings, M. Rao, S. Tovanabutra, E. 
Sanders-Buell, M. Weijtens, M. G. Pau, H. Schuitemaker, M. L. Robb, J. H. Kim, B. T. Korber, 
and N. L. Michael. 2013. Protective Efficacy of a Global HIV-1 Mosaic Vaccine against 
Heterologous SHIV Challenges in Rhesus Monkeys. Cell 155: 531–539. 
12. Barouch, D. H., G. Alter, T. Broge, C. Linde, M. E. Ackerman, E. P. Brown, E. N. Borducchi, 
K. M. Smith, J. P. Nkolola, J. Liu, J. Shields, L. Parenteau, J. B. Whitney, P. Abbink, D. M. 
Ng'ang'a, M. S. Seaman, C. L. Lavine, J. R. Perry, W. Li, A. D. Colantonio, M. G. Lewis, B. 
Chen, H. Wenschuh, U. Reimer, M. Piatak, J. D. Lifson, S. A. Handley, H. W. Virgin, M. 
Koutsoukos, C. Lorin, G. Voss, M. Weijtens, M. G. Pau, and H. Schuitemaker. 2015. Protective 
efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349: 
320–324. 
13. Victora, G. D., and M. C. Nussenzweig. 2012. Germinal centers. Annu Rev Immunol 30: 
429–457. 
14. Lane, P., A. Traunecker, S. Hubele, S. Inui, A. Lanzavecchia, and D. Gray. 1992. Activated 
human T cells express a ligand for the human B cell-associated antigen CD40 which participates 
in T cell-dependent activation of B lymphocytes. Eur J Immunol 22: 2573–2578. 
15. Shulman, Z., A. D. Gitlin, S. Targ, M. Jankovic, G. Pasqual, M. C. Nussenzweig, and G. D. 
Victora. 2013. T Follicular Helper Cell Dynamics in Germinal Centers. Science 341: 673–677. 
16. Han, S., K. Hathcock, B. Zheng, T. B. Kepler, R. Hodes, and G. Kelsoe. 1995. Cellular 
interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J 
Immunol 155: 556–567. 
17. Provine, N. M., R. A. Larocca, P. Penaloza-Macmaster, E. N. Borducchi, A. McNally, L. R. 
Parenteau, D. R. Kaufman, and D. H. Barouch. 2014. Longitudinal Requirement for CD4+ T 
! 154!
Cell Help for Adenovirus Vector-Elicited CD8+ T Cell Responses. J Immunol 192: 5214–5225. 
18. Benjamin, R. J., and H. Waldmann. 1986. Induction of tolerance by monoclonal antibody 
therapy. Nature 320: 449–451. 
19. Goronzy, J., C. M. Weyand, and C. G. Fathman. 1986. Long-term humoral unresponsiveness 
in vivo, induced by treatment with monoclonal antibody against L3T4. J Exp Med 164: 911–925. 
20. Goronzy, J. J., and C. M. Weyand. 1989. Persistent suppression of virus-specific cytotoxic T 
cell responses after transient depletion of CD4+ T cells in vivo. J Immunol 142: 4435–4440. 
21. Biasi, G., A. Facchinetti, M. Panozzo, P. Zanovello, L. Chieco-Bianchi, and D. Collavo. 
1991. Moloney murine leukemia virus tolerance in anti-CD4 monoclonal antibody-treated adult 
mice. J Immunol 147: 2284–2289. 
22. Aubert, R. D., A. O. Kamphorst, S. Sarkar, V. Vezys, S. J. Ha, D. L. Barber, L. Ye, A. H. 
Sharpe, G. J. Freeman, and R. Ahmed. 2011. Antigen-specific CD4 T-cell help rescues 
exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci USA 108: 21182–
21187. 
23. Abbink, P., A. A. C. Lemckert, B. A. Ewald, D. M. Lynch, M. Denholtz, S. Smits, L. 
Holterman, I. Damen, R. Vogels, A. R. Thorner, K. L. O'Brien, A. Carville, K. G. Mansfield, J. 
Goudsmit, M. J. E. Havenga, and D. H. Barouch. 2007. Comparative seroprevalence and 
immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B 
and D. J Virol 81: 4654–4663. 
24. Chen, B., G. Zhou, M. Kim, Y. Chishti, R. E. Hussey, B. Ely, J. J. Skehel, E. L. Reinherz, S. 
C. Harrison, and D. C. Wiley. 2000. Expression, purification, and characterization of gp160e, the 
soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, 
gp160. J Biol Chem 275: 34946–34953. 
25. Wherry, E. J., V. Teichgräber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. Von 
Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T 
cell subsets. Nature Immunology 4: 225–234. 
26. Barouch, D. H., M. G. Pau, J. H. H. V. Custers, W. Koudstaal, S. Kostense, M. J. E. Havenga, 
D. M. Truitt, S. M. Sumida, M. G. Kishko, and J. C. Arthur. 2004. Immunogenicity of 
recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. 
J Immunol 172: 6290. 
27. Mann, J. F. S., P. F. McKay, A. Fiserova, K. Klein, A. Cope, P. Rogers, J. Swales, M. S. 
Seaman, B. Combadière, and R. J. Shattock. 2014. Enhanced immunogenicity of an HIV-1 DNA 
vaccine delivered with electroporation via combined intramuscular and intradermal routes. J 
Virol 88: 6959–6969. 
28. Badamchi-Zadeh, A., P. F. McKay, M. J. Holland, W. Paes, A. Brzozowski, C. Lacey, F. 
Follmann, J. S. Tregoning, and R. J. Shattock. 2015. Intramuscular Immunisation with 
Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies. PLoS ONE 10: 
! 155!
e0141209. 
29. Sarzotti-Kelsoe, M., R. T. Bailer, E. Turk, C.-L. Lin, M. Bilska, K. M. Greene, H. Gao, C. A. 
Todd, D. A. Ozaki, M. S. Seaman, J. R. Mascola, and D. C. Montefiori. 2014. Journal of 
Immunological Methods. J Immunol Methods 409: 131–146. 
30. Seaman, M. S., H. Janes, N. Hawkins, L. E. Grandpre, C. Devoy, A. Giri, R. T. Coffey, L. 
Harris, B. Wood, M. G. Daniels, T. Bhattacharya, A. Lapedes, V. R. Polonis, F. E. McCutchan, P. 
B. Gilbert, S. G. Self, B. T. Korber, D. C. Montefiori, and J. R. Mascola. 2010. Tiered 
categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing 
antibodies. J Virol 84: 1439–1452. 
31. Johnston, R. J., A. C. Poholek, D. DiToro, I. Yusuf, D. Eto, B. Barnett, A. L. Dent, J. Craft, 
and S. Crotty. 2009. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular 
helper cell differentiation. Science 325: 1006–1010. 
32. Crotty, S. 2011. Follicular Helper CD4 T Cells (T(FH)). Annu Rev Immunol 29: 621–663. 
33. McIntosh, J. H., M. Cochrane, S. Cobbold, H. Waldmann, S. A. Nathwani, A. M. Davidoff, 
and A. C. Nathwani. 2012. Successful attenuation of humoral immunity to viral capsid and 
transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody 
and cyclosporine. Gene Ther 19: 78–85. 
34. Matloubian, M., R. J. Concepcion, and R. Ahmed. 1994. CD4+ T cells are required to sustain 
CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68: 8056–8063. 
35. Penaloza-Macmaster, P., N. M. Provine, E. Blass, and D. H. Barouch. 2015. CD4 T Cell 
Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply 
Exhausted CD8 T Cells. J Immunol 195: 1054–1063. 
36. King, C. C., B. D. Jamieson, K. Reddy, N. Bali, R. J. Concepcion, and R. Ahmed. 1992. 
Viral infection of the thymus. J Virol 66: 3155–3160. 
37. Liu, Y. J., J. Zhang, P. J. Lane, E. Y. Chan, and I. C. MacLennan. 1991. Sites of specific B 
cell activation in primary and secondary responses to T cell-dependent and T cell-independent 
antigens. Eur J Immunol 21: 2951–2962. 
38. Garside, P., E. Ingulli, R. R. Merica, J. G. Johnson, R. J. Noelle, and M. K. Jenkins. 1998. 
Visualization of specific B and T lymphocyte interactions in the lymph node. Science 281: 96–99. 
39. Reif, K., E. H. Ekland, L. Ohl, H. Nakano, M. Lipp, R. Förster, and J. G. Cyster. 2002. 
Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. 
Nature 416: 94–99. 
40. Peters, V. B., and S. K. Sood. 1994. Immunity to Haemophilus influenzae type b 
polysaccharide capsule in children with human immunodeficiency virus infection immunized 
with a single dose of Haemophilus vaccine. J. Pediatr. 125: 74–77. 
! 156!
41. Small, T. N., A. D. Zelenetz, A. Noy, R. D. Rice, T. M. Trippett, L. Abrey, C. S. Portlock, E. 
J. McCullagh, J. M. Vanak, A. M. Mulligan, and C. H. Moskowitz. 2009. Pertussis Immunity 
and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after 
Autologous Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant 15: 
1538–1542. 
42. Veit, O., M. Niedrig, C. C. Taillard, M. Cavassini, E. Mossdorf, P. Schmid, H. G. Bae, N. 
Litzba, T. Staub, C. Hatz, and H. Furrer. 2009. Immunogenicity and safety of yellow fever 
vaccination for 102 HIV-infected patients. CLIN INFECT DIS 48: 659–666. 
43. Landrum, M. L., K. H. K. Hullsiek, A. Ganesan, A. C. Weintrob, N. F. Crum-Cianflone, R. 
V. Barthel, R. J. O’Connell, A. Fieberg, H. M. Chun, V. C. Marconi, M. J. Dolan, and B. K. 
Agan. 2010. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. 
AIDS 24: 545–555. 
44. Beck, C. R., B. C. McKenzie, A. B. Hashim, R. C. Harris, and J. S. Nguyen-Van-Tam. 2012. 
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by 
etiology. J Infect Dis 206: 1250–1259. 
 
  
 
 
 
 
 
 
 
 
 
Chapter 5: Conclusions  
! 158!
TIMING OF CD4+ T CELL HELP IS CRITICAL 
The unifying theme of this thesis is that the timing of CD4+ T cell help to CD8+ T cells and B 
cells is critical for the generation of optimal, fully functional immune responses. The data 
presented in chapters 2 and 3 allow for a very clear picture of the exact timing of CD4+ T cell 
help for the generation of CD8+ T cell responses following Ad vector immunization. 
Furthermore, the data presented in chapter 3 provide mechanistic insights into how CD4+ T cells 
regulate Ad vector-elicited CD8+ T cell responses. Finally, the data in chapter 4 provide details 
on the timing of CD4+ T cell help to B cells to promote the generation of antibody responses, and 
demonstrate that CD4+ T cell help can be temporally separated from the time of immunization. 
 
Timing of CD4+ T cell help to CD8+ T cells 
Following immunization or natural infection with a subset of agents, CD4+ T cell help is critical 
for the optimal expansion of primary CD8+ T cell responses. This class of 
pathogens/immunogens includes vaccinia virus infection, and immunization with antigen-loaded 
splenocytes, DNA plasmids, and Adenovirus serotype 5 (Ad5) vectors (1-4). In contrast, some 
pathogens, such as lymphocytic choriomenengitis virus (LCMV) and Listeria monocytogenes, 
can induce robust primary CD8+ T cell responses in the absence of CD4+ T cells (5-7). I, and 
others (8), postulate that the difference between these two classes of pathogens/immunizations 
with regards to degree of CD4+ T cell independence is due to differences in innate immune 
stimulatory capacity. Namely, pathogens that induce robust innate immune responses do not 
require CD4+ T cell help for primary CD8+ T cell responses, while those that induce modest 
innate immune activation do. In support of this model, administration of poly(I:C), to induce 
type I interferon production, can rescue the proliferation of unhelped CD8+ T cells following 
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vaccinia virus infection (9). For both vaccinia virus infection and antigen-loaded splenocyte 
immunization, a primary mechanism of CD4+ T cell help is maturation of dendritic cells via the 
CD40 signaling pathway (1, 10). However, a mechanism of CD4+ T cell help in the context of 
Ad5 vector immunization has not been defined. 
 The applicability of the CD40-dependent model of CD4+ T cell help to Ad vector-elicited 
immune responses was investigated. Adenovirus serotype 26 (Ad26)-induced CD8+ T cell 
responses, like Ad5, require CD4+ T cell help at priming. However, no role was identified for 
CD40 signaling in modulating expansion of primary CD8+ T cell responses following Ad26 (Fig. 
2.8) or Ad5 (data not shown) vector immunization. No prior studies have identified the timing of 
CD4+ T cell help in the context of the primary CD8+ T cell responses. In prior studies, CD4 
knockout (KO) or MHC class II KO mice, which permanently lack CD4+ T cells, were used, or 
CD4+ T cells were depleted by monoclonal αCD4 antibody administration prior to immunization. 
Thus, I postulated that identifying the timing of CD4+ T cell help for promoting primary CD8+ T 
cell responses by Ad vector immunization would provide insights into how CD4+ T cell help is 
mediated. 
 Fine mapping of the timing of CD4+ T cell help was performed using αCD4 antibody-
mediated depletion of CD4+ T cells, and reconstitution of CD4+ T cells by adoptive transfer of 
antigen-specific CD4+ T cells. Post-Ad26 immunization, CD4+ T cell help is required for eight 
days after immunization to drive maximal expansion of the primary CD8+ T cell response. The 
impact depletion of CD4+ T cells has on the magnitude of the CD8+ T cell response wanes 
smoothly from absolute ablation when cells are depleted prior to immunization to no impact 
when cells are depleted on day nine post-immunization. To complete the fine mapping of the 
timing of CD4+ T cell help, the reciprocal experiment where CD4+ T cells were reconstituted at 
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various times post-immunization was performed. Following Ad5 vector immunization, adoptive 
transfer of antigen-specific CD4+ T cells to mice lacking CD4+ T cells partially rescues 
proliferation of CD8+ T cells if the transfer is performed on day 3, but not on day 7 post-
immunization. Thus, provision of CD4+ T cell help beginning a few days after initial antigen-
exposure can partially rescue defects in CD8+ T cell proliferation. In conclusion, CD4+ T cell 
help is required for a prolonged period following immunization but is not strictly necessary at the 
time of immunization, and that help is being continuously provided during this period. 
There are a few minor technical points to consider when interpreting these results. In 
these experiments, naïve antigen-specific CD4+ T cells were transferred, so the partial rescue of 
CD8+ T cell responses may reflect a lag in provision of CD4+ T cell help due to the need for the 
CD4+ T cells to become activated. Alternatively, it may suggest that multiple CD4+ T cell-
derived signals are required for optimal CD8+ T cell expansion, and that the first of these signals 
is provided prior to day three post-immunization. A limitation of comparing these data to those 
generated in the αCD4 antibody-mediated depletion experiments is that the two immunizing 
vector serotype are different, and the CD8+ T cell responses induced by these vectors expand 
with different kinetics (11, 12). Thus, the exact time when CD4+ T cell help is no longer needed 
may differ slightly between the two experimental systems. Regardless of these minor technical 
points, these data provide the greatest temporal detail on the timing of CD4+ T cell help to CD8+ 
T cells in any system. 
These fine mapping data of the timing of CD4+ T cell help provides insights into 
potential mechanisms of CD4+ T cell help. The lack of a sharp demarcation between one day and 
the next with regards to the impact of CD4+ T cell depletion on the magnitude of the CD8+ T cell 
response strongly argues against a mechanism of CD4+ T cell help that involves programming of 
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CD8+ T cells to subsequently undergo autonomous CD4+ T cell-independent proliferation. Such 
a process of cell autonomous proliferation has been shown to occur following CD8+ T cell 
recognition of cognate antigen (13-15). Instead, the prolonged, gradually declining need for 
CD4+ T cell help suggests a continuous provision of CD4+ T cell-derived helper signals. 
Furthermore, given the relative overabundance of antigen-specific CD8+ T cells compared to 
antigen-specific CD4+ T cells following Ad vector immunization (16), it seems unlikely that 
direct cell-cell contact between CD4+ T cells and CD8+ T cells could be a major mechanism of 
CD4+ T cell help. Consistent with this hypothesis, the absence of CD4+ T cells results in 
strikingly decreased expression of the high-affinity IL-2Rα subunit (CD25) on CD8+ T cells. 
Importantly, specific absence of CD25 expression on CD8+ T cells results in profound 
impairment in expansion of these cells post-Ad vector immunization, and administration of 
recombinant IL-2 (rIL-2) can partially rescue the proliferative defects of unhelped CD8+ T cells. 
These data suggest that CD4+ T cell-derived IL-2 is a critical factor in driving optimal expansion 
of CD8+ T cell responses following Ad vector immunization. Further experimentation to 
specifically abolish IL-2 production by CD4+ T cells will be required to validate this model. 
Pro-inflammatory “signal 3” cytokines are usually required for the induction of optimal 
CD8+ T cell responses, and these cytokines include IL-12, type I interferons, and IL-21 (17-20). 
However, following Ad vector immunization, neither absence of type I interferons nor the 
absence of IL-21 substantially alters CD8+ T cell primary expansion (21, 22). Additionally, no 
IL-12 is detected in serum following Ad vector immunization of non-human primates (23), 
which suggests that IL-12 does not play a major role in regulating Ad vector-elicited CD8+ T cell 
responses. In summary, it does not appear that any of the described “signal 3” cytokines regulate 
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Ad vector-elicited CD8+ T cell proliferation. Instead, IL-2, likely produced by CD4+ T cells, 
appears to be the critical regulator of CD8+ T cell proliferation. 
IL-2 has a very well established role in driving T cell proliferation (24). IL-2 is 
dispensable in vivo for the initial proliferation of responding CD8+ T cells, but is required to 
maintain proliferation of CD8+ T cells (25), and is especially important for accumulation of 
antigen-specific CD8+ T cells in non-lymphoid tissues (26). At very early times post-
immunization (before day 6) the accumulation of unhelped Ad vector-elicited CD8+ T cells is 
equivalent to the accumulation of helped CD8+ T cells, but the relative proliferation rates then 
diverge. This very closely mimics the previously reported proliferative characteristics of CD8+ T 
cells that lack expression of CD25. Following vaccinia virus infection, the absence of CD4+ T 
cell-derived IL-2 substantially impairs accumulation of antigen-specific CD8+ T cells, and 
absence of high affinity IL-2Rα expression on CD8+ T cells recapitulates the absence of CD4+ T 
cells (10). These data are highly consistent with the proposed model of how CD4+ T cells 
provide help to Ad vector-elicited CD8+ T cell responses. This suggests that CD4+ T cell-derived 
IL-2 is a generalizable mechanism by which CD4+ T cells provide help in the context of 
infections/immunizations where primary CD8+ T cell expansion requires CD4+ T cell help. 
In addition to promoting the primary expansion of CD8+ T cell responses, CD4+ T cells 
are also critical for regulating the contraction of CD8+ T cell responses following Ad26 vector 
immunization. Such a role for CD4+ T cells has been reported following infections in other 
systems (6, 27, 28), but in these prior studies the timing of CD4+ T cell help was not investigated. 
Following Ad26 vector immunization, CD4+ T cell help is required for one month to regulate 
post-peak contraction of the CD8+ T cell response. After which CD8+ T cell responses were 
maintained steadily in the absence of CD4+ T cells. As with regulating expansion of CD8+ T 
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cells, there was a progressive long-term need for CD4+ T cell help. Interestingly, Ad vector 
immunization of IL-21R KO mice induces CD8+ T cell responses that exhibit more profound 
post-peak contraction than in WT mice (22). As CD4+ T cells are major producers of IL-21 (29), 
these data suggest that CD4+ T cell-derived IL-21 is likely one of the key factors for regulating 
CD8+ T cell contraction following Ad vector immunization. Further experiments will be required 
to directly test this hypothesis. 
Finally, CD4+ T cell help can regulate the anamnestic potential of CD8+ T cells (6, 7, 30-
33). A need for CD4+ T cell help in potentiating secondary proliferative capacity appears to be 
widely required for both “high-inflammation” and “low-inflammation” T cell stimuli, and thus, 
does not follow the demarcation observed for CD4+ T cell help and primary CD8+ T cell 
responses (8). The current model of how CD4+ T cell help regulates this process involves DCs 
acting as an intermediary between CD4+ T cells and CD8+ T cells (1, 31-35). In this model, 
CD4+ T cells license DCs by ligating the CD40 receptor expressed on DCs. In turn, this induces 
increased expression of CD70 on DCs, which interacts with its receptor, CD27, on CD8+ T cells. 
This CD70-CD27 signaling axis potentiates the CD8+ T cell to make IL-2, thereby enhancing 
their anamnestic potential. Based on these data, a model of CD4+ T cell regulation of anamnestic 
potential appears quite complete. 
Unexpectedly, one report identified no defect in anamnestic potential of CD8+ T cells 
following Ad5 vector immunization when the cells were primed in MHC class II KO mice and 
transferred into a WT recipient prior to secondary antigen exposure (4). This study also reported 
secondary proliferation of CD8+ T cells in MHC class II KO mice upon antigen exposure even 
when adoptive transfers were not performed. However, these secondary effector cells displayed 
alterations in IFN-γ and TNF-α production. In my work, when CD4+ T cells were depleted on 
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day 5 post-Ad26 immunization the resultant CD8+ T cell response, despite exhibiting reduced 
primary expansion and alterations in phenotype, display normal anamnestic potential compared 
to cells from CD4+ T cell containing mice after adoptive transfer into naïve hosts. Unfortunately, 
the same experiment could not be performed using an earlier time of CD4+ T cell depletion due 
to liming CD8+ T cell numbers. However, it appears that following Ad vector immunization, 
CD4+ T cell help is not required at priming for CD8+ T cells to expand normally upon secondary 
antigen exposure. 
Interestingly, Ad vector-elicited CD8+ T cells from CD40L KO and CD40 KO mice have 
major defects in secondary expansion upon antigen re-exposure even if the cells are transferred 
into a WT recipient mouse prior to the boosting immunization. It has been reported that DCs and 
CD8+ T cells can signal directly via the CD40 pathway (36). Thus, while this pathway is 
important for regulating CD8+ T cell anamnestic potential following Ad vector immunization, it 
does not appear to involve CD4+ T cells. Further experiments will be required to confirm that 
CD8+ T cell anamnestic potential following Ad vector immunization does not require CD4+ T 
cells, and to identify exactly how CD40 is involved in this process. 
 The results presented in this thesis, when synthesized with prior published work, describe 
a very detailed picture of the role of CD4+ T cell help in expansion and contraction of the 
primary CD8+ T cell response following Ad vector immunization, as well as the apparent lack of 
a role for CD4+ T cells in regulating anamnestic potential. These data demonstrate the early and 
prolonged requirement for CD4+ T cell help in the expansion of the primary CD8+ T cell 
response, which appears to be mediated largely by IL-2. Additionally, a prolonged need for 
CD4+ T cell help is observed to maintain CD8+ T cell numbers during the post-priming 
contraction phase. In conclusion, this work substantially enhances our fundamental 
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understanding of how Ad vector-elicited CD8+ T cell responses are regulated, and this may have 
relevance for the use of Ad vectors in the clinical setting. 
 
Timing of CD4+ T cell help to B cells 
 CD4+ T cells have a well-established role in promoting antibody responses (37, 38). In the 
context of antibody responses, CD4+ T cell help is provided primarily by a subset of CD4+ T 
cells known as T follicular helper (TFH) cells, and one of the major functions of these cells is to 
initiate and maintain germinal center B cell responses (39). As part of this process, CD4+ T cells 
provide signals to germinal center B cells allowing these cells to undergo somatic hyper-
mutation and ultimately leave the germinal center and become antibody-secreting plasma cells 
(39). A critical pathway involved in these processes is CD40, where CD40L expressed on CD4+ 
T cells binds to CD40 expressed on B cells to provide the relevant positive signals (40). This 
group thus utilized antibody-mediated blockade of CD40 signaling to determine the timing of 
CD4+ T cell help. Following immunization with a haptenated-protein formulated in alum, the 
administration of αCD40L blocking antibody from day -1 to 3 post-immunization abolished the 
germinal center B cell responses and reduced serum antigen-specific antibody titers, while 
αCD40L blocking antibody treatment begun on day 6 post-immunization had no effect on 
antigen-specific antibody titers (40). Subsequent detailed microscopy analysis has observed 
prolonged interactions between TFH cells and B cells following immunization with a haptenated-
protein (41). Thus, there is strong data showing a multi-day need for CD4+ T cell help for the 
optimal development of antibody responses following protein immunization. 
 When the role and timing of CD4+ T cell help was examined following Ad vector 
immunization many parallels were observed. CD4+ T cell help is required for transgene-specific 
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antibody responses, CD40 signaling is a critical signaling pathway, and CD4+ T cells modulate 
germinal center B cell responses. Furthermore, longitudinal depletion of CD4+ T cells following 
immunization identified that CD4+ T cell help is needed for between 10 and 14 days and that 
CD4+ T cell help and is most required early post-immunization and less so by day 10. Thus, the 
role of CD4+ T cell help in Ad vector immunization appears analogous to that observed in 
protein immunization, with minor differences in timing, which likely reflects differences in the 
overall kinetics of the Ad vector-induced immune response. 
 While depletion of CD4+ T cells at the time of Ad vector immunization completely 
ablates the development of transgene antigen-specific antibody responses at day 30 post-
immunization, this does not result in a permanent defect in the antigen-specific antibody 
responses. When CD4+ T cells are depleted transiently using αCD4 antibody, the antigen-
specific antibody responses are simply delayed until the αCD4 antibody is cleared from the 
animal and CD4+ T cell compartment recovers. This phenomenon was also observed following 
immunization with a soluble protein formulated in alum adjuvant. Such an observation has not 
been previously reported, and several other studies have demonstrated long-term tolerance to the 
original immunizing antigen if CD4+ T cells were transiently depleted by monoclonal αCD4 
antibody administration (42-46). 
I hypothesize that long-term antigen persistence and the development of antigen-specific 
CD4+ T cell responses following transient CD4+ T cell depletion are two necessary factors for 
these delayed antibody responses to occur. Transient depletion of CD4+ T cells in the context of 
chronic LCMV infection results in persistent antigen expression (47). However, antigen-specific 
CD4+ T cell responses do not develop (47, 48). But if naive antigen-specific CD4+ T cells are 
transferred into chronically LCMV infected mice, the CD4+ T cells become primed and LCMV-
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specific antibody responses develop (46). Using these data as a template for how delayed 
antibody responses can be induced, it appears that persistent antigen (to prime recovering CD4+ 
T cells) and antigen-specific CD4+ T cells are required. Ad vector immunization has persistent 
antigen expression when CD4+ T cells are absent ((4) and Fig. 3.S1), which would allow for T 
cell priming. Further experiments will be required to confirm the presence of antigen-specific 
CD4+ T cells following transient CD4+ T cell depletion in the context Ad vector immunization, 
as hypothesized. In summary, these data demonstrate that antibody responses can be elicited by 
Ad vector or alum-adjuvanted protein immunization at a time markedly distinct from the time of 
immunization by modulating CD4+ T cell help. An ability to temporally separate the time of 
antibody induction from the time of antigen exposure has not been previously reported. This 
observation likely has substantial clinical relevance as it demonstrates that therapeutic efforts to 
increased CD4+ T cell frequency and/or function, even after the time of immunization, can 
dramatically improve Ad vector vaccine immunogenicity. Hopefully future clinical successes 
will corroborate this hypothesis. 
 
ABERRANT DIFFERENTIATION OF CD8+ T CELLS IN THE ABSENCE OF CD4+ T 
CELLS 
The second major finding of this thesis is that following Ad vector immunization, CD4+ T cells 
play a critical role in proper differentiation of functional CD8+ T cell responses, in addition to 
regulating the magnitude of the responses, as discussed in the previous section. The data 
presented in chapter 2 provide initial description of the phenotypic abnormalities of CD8+ T cells 
in the absence of CD4+ T cells. The experiments performed in chapter 3 describe the phenotypic 
abnormalities of CD8+ T cells primed without CD4+ T cell help in more detail, and demonstrate 
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that functional defects are also present. Furthermore, the data in chapter 3 clearly demonstrate 
that the mechanisms of CD4+ T cell help are multi-factorial, and presents data for a subset of 
these processes. A role for CD4+ T cells in promoting effector CD8+ T cell differentiation is not 
well established, as prior reports have observed no alteration in effector differentiation or 
increased effector differentiation in the absence of CD4+ T cells (49-51). Thus, the work 
presented here identifies a new aspect of CD4+ T cell regulation of CD8+ T cell responses. 
 
Functional CD8+ T cell responses: effector and memory subsets 
CD8+ T cells differentiate into two highly functional subsets upon priming with an acutely 
cleared pathogen or immunization regimen: 1) effector cells, which have robust cytotoxic and 
cytokine producing potential, and 2) memory cells, which have increased long-term survival and 
anamnestic capacity (52). In mice, short-lived effector cells can be identified using cell surface 
markers as KLRG1hiCD127lo, while long-lived memory precursor cells have reciprocal 
expression of these two markers (KLRG1loCD127hi) (53, 54). Following Ad vector 
immunization, a sizeable fraction of long-lived memory cells that are KLRG1hiCD127hi develop 
at late times post-immunization (Fig. 2.6 (12)), and such cells appear to have intermediate 
characteristics of memory and effector cells (52). The regulation of effector versus memory cell 
is controlled by a number of transcription factors and transcriptional repressors, including the 
effector promoting T-bet, Blimp-1, and Id2, and the memory promoting Eomes, Bcl-6, Id3, and 
TCF1 (55-61). 
 In the absence of CD4+ T cells Ad vector-elicited CD8+ T cells have a defect in 
differentiation to an effector state. Unhelped CD8+ T cells do not acquire an effector phenotype 
as evidenced by decreased expression of KLRG1. Defects in canonical effector function are also 
! 169!
observed, as unhelped CD8+ T cells are less cytotoxic and produce fewer cytokines. These 
functional defects correspond to reduced expression of T-bet and Eomes. Eomes expression is 
positively regulated by IL-2, and its expression is require for optimal cytoxic function (62). 
Following Ad vector immunization, absence of CD8+ T cell-intrinsic high affinity IL-2 signaling 
recapitulates the reduced cytotoxic phenotype of unhelped CD8+ T cells, and administration of 
rIL-2 to CD4+ T cell depleted mice can rescue the cytotoxic phenotype of unhelped CD8+ T cells. 
In the absence of CD4+ T cells Ad vector-elicited CD8+ T cells fail to acquire effector phenotype 
and function, and this appears to be due, in part, to the absence of CD4+ T cell-derived IL-2. 
 CD8+ T cells primed by Ad vector immunization in the absence of CD4+ T cells have 
increased phenotypic characteristics of memory cells, but this does not appear to correspond to 
increased functional potential. Unhelped CD8+ T cells express elevated levels of CD127 as well 
as CD62L, a canonical marker of central memory cells (63). However, unhelped CD8+ T cells 
express less CD27, another canonical marker of memory cells (64). These cells also express less 
Eomes and Bcl6, which are both transcriptional regulators that promote long-term memory 
differentiation. Central memory cells have greater anamnestic potential than other memory cells 
(63). If unhelped CD8+ T cells really were enriched for central memory cells based on increased 
expression of CD62L, then unhelped CD8+ T cells should have increased proliferative capacity 
upon secondary antigen exposure compared to helped CD8+ T cells. However, when cells are 
adoptively transferred to normalize cell number prior to boosting immunization, Ad vector-
elicited CD8+ T cells that have only received help for 5 days and have elevated expression of 
CD62L have equivalent anamnestic expansion as helped CD8+ T cells. Other aspects of memory 
capacity, such as proliferation in response to homeostatic cytokines, were not compared between 
helped and unhelped cells, but this would be an interesting area of future investigation to more 
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fully understand the altered characteristics of unhelped CD8+ T cells. In sum, it appears that 
despite some phenotypic characteristics suggesting increased memory properties of unhelped 
CD8+ T cells, these cells do not actually exhibit increased memory functionality by the crucial 
measure tested. 
 CD8+ T cells primed by Ad vector immunization have profound defects in effector 
phenotype and function. These cells also have atypical expression of memory markers, but do 
not have increased memory cell functionality. Instead, unhelped CD8+ T cells are highly 
dysfunctional and share many functional and transcriptional characteristics of several hypo-
functional T cell differentiation states. 
 
Hypo-functional CD8+ T cell responses: exhaustion, tolerance, and anergy 
In addition to the functional T cell differentiation states of effector cells and memory cells, there 
are three well defined differentiation states of T cell hypo-functionality: exhaustion, tolerance, 
and anergy (65, 66). Given the clear defect in differentiation of unhelped CD8+ T cells towards a 
functional effector state, it is important to understand how, if at all, these abnormal unhelped 
CD8+ T cells relate to one of these well-described hypo-functional states. 
Exhaustion occurs in the setting of persistent antigen exposure, such as chronic infection 
or cancer (67). Exhausted CD8+ T cells are characterized by a distinct expression pattern of cell 
surface molecules with substantial upregulation of multiple inhibitory receptors (68-72). 
Exhausted cells also have major defects in cytokine production and altered cytotoxic capacities 
(70, 73, 74). Unhelped Ad vector-elicited CD8+ T cell responses share many of these phenotypic 
and functional characteristics with exhausted cells. The absence of CD4+ T cells results in 
increased expression of inhibitory receptors on Ad vector-elicited CD8+ T cells. Unhelped CD8+ 
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T cells have defects in cytokine production and cytotoxicity that are very similar to those 
reported in exhausted cells. Although it is now clear that elevated inhibitory receptor expression 
is not causative of exhaustion (75), modulation of inhibitory receptor signaling can improve 
exhausted T cell functionality (69, 70, 76). Similarly, blockade of PD-1 signaling during priming 
of CD8+ T cells in the absence of CD4+ T cells partially prevents this impaired effector 
differentiation. Exhausted CD8+ T cells can be reinvigorated in vivo by treatment with rIL-2 (77), 
and rIL-2 administration can partially rescue effector functionality of unhelped Ad vector-
elicited CD8+ T cells. In sum, unhelped Ad vector elicited CD8+ T cells share many phenotypic 
and functional traits with exhausted CD8+ T cells, including being functionally regulated by 
inhibitory receptors. 
Exhausted CD8+ T cells have an unique transcriptional profile and an altered 
transcriptional network compared to either effector or memory T cells (71, 78). This altered 
transcriptional network includes altered expression of T-bet and Eomes (79). The transcriptional 
signature of exhaustion reported in two studies (71, 80) is shared with unhelped CD8+ T cells. 
However, specific longitudinal network analysis has not been performed on unhelped Ad vector-
elicited CD8+ T cells, and this would be an ideal area of future investigation. Alterations in T-bet 
and Eomes expression, which broadly represent the perturbations in exhausted cells, were 
observed in unhelped CD8+ T cells (data not shown), but functional lineage relationship analysis 
needs to be performed before it can be determined if altered T-bet an Eomes signaling are 
functionally important for the dysregulated differentiation of unhelped CD8+ T cells. A very 
clear signal for atypical NFAT signaling was observed in unhelped CD8+ T cells (Fig. 3.3). AP-
1-independent NFAT signaling drives expression of a distinct subset of genes that includes 
exhaustion genes (81), and these AP-1-independent NFAT target genes, including exhaustion 
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genes, are significantly enriched in unhelped CD8+ T cells. In addition to sharing functional and 
phenotypic abnormalities with exhausted CD8+ T cells, unhelped CD8+ T cells share 
transcriptional signatures with exhausted CD8+ T cells. Future work will be required to 
determine to what degree this reflects shared alterations in transcriptional networks, and to 
identify the key transcription factors that regulate this unhelped CD8+ T cell phenotype. 
T cell exhaustion occurs due to exposure of cells to persistent antigen (82-84), and 
elevated type I interferon signaling plays a critical role (85, 86). However, neither of these 
processes are major factors in the dysfunction of unhelped CD8+ T cells (Fig. 3.S4 and data not 
shown). Additionally, exhaustion is a progressive phenomenon wherein the cells become more 
exhausted over time (73, 74). This means that exhaustion can be prevented if CD8+ T cells are 
removed from the exhausting environment early enough (87). In contrast, unhelped CD8+ T cells 
display functional abnormalities immediately upon priming, and these cells were irreversibly 
committed to this aberrant differentiation program by day 3 post-immunization. While unhelped 
dysfunctional CD8+ T cells share functional, phenotypic, and transcriptional characteristics with 
exhausted CD8+ T cells, these data suggest the underlying causative mechanisms are largely 
distinct. 
 Similar to immune exhaustion, tolerance is a progressive process wherein cells lose 
functionality over time. In peripheral tolerance, self-reactive T cells that have escaped negative 
thymic selection are driven to a non-functional state. This program is maintained by continuous 
exposure to self-antigen (88). Peripheral tolerance can also be induced against foreign antigens 
by repeated peptide administration in the absence of sufficient stimulatory signals (17, 89, 90). 
This state of peripheral tolerance has recently been demonstrated to involve a distinct 
transcriptional program from other states of T cell hypo-functionality (91). This genetic signature 
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of peripheral tolerance was used to determine whether CD8+ T cells primed by Ad vector 
immunization without CD4+ T cell help express a transcriptional signature of tolerance. The 
tolerance gene signature is not significantly enriched in CD8+ T cells primed without CD4+ T 
cell help (data not shown). Thus, at the transcriptional level it does not appear that CD8+ T cells 
primed without CD4+ T cell help have been tolerized. 
 The final well-described hypo-functional state is anergy, which occurs when T cells 
undergo incomplete priming. It is now understood that the term anergy actually describes a large 
number of mechanistically distinct states of incomplete priming and immediate dysfunction (92). 
The unifying theme of these mechanistically distinct processes is that incomplete T cell priming 
due to the absence of one or more critical stimulatory signal is the cause, and that anergy is a 
process of immediate hypo-functionality. Transcriptional profiling of CD4+ T cells anergized in 
vitro by TCR stimulation in the absence of CD28 co-stimulation has provided a transcriptomic 
understanding of how this specific type of anergy is regulated (93). This anergic transcriptional 
signature is significantly enriched in unhelped CD8+ T cells following Ad vector immunization. 
As discussed above, the transcriptional signature of AP-1-independent NFAT signaling is 
enriched in unhelped CD8+ T cells. AP-1-independent NFAT target genes also include genes 
upregulated in anergy (81), and the gene signature for these anergy-related AP-1 independent 
NFAT target genes is enriched in unhelped CD8+ T cells. Thus, non-canonical NFAT signaling 
appears to be an important modulator of the anergic transcriptional profile observed in unhelped 
CD8+ T cells. 
However, perturbation of CD28-mediated signaling does not appear be the reason for 
anergy of unhelped CD8+ T cells induced by Ad vector immunization. Absence of CD28 
signaling completely abolished the CD8+ T cell response following Ad vector immunization, 
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consistent with a prior report (94). Additionally, the absence of CD4+ T cells does not alter the 
upregulation of CD80 and CD86 on dendritic cells in the draining LNs following Ad vector 
immunization (data not shown). Thus, the absence of co-stimulation and the absence of CD4+ T 
cells are not equivalent in this system. However, as transcriptional signatures for anergy induced 
by other experimental protocols do not exist, it is possible that the transcriptional signature of 
anergy is conserved across anergy induced by different mechanisms. This would potentially 
explain why unhelped CD8+ T cells express the transcriptional signature of anergy induced by 
absence of co-stimulation despite all evidence suggesting co-stimulation is unimpaired when 
CD4+ T cells are absent. More detailed analysis of the transcriptional processes of anergy may 
clarify this possibility. 
CD8+ T cells can undergo a specific form of anergy termed split-anergy (or activation-
induced non-responsiveness), where CD8+ T cells fail to receive the complete array of priming 
signals and immediately enter a hypo-functional state (95). This split-anergy is characterized by 
normal IFN-γ production and cytotoxic function, but impaired proliferative capacity (96). 
Unhelped CD8+ T cells do not appear to be in a state of split-anergy as these cells have major 
defects in proliferation and also have dramatic impairments in IFN-γ production and cytotoxic 
function. Administration of rIL-2 has been demonstrated to reverse anergy, including split-
anergy (97, 98). In our system, administration of rIL-2 corrects the dysfunctional CD8+ T cell 
phenotype, and absence of IL-2 signaling is sufficient to reproduce some facets of the observed T 
cell dysfunction. The responsiveness of unhelped CD8+ T cells to IL-2 treatment is in good 
agreement with the observed transcriptional signature of anergy. The dysfunction of unhelped 
CD8+ T cells we observe can be defined as anergy given the immediacy of the impairment and a 
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common transcriptional signature, but the functionality and phenotype of the responding cells are 
distinct from the previously reported states of anergy. 
 In sum, unhelped CD8+ T cells exhibit a dysfunctional profile that is best described as a 
combination of exhaustion and anergy. Transcriptional profiles of both hypo-functional states are 
observed in unhelped CD8+ T cells, likely due to increased non-canonical NFAT signaling. The 
immediacy of the dysfunction mirrors anergy, while the decreased functionality and increased 
expression of inhibitory receptors mirrors T cell exhaustion. Most importantly, CD4+ T cells 
have not been previously reported to play a major role in regulating CD8+ T cell effector 
differentiation, but following Ad vector immunization, CD4+ T cells clearly play a major role in 
preventing T cell dysfunction. 
 
The role of CD4+ T cell help in influencing primary CD8+ T cell functionality in other models 
CD4+ T cells have well-established roles in regulating primary CD8+ T cell expansion, 
maintenance, and anamnestic potential. However, a role for CD4+ T cells in regulating CD8+ T 
cell effector differentiation is not well established. Two studies have observed increased 
differentiation of CD8+ T cells towards an effector phenotype following infection with LCMV 
(50) or vaccinia virus (51) in the absence of CD4+ T cells. However, a separate study found no 
alternation in effector phenotype of CD8+ T cells primed by vaccinia virus in the absence of 
CD4+ T cells (49). In contrast, following Ad vector immunization, CD4+ T cells are absolutely 
critical for acquisition of effector phenotype and functions by CD8+ T cells, and appear to 
regulate all aspects of CD8+ T cell functionality. 
The hyper-effector phenotype observed in unhelped CD8+ T cells following LCMV 
infection is due to elevated expression of the transcription factor T-bet (50). By contrast, 
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unhelped CD8+ T cells elicited by Ad vector immunization have decreased expression of T-bet. 
T-bet expression can be driven by inflammatory signals (62). It has been discussed above that the 
need for CD4+ T cell help to drive primary effector differentiation in different experimental 
systems appears to depend on whether the infection/immunization induces strong inflammation 
(8). This same demarcation appears to apply with regards to the requirement for CD4+ T cell 
help and effector differentiation of CD8+ T cells. High inflammation environments, such as 
LCMV infection, can induce effector-lineage promoting transcription factors independent of 
CD4+ T cells, while low inflammation environments require CD4+ T cell-derived signals, IL-2 
being one factor, to induce expression of these transcription factors. Consistent with this 
hypothesis, replication-incompetent NYVAC poxvirus vector induced CD8+ T cell responses, 
like Ad vector-elicited responses, had decreased effector phenotype, and these vectors induce 
very modest innate inflammation (99). In summary, the ability of CD8+ T cells to acquire 
effector functionality is dependent on CD4+ T cell help following priming with multiple 
replication-incompetent viral vectors. Further experiments will be required to determine how 
widespread is the need for CD4+ T cell help to promote effector CD8+ T cell differentiation. 
 
SUMMARY 
In conclusion, the data presented in this thesis identify the key role of CD4+ T cells in promoting 
optimal cellular and humoral immune responses following adenovirus vector immunization. 
These data thoroughly demonstrate for the first time the time-dependent effects of CD4+ T cell 
help. With regards to CD4+ T cell help to CD8+ T cells, these data demonstrate a previously 
unappreciated role for CD4+ T cells in promoting functional cytotoxic effector differentiation of 
CD8+ T cells. CD4+ T cell help to CD8+ T cells is a multifactorial process that involves IL-2, 
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regulation of NFAT signaling, and other to-be-identified factors. Unexpectedly, in the context of 
antibody responses, CD4+ T cell help can be provided at a time temporally distinct from the time 
of immunization. Such a temporal separation of CD4+ T cell help from the time of antigen 
exposure has not been previously reported. Thus, while CD4+ T cell help is critical for both 
cellular and humoral immune responses, the timing and mechanisms of help are distinct. These 
data have major implications for our understanding of the process that govern vaccine-elicited 
CD8+ T cell and antibody responses, and for understanding how the processes that regulate 
vaccine-elicited responses are similar or different from responses induced by natural infection. 
This knowledge can be applied to the development of improved, rationally designed, next-
generation vaccines. 
 
FUTURE DIRECTIONS 
Identifying additional pathways involved in CD4+ T cell regulation of CD8+ T cells 
The major outstanding question regarding the role of CD4+ T cells in the regulation of Ad 
vector-elicited CD8+ T cell responses is: in addition to IL-2, what other pathways are involved? 
Three complimentary approaches can be taken to begin to address this question. 
First, it should be determined definitively whether CD4+ T cells provide help to Ad 
vector-elicited CD8+ T cells by providing activating signals to dendritic cells, as has been 
described in other systems (31-33, 35, 100). Data in this thesis demonstrates that CD40 signaling 
is not a major mechanism of CD4+ T cell help in this system, but there are other pathways by 
which CD4+ T cells can activate dendritic cells. To formally assess a role for CD4+ T cell-
mediated dendritic cell maturation a mixed bone marrow chimera experiment should be 
performed. As described in (35), wild type mice will be irradiated and reconstituted with a 50/50 
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mixture of MHC class I KO and MHC class II KO bone marrow. Upon reconstitution, these mice 
will be capable of mounting both CD4+ T cell and CD8+ T cell responses, but a single dendritic 
cell cannot present cognate antigen to both a CD4+ T cell and a CD8+ T cell (since any given 
dendritic cell will lack either MHC class I or MHC class II). Thus, this experimental setup allows 
for definitive clarification as to whether CD4+ T cells provide cell-cell contract-dependent 
maturation signals to dendritic cells following Ad vector immunization. This knowledge will 
allow for the exclusion, or inclusion, of a large number of possible mechanisms of CD4+ T cell 
help. 
Second, transcriptional profiling should be performed on day 4 (or 5 if cell numbers are 
limiting) post-immunization antigen-specific CD8+ T cells from αCD4 antibody treated or 
untreated control mice. Gene set enrichment analysis and pathway analysis can be performed, as 
in Fig 3.3, on these data to identify possible pathways that are differentially activated when 
CD4+ T cells are present or absent. Synthesizing these data with the data generated from the first 
experiment should identify candidate pathways of CD4+ T cell help. These candidate pathways 
can then be validated in the following experiment. 
Third, candidate pathways of CD4+ T cell help identified in experiments one and two 
should be validated experimentally. If gene knockout animals for a candidate pathway are 
available then a given pathway can be tested easily. However, a more systematic approach is 
preferred. Specifically, the experimental technique of adoptive transfer of antigen-specific CD4+ 
T cells into thymectomized mice, as in Fig. 3.4, to experimentally control the characteristics of 
CD4+ T cells can be utilized. The antigen-specific CD4+ T cells can have specific genes knocked 
down by retroviral shRNA vectors prior to adoptive transfer. Alternatively, CRISPR-Cas9-
mediated gene deletion could be utilized. Such an approach would allow for a reasonably high-
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throughput setup to rapidly screen a number of putative pathways. Furthermore, this technique 
would demonstrate the specific role for a given pathway on CD4+ T cells, which is the critical 
factor for demonstrating a given pathway is a direct mechanism of CD4+ T cell help. Thus, this 
experimental technique represents a robust means to experimentally validate additional 
mechanisms of CD4+ T cell help. 
Together, these data will provide additional mechanistic insights into how CD4+ T cells 
provide help to CD8+ T cells following Ad vector immunization. 
 
Enhancing our understanding of delayed antibody responses 
To better understand how delayed antibody responses develop following transient depletion of 
CD4+ T cells, the following experiments should be performed. 
 First, the nature of CD4+ T cell help following transient depletion of CD4+ T cells should 
be better described. It is presumed that following transient depletion of CD4+ T cells in the 
context of Ad vector or alum-adjuvanted recombinant protein immunization, the recovering 
CD4+ T cell population contains activated antigen-specific CD4+ T cells. This hypothesis should 
be confirmed, and the necessity of antigen-specific cells should be demonstrated. To confirm the 
presence of antigen-specific CD4+ T cells intracellular cytokine staining (ICS) after cognate 
peptide stimulation can be performed. Additionally, TFH phenotype cells (PD-1+ CXCR5hi) can 
be identified by surface marker analysis, and these cells should only be present in antigen-
experienced animals. To determine whether antigen-specific CD4+ T cells are necessary for these 
delayed antibody responses to develop, antigen-specific CD4+ T cells or irrelevant antigen CD4+ 
T cells can be adoptively transferred into thymectomized mice on day 30 post-immunization. As 
thymectomized mice do not develop delayed antibody responses (Fig. 4.4), this experimental 
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approach allows for the specific investigation of the need for antigen-specific CD4+ T cells in 
this process. These experiments will test the hypothesis that the development of a delayed 
antibody response requires the involvement of antigen-specific CD4+ T cells. 
 Second, how persistent antigen is involved in the induction of delayed antibody responses 
remains to be determined. In the absence of CD4+ T cells, transgene expressing cells are 
abundant for months post-immunization (Fig. 3.S1), or following immunization with protein 
formulated in adju-phos the protein may be retained within an antigen depot. Therefore, free 
antigen may be responsible for the induction of delayed antibody responses. Alternatively, 
follicular dendritic cells (FDCs) can retain antigen in the form of immune complexes for 
extended periods (101), and thus free soluble antigen may be dispensable for this process. To test 
these two possibilities several experiments can be performed. To determine if antigen depoting is 
necessary for this phenomenon, protein can be formulated in a non-depoting adjuvant (ie. CpG) 
or a depoting adjuvant (ie. CpG + emulsigen) prior to immunization. If depoting is required then 
only that formulation should induce a delayed antibody response. Alternatively, a transgene-
silencing Ad vector, as used in Fig. 3.S4, could be constructed expressing SIV Env. To directly 
test the role of FDCs in the induction of delayed antibody responses, mice that lack fully 
functional FDCs due to specific gene knockout can be utilized. These experiments will provide 
greater insights into the exact nature of the antigen that is required for the induction of a delayed 
antibody response. 
 Third, the exact nature and timing of B cell priming in the context of a delayed antibody 
response should be investigated. The major outstanding question is: are B cells primed at the 
time of immunization and remain quiescent until CD4+ T cell help is provided, or are B cells 
newly primed when CD4+ T cells recover? To directly test this, all B cells can be transiently 
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depleted via anti-CD20 antibody after immunization. If transient depletion of B cells prior to the 
recovery of CD4+ T cells prevents the development of a delayed antibody response then B cell 
priming at the time of immunization can be presumed to be critical for this process to occur. As 
an additional set of experiments, T cell-independent B cell responses can be assessed by antigen-
specific IgM ELISPOT to detect the presence and activation of non-class-switched B cells at 
various times prior to and after the recovery of CD4+ T cells. Finally, if B cell activation is 
observed at the time of immunization in the absence of CD4+ T cells then fate tracking can be 
performed to determine if these B cells are the ones that give rise to the delayed antibody 
response after recovery of CD4+ T cells. These experiments will better define when B cells get 
activated and primed for the induction of a delayed antibody response. 
 Collectively, these three areas of investigation will dramatically enhance our 
understanding of the processes that regulate the induction of a delayed antibody response 
following transient depletion of CD4+ T cells. 
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Figure 3.S1. Long-term dysfunctional phenotype of CD8+ T cells primed in the absence of 
CD4+ T cells. 
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Figure 3.S1 (Continued) 
(A-E) C57BL/6 mice were treated with αCD4 antibody or left untreated and immunized 
intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. (A) Frequency of CD4+ T cells in the blood. 
(B) Absolute number of Kb/OVA+ CD8+ T cells in the spleen. (C) Expression of KLRG1 and 
CD127 on Kb/OVA+ CD8+ T cells in the blood. (D) Expression of CD27 and CD43 on Kb/OVA+ 
CD8+ T cells in the spleen day 14 post-immunization. (E) in vivo luciferase transgene expression 
in a single representative animal per group over time or group average as quantified by IVIS. (F-
H) C57BL/6, CD4 KO, or MHC II KO mice were immunized intramuscularly with 109 vp of 
Ad5-SIINFEKL-Luc. (F) Frequency of Kb/OVA+ cells as a fraction of CD8+ cells in the blood. 
(G) Frequency of IFN-γ-secreting CD8+ T cells in the spleen on day 45 following ex vivo 
OVA257-264 peptide stimulation and MFI of IFN-γ in IFN-γ+ cells. (H) TNF-α expression by IFN-
γ+ CD8+ T cells following ex vivo stimulation with OVA257-264 peptide.  (A, C, D) Data are 
representative of three experiments (n=5-6/group per experiment). (B) Data are pooled from 
three experiments (n=5/group per experiment). (E-H) Date are representative of two experiments 
(n=5/group per experiment). Mean ± SEM are shown. ***, P<0.001; **, P<0.01; *, P<0.05; 
Mann-Whitney U test. 
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Figure 3.S2. Elevated expression of inhibitory receptors on CD8+ T cells in multiple 
experimental settings of CD4+ T cell deficiency. (A) C57BL/6, CD4 KO, or MHC II KO mice 
were immunized intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. Frequency of Kb/OVA+ 
cells as a fraction of CD8+ cells in the blood. Data are representative of two experiments 
(n=5/group per experiment). (B, C) C57BL/6 mice were treated with αCD4 antibody or left 
untreated and immunized intramuscularly with 109 vp of Ad5HVR48-Gag. (B) Frequency of 
Db/AL11+ CD8+ T cells in the spleen on day 14 post-immunization. (C) KLRG1, PD-1, Lag-3, 
and Tim-3 expression on Db/AL11+ CD8+ T cells in the spleen. Data are pooled (B) or 
representative (C) of six experiments (n=5-7/group per experiment). (D-G) C57BL/6 mice were 
treated with αCD4 antibody or left untreated and immunized intramuscularly with 106 pfu of 
NYVAC-Env (n=7/group). (D) Frequency of IFN-γ+ Env-specific CD8+ T cells in the spleen on 
day 14. (E) Per cell production of IFN-γ by IFN-γ+ CD8+ T cells as measured by mean 
fluorescence intensity (MFI). (F) CD107a expression by IFN-γ+ CD8+ T cells upon Env peptide 
pool stimulation. (G) PD-1 expression on IFN-γ+ CD8+ T cells.  Mean ± SEM are shown. **, 
P<0.01; *, P<0.05; #, P=0.06; Mann-Whitney U test. 
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Figure 3.S3. Experimental validation of gene expression profiling findings. (A-D) C57BL/6 
mice were treated with αCD4 antibody or left untreated and immunized intramuscularly with 109 
vp of Ad5HVR48-Gag. (A) Ki-67 expression by Db/AL11+ CD8+ T cells in the spleen on day 14 
post-immunization. (B) Frequency of Annexin V+ vital dye+ apoptotic Db/AL11+ CD8+ T cells in 
the spleen on day 14 post-immunization. (C) Enrichment of the effector gene signature from 
[GSE9650 (24), GSE30962 (23)] in untreated control Db/AL11+ CD8+ T cells. (D) Enriched 
genes from the leading edge analysis of (C). (E) C57BL/6 mice were treated with αCD4 
antibody or left untreated and immunized intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. 
Frequency of Kb/OVA+ CD8+ T cells in the blood was assessed. (A,B) Data are pooled from two 
experiments (n=5-7/group per experiment. (C,D) Data are from one experiment. (E) Data are 
representative of two experiments (n=5/group per experiment). Mean ± SEM are shown. **, 
P<0.01; *, P<0.05; #, P=0.06; Mann-Whitney U test. ! !
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Figure 3.S4. Reduced transgene clearance in the absence of CD4+ T cells does not alter 
CD8+ T cell responses. 500 naïve OT-I CD8+ T cells were transferred into CD45.1+ congenic 
recipient mice. Mice were treated with αCD4 antibody and immunized intramuscularly with 1010 
vp of Ad5-tTA-SIINFEKL-Luc. (A) in vivo luciferase transgene expression in a single 
representative animal per group over time and group average as quantified by IVIS. (B) 
Representative plots and group average of  CD45.1+ donor OT-I CD8+ T cells. (C) KLRG1 
expression on CD45.1+ OT-I CD8+ T cells. (D) PD-1 expression on CD45.1+ OT-I CD8+ T cells. 
(E) Representative plot of expression of IFN-γ and TNF-α on CD45.1+ OT-I CD8+ T cells 
following OVA257-264 peptide stimulation. (F) Fraction of CD45.1+ OT-I CD8+ T cells that 
produce IFN-γ upon OVA257-264 peptide stimulation. (G) Mean fluorescence intensity (MFI) of 
IFN-γ+ OT-I CD8+ T cells. (H) TNF-α production by IFN-γ+ OT-I CD8+ T cells. Data are pooled 
from three experiments (B, C, H), pooled from two experiments (F), or representative of three 
experiments (A, D, E, G). N=5/group per experiment. Mean ± SEM are shown. **, P<0.01; *, 
P<0.05; Mann-Whitney U test. 
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Figure 3.S5. Anti-PD-1 antibody treatment partially rescues the functionality of CD8+ T 
cells primed in the absence of CD4+ T cells. C57BL/6 mice were treated with αCD4 antibody 
or left untreated and immunized intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. αCD4 
antibody treated mice were treated with either αPD-L1, αPD-1, or isotype control antibody every 
three days from day 0 to 12. (A) Frequency of IFN-γ producing CD8+ T cells from the spleen 
upon ex vivo stimulation with OVA257-264 peptide. (B) Absolute number of OVA257-264-specific 
CD8+ T cells that produce IFN-γ. (C) Per cell expression of IFN-γ as measured by mean 
fluorescence intensity (MFI). (D) Fraction of Kb/OVA257-264-specific CD8+ T cells capable of 
producing IFN-γ. (E) Frequency of IFN-γ producing CD8+ T cells that co-produce TNF-α. (F) 
Absolute number of OVA257-264-specific CD8+ T cells that co-produce IFN-γ and TNF-α. (A, B, 
D-F) Data are pooled from 2 independent experiments (n=5-7 mice/group per experiment). (C) 
Data are representative of two independent experiments (n=5-7 mice/group per experiment). All 
data are day 14 post-immunization from the spleen. Mean ± SEM are shown. ***, P<0.001; **, 
P<0.01; *, P<0.05; Mann-Whitney U test. ! !
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Figure 3.S6. Early phenotype of antigen-specific CD8+ T cells primed without CD4+ T cell 
help. C57BL/6 mice were treated with αCD4 antibody or left untreated and immunized 
intramuscularly with 109 vp of Ad5-SIINFEKL-Luc. (A) Representative flow plots of Kb/OVA+ 
CD8+ T cells in the iliac LNs. (B) Frequency of Kb/OVA+ CD8+ T cells in the iliac LNs. (C) 
Absolute number of Kb/OVA+ CD8+ T cells in the iliac LNs. (D) Representative flow plots of 
cellular morphology, activation markers, co-stimulatory receptors, metabolic receptors, and 
effector/memory markers on Kb/OVA+ CD8+ T cells in the iliac LNs. (E) Group average 
expression of markers with significant differences from panel D. Data are representative of two 
independent experiments (n=5 mice/group per experiment). Mean ± SEM are shown. **, P<0.01; 
*, P<0.05; #, P=0.06; Mann-Whitney U test. 
 
